UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549   FORM 20-F /A (Mark One)  [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934  OR  [  X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2007  OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  [ ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  Date of Event requiring this shell company report ..  For the transition period from ___________________ to ______________________  Commission file number: 0-51848  ALDA Pharmaceuticals Corp. (Exact name of Registrant as specified in its charter)  Not applicable (Translation of Companys name into English)  Province of British Columbia, Canada (Jurisdiction of incorporation or organization)  635 Columbia St. New Westminster, B.C., Canada, V3M 1A7 (Address of principal executive offices)  Securities registered or to be registered pursuant to Section 12(b) of the Act.  Title of each class Name of each exchange on which registered  Not Applicable Not Applicable  Securities registered or to be registered pursuant to Section 12(g) of the Act.  Common Shares Without Par Value (Title of Class)   Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.  None (Title of Class)   Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.  32,192,404 common shares  Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  o     No [ X ]  If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  Yes  o     No [ X ]   Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  o     No [ X ]  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.  See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act (check one):  Large accelerated filer  o                   Accelerated filero                 Non-Accelerated filer [ X ]   Indicate by check mark which financial statement item the Company has elected to follow.  Item 17 [ X ]    Item 18o  (APPLICABLE ONLY TO ISSUES INVOLVED IN BANKRUPTCY PROCEEDING DURING THE PAST FIVE YEARS)  Indicate by check mark whether the Company has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.  Yes  o     Noo  The information set forth in this Annual Report on Form 20-F is as at June 30, 2007 unless an earlier or later date is indicated.  Alda Pharmaceuticals Corp. 2007 20F/A Page 1------------------------------------------------------------------------------------------------------------------------------------------------   Financial information is presented in accordance with accounting principles generally accepted in Canada (Canadian GAAP) which are substantially the same as principles applicable in the United States (US GAAP) and practices prescribed by the United States Securities and Exchange Commission (SEC) except as set forth in Note 16 to the accompanying Financial Statements of the Company.  Contact person: Terrance Owen, President & CEO, 635 Columbia Street, New Westminster, BC, V3M 1A7, Phone: 604-521-8300 (Ext. 1), Fax: 604-521-8322, E-mail: terryowen@telus.net.   Alda Pharmaceuticals Corp. 2007 20F/A Page 2------------------------------------------------------------------------------------------------------------------------------------------------   FORM 20-F ANNUAL REPORT TABLE OF CONTENTS   Part I                                                   Page Item 1.Identity of Directors, Senior Management and Advisors5Item 2.Offer Statistics and Expected Timetable6Item 3.Key Information6Item 4.Information on the Company17Item 5.Operating and Financial Review and Prospects35Item 6.Directors, Senior Management and Employees41Item 7.Major Shareholders and Related Party Transactions49Item 8.Financial Information51Item 9.The Offer and Listing52Item 10.Additional Information55Item 11.Quantitative and Qualitative Disclosures About Market Risk65Item 12.Description of Securities Other Than Equity Securities65  Part II  Item 13.Defaults, Dividend Arrearages and Delinquencies65Item 14.Material Modifications to the Rights of Security Holders and Use of Proceeds65Item 15.Controls and Procedures65Item 16.Reserved66Item 16A.Audit Committee Financial Expert66Item 16B.Code of Ethics67Item 16C.Principal Accountant Fees and Services67Item 16D.Exemptions from the Listing Standards for Audit Committee68Item 16E.Purchases of Equity Securities by the Company and Affiliated Purchasers68 Part III  Item 17.Financial Statements68Item 18.Financial Statements68Item 19.Exhibits68   Alda Pharmaceuticals Corp. 2007 20F/A Page 3------------------------------------------------------------------------------------------------------------------------------------------------   INTRODUCTION  The Company was incorporated by registration of its Memorandum and Articles under the BC Companies Act on May 30, 2000 under the name Duft Biotech Capital Ltd. On November 13, 2003, the Company acquired the assets of ALDA Pharmaceuticals Inc. (API), a private company founded in 1996. On November 26, 2003 the Company changed its name to ALDA Pharmaceuticals Corp. (the Company)  The Company is still a British Columbia, Canada, company. Effective August 19, 2005, the authorized share capital of the Company was increased to an unlimited number of common shares without par value. There are no Indentures or Agreements limiting the payment of dividends and there are no conversion rights, special liquidation rights, pre-emptive rights or subscription rights.  BUSINESS OF ALDA PHARMACEUTICALS CORP.  The Company is principally in the business of developing infection control products for industrial and consumer use and for the treatment of topical infections  FINANCIAL AND OTHER INFORMATION  The Companys reporting currency and domestic currency is Canadian Dollars.  In this Annual Report, unless otherwise specified, all dollar amounts are expressed in Canadian Dollars (CDN$ or $).  The Government of Canada permits a floating exchange rate to determine the value of the Canadian Dollar against the U.S. Dollar (US$).  Comparisons of historic exchange rates between the US$ and the CDN$ are contained in Section 3.A.3.  FORWARD-LOOKING STATEMENTS  This Annual Report on Form 20-F contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, principally in ITEM #4, Information on the Company and ITEM #5, Managements Discussion and Analysis of Financial Condition and Results of Operations.  These statements may be identified by the use of words like plan, expect, aim, believe, project, anticipate, intend, estimate, will, should, could and similar expressions in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends.  In particular, these include statements about the Companys strategy for growth, future performance or results of current sales and production, interest rates, foreign exchange rates, and the outcome of contingencies, such as acquisitions and/or legal proceedings and intellectual property issues. Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties.  Actual future results and trends may differ materially from historical results or those projected in any such forward-looking statements depending on a variety of factors, including, among other things, the factors discussed in this Annual Report under ITEM #3, Key Information, Risk Factors and factors described in documents that the Company may furnish from time to time to the Securities and Exchange Commission.  The Company undertakes no obligation to update publicly or revise any forward-looking statements because of new information. MEASUREMENT INFORMATION Canada uses the metric measurement system and all of the measures used by the Company adhere to the standards of the metric system.  Alda Pharmaceuticals Corp. 2007 20F/A Page 4------------------------------------------------------------------------------------------------------------------------------------------------  PART I ITEM 1. IDENTITY OF DIRECTORS SENIOR MANAGEMENT AND ADVISERS 1.A.1. Directors and senior management Table No. 1 lists as of June 30, 2007 the names of the Directors of the Company.  Table No. 1 Directors  Name and Residential AddressAgeDate First Elected or AppointedTerrance G. Owen
635 Columbia Street
New Westminster, BC, Canada V3M 1A761May 30, 2000Peter Chen (1)
635 Columbia Street
New Westminster, BC, Canada V3M 1A745May 30, 2000Eugene Hodgson (1)
1400  601 West Hastings Street
Vancouver, BC, Canada V6B 5A651October 12, 2004Linda Allison (1)
3074 Spencer Place
West Vancouver, BC, Canada V7V 3C960June 30, 2003Ronald Zokol
470 West Tower 555 West 12th Avenue
Vancouver, BC, Canada V5Z 3X758November 13, 2003William F. McCoy
735 Thornapple Drive
Naperville, IL,. USA 6054052March 17, 2005  (1) Member of Audit Committee    1.A.2.  Senior Management Table No. 2 lists the names of the Senior Management of the Company.  The Senior Management serves at the pleasure of the Board of Directors.  Table No. 2 Senior Management  Name and PositionAgeDate of First AppointmentTerrance Owen, President & CEO61May 30, 2000Peter Chen, CFO and Secretary45May 30, 2000    Mr. Owens business functions, as President and CEO of the Company, include overall supervision of all officers and consultants, as well as strategic planning, business development, operations, liaison with auditors, accountants, lawyers, regulatory authorities, the financial community and shareholders; and reporting to the Board of Directors.  Alda Pharmaceuticals Corp. 2007 20F/A Page 5------------------------------------------------------------------------------------------------------------------------------------------------  Mr. Chens business functions, as CFO, include financial statement preparation, accounting, liaising with auditors, accountants, lawyers and regulatory authorities and preparation, payment and organization of the expenses, taxes, and other financial activities of the Company and reporting to the Board of Directors Mr. Chens business functions, as Corporate Secretary, include attending and being the secretary of all meetings of the Board, shareholders and committees of the Board and entering, or causing to be entered in records kept for that purpose, minutes of all proceedings thereat; gives or causes to be given, as and when instructed, all notices to shareholders, Directors, officers, auditors and members of committees of the Board; is the custodian of the stamp or mechanical device generally used for affixing the corporate seal of the Company and of all books, records and instruments belonging to the Company, except when some other officer or agent has been appointed for that purpose; and in the future can have such other powers and duties as the Board of the chief executive officer may specify.  Mr. Chen may delegate all or part of his duties as Corporate Secretary to a nominee or to corporate counsel from time to time. 1.B. Legal Advisors The legal advisors for the Company are Getz Prince Wells, Barristers & Solicitors, 1810  1111 West Georgia St., Vancouver, B.C. V6E 4M3., Phone 604-605-4293 Fax 604 685-9798.  As of October 2, 2007, the Company has retained Stanislaw Ashbaugh LLP, 4400 - 701 Fifth Avenue, Seattle, WA 98104 to assist in drafting of this report on Form 20F and to provide assistance with matters concerning securities laws in the United States but that firm does not provide other legal services to the Company. The Companys Bank is the Canadian Imperial Bank of Commerce.  Its business address and telephone number are 554 6th Street, New Westminster, British Columbia Canada V3L 3B5. Tel: (604) 665-7925. 1.C. Auditors On June 30, 2007, the auditors for the Company were Berris Mangan, Chartered Accountants of 1827 West 5th Avenue, Vancouver, British Columbia, Canada, V6J 1P5 (previously known as BME + Partners). On August 31, 2007, the Company changed auditors, due to a decision by Berris Mangan to focus its practice on companies with Canadian reporting responsibilities that are listed on the Toronto Stock Exchange. On the same date the Company appointed HLB Cinnamon Jang Willoughby, Charted Accountants (CJW) of 1827 West 5thAvenue Vancouver, BC, Canada, V6J 1 P5 on an interim basis to conduct the year-end audit. CJW was appointed as the Companys auditor at the Annual General Meeting held on December 12, 2007.  ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE  No disclosure necessary.   ITEM 3. KEY INFORMATION 3.A.1. Selected Financial Data The selected financial data should be read in conjunction with the financial statements and other financial information included elsewhere in the Annual Report.  The Company has not declared any dividends since incorporation and does not anticipate that it will do so in the foreseeable future.  The present policy of the Company is to retain all available funds for use in its operations and the expansion of its business.  Table No. 3 is derived from the audited financial statements of the Company, which have been prepared in accordance with generally accepted accounting principles in Canada (Canadian GAAP), which are substantially the same as principles applicable to United States (US GAAP) and practices prescribed by the United States Securities and Exchange Commission (SEC), except the practices described in footnotes to the audited financial statements for the years ended June 30, 2007, 2006, 2005, 2004, and 2003.  Alda Pharmaceuticals Corp. 2007 20F/A Page 6------------------------------------------------------------------------------------------------------------------------------------------------   Table No. 3 Selected Financial Data (CDN$) Year
Ended
2007Year
Ended
2006Year
Ended
2005Year
Ended
2004Year
Ended
2003CANADIAN GAAPRevenue256,243223,586239,271111,3630Net (Loss) for the Year(562,090)(378,301)(796,301)(731,479)(53,479)Basic Income (Loss) Per Share(0.02)(0.02)(0.06)(0.08)(0.02)Dividends Per Share00000Wtg. Avg. Shares (000)22,582,02617,857,70913,663,8569,027,1792,407,502Period-end Shares32,192,40420,800,40415,784,40412,784,4042,451,475Working Capital627,73033,169138,548415,167(49,304)Long-Term Debt00000Capital Stock2,658,8682,094,7701,856,2851,607,620279,309Shareholders Equity (Deficit)779,898157,368271,028800,222182,984Total Assets854,166216,872300,893830,764286,544US GAAPNet Loss(562,090)(378,301)(796,301)(731,479)(53,479)Loss Per Share(0.02)(0.02)(0.06)(0.08)(0.02)Shareholders Equity779,898157,368271,028800,222182,984Total Assets854,166216,872300,893830,764286,544    3.A.3.  Exchange Rates  In this Annual Report, unless otherwise specified, all dollar amounts are expressed in Canadian Dollars (CDN$).  The Government of Canada permits a floating exchange rate to determine the value of the Canadian Dollar against the U.S. Dollar (US$). Table No. 4 sets forth the exchange rates for the Canadian Dollar at the end of five most recent fiscal years ended June 30, 2007, the average rates for the period and the range of high and low rates for the period.  The data for each month during the most recent six months is also provided. For purposes of this table, the rate of exchange means the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York. The table sets forth the number of US Dollars required under that formula to buy one Canadian Dollar.   For example, where the number 0.8704 is quoted in the upper left hand number in the table, it means that it took on average in February 2006, 87.04 cents US to purchase one Canadian dollar.  For all periods presented, the Canadian dollar has been worth less than one US dollar.  Alda Pharmaceuticals Corp. 2007 20F/A Page 7------------------------------------------------------------------------------------------------------------------------------------------------   Table No. 4 U.S. Dollar/Canadian Dollar   PeriodAverageLowHighCloseOctober 20080.85530.77260.94260.8302September 20080.94600.92630.96730.9397August 20080.95640.93650.97530.9416July 20080.98990.97460.99840.9766June 20080.98680.97260.1.00580.9807May 20080.99810.98151.01581.0070April 20080.98860.97370.99750.9929March 20081.00030.97291.02060.9742February 20081.00190.98141.02891.0158January 20080.98780.96860.99050.9962Three Months Ended June 30, 20080.98900.97261.01580.9901Three Months Ended March 31, 20081.00100.96861.02890.9955Fiscal Year Ended June 30, 20080.99530.92981.09050.9898Fiscal Year Ended June 30, 20070.89040.85240.93600.8828Fiscal Year Ended June 30, 20060.85720.80240.90650.8602Fiscal Year Ended June 30, 20050.80640.74620.84740.8403Fiscal Year Ended June 30, 20040.71940.63290.77520.7752    3.B.  Capitalization and Indebtedness  Table No. 5 sets forth the capitalization and indebtedness of the Company as of June 30, 2007.  During the year ended June 30, 2007, the Company has completed two private placements of securities which increased the number of outstanding shares by  9,430,000 common shares and increased the number of outstanding share purchase warrants by  9,430,000 share purchase warrants.   1,430,000 warrants were exercisable until September 12, 2007 at an exercise price of $0.10 and 8,000,000 were exercisable until June 7, 2008 at an exercise price of $0.20 and, thereafter at a price of $0.30 per share until June 7, 2009. During the year ended June 30, 2007, 1,062,000 warrants were exercised by the holders at a price of $0.10 per unit for gross proceeds of $106,200.  Subsequent to June 30, 2007, 3,220,000 warrants were exercised by the holders at a price of $0.10 per unit for gross proceeds of $322,000. During the year ended June 30, 2007, the Company granted total of 3,530,000 options at an exercise price range of $0.10-0.12 to certain consultants, scientific advisors, employees, directors and senior officers of the Company.  During the year ended June 30, 2007, options granted to an employee to acquire 150,000 common shares of the Company were cancelled due to the employees departure.  900,000 options were exercised at an exercise price of $0.10 per option for gross proceeds of $90,000.  Subsequent to June 30, 2007, 100,000 options were exercised by the option holders at an exercise of $0.10 per unit for gross proceeds of $10,000.  Alda Pharmaceuticals Corp. 2007 20F/A Page 8------------------------------------------------------------------------------------------------------------------------------------------------  Table No. 5 Capitalization and Indebtedness As of June 30, 2007 _____________________________________________________________________________________  SHAREHOLDERS EQUITYCommon shares issued and outstanding32,192,404Share Capital$ 2,658,868Contributed Surplus-Warrants$ 553,627Contributed Surplus  Options$171,194Retained Earnings (deficit)$( 2,603,791)Net Shareholders Equity$ 854,166TOTAL CAPITALIZATIONStock Options Outstanding (2):2,480,000Warrants Outstanding (1):12,364,000Capital Leases:NoneGuaranteed DebtNoneSecured Debt:None (1)  Of the 12,364,000 warrants outstanding, 1,430,000 were exercisable until September 12, 2007 at an exercise price of $0.10, 2,934,000 were exercisable until December 22, 2007 at an exercise price of $0.10 and 8,000,000 were exercisable until June 7, 2008 at an exercise price of $0.20, and, thereafter at a price of $0.30 per share until June 7, 2009 (2)  See Table 11 for exercise prices and terms of these options. _____________________________________________________________________________________ 3.C.    Reasons for the Offer and Use of Proceeds No disclosure necessary. 3.D.   Risk Factors Risks pertaining to the Company: The Company's limited operating history makes it difficult to evaluate the Companys current business and forecast future results. The Company has been operating only since November, 2003 and has operating losses of $562,090, $380,026, and $798,028 in the years ended June 30, 2007, 2006 and 2005, respectively. This limited operating history and the varying amount of funds spent on activities such as patenting, trademark protection and product development and testing leads the Company to believe that period-to-period comparisons of its operating results may not be meaningful and that the results for any particular period should not be relied upon as an indication of future performance. For example, over the last three fiscal years, the revenues generated from the sale of T36® Disinfectant have been relatively consistent. In 2005 revenues were $239,271, decreased by 6.5% in 2006 to $223,586, most likely due to the timing of customer orders. Revenues increased again in 2007 by 15% to $256,243, a level that was 7% higher than 2005 likely due to the timing of customer orders and the introduction of the new T36® Hand Sanitizer. There is more variability in operating expenses which decreased from $642,224 for 2005 to $498,616 in 2006 and increased again to $662,958 in 2007. These decline in costs that were observed in 2006 were due to reductions in consulting fees paid to executives of the Company and to outside consultants, lower investor relations costs and a decline  Alda Pharmaceuticals Corp. 2007 20F/A Page 9------------------------------------------------------------------------------------------------------------------------------------------------  wages and benefits.  An impairment loss of $245,000 on intangible assets was claimed during the fiscal year of 2005 due to the revenues of the Company not matching the expectations that were established during the valuation for the Qualifying Transaction. In connection with the settlement of legal disputes, the Company recognized a net gain of $10,545 and $37,383 in fiscal years 2007 and 2006, respectively, with no such gain in 2005. In the future, the Company is intending to invest varying amounts in continued intellectual property protection, product development, product testing of therapeutic products and clinical trials. All of these discretionary activities depend on the availability of external funds. Since the Company cannot depend on being able to raise funds as needed for its planned activities, the expenditures will match the availability of external funds. Therefore, the levels of these discretionary expenditures are not predictable. Also, the Company has been working on new products that may be introduced to the market but the timing of such product introductions is never certain. As a result, the Company cannot predict its expenditures, revenues or losses with any certainty. However, since an ambitious program of product testing and registrations are planned, it is certain that the any funds that are raised will be invested in these activities and that losses will be incurred for the foreseeable future the magnitude of these losses cannot be predicted. The Company has no significant source of operating cash flow and failure to generate revenues in the future could cause the Company to go out of business. Based upon current plans to introduce T36® Disinfectant into additional markets in Canada and internationally, pursue the patent applications and regulatory approvals for the T36®technology, develop new products, maintain the Companys public listing on the TSX Venture Exchange and secure a listing in the US, the Company expects to incur operating losses in future periods. These loses will occur because there are continuing expenses associated with the marketing and production of the Companys products, research and development, intellectual property protection, registration of products with regulatory bodies, legal and accounting fees, the maintenance of its public listing and other expenses associated with running an operating business. The Company has a burn rate of approximately $45,000 per month. At this burn rate, the cash on hand of $356,127 as of June 30, 2007 will last approximately eight months and further fund raising will be required to continue operations. Also, the Company may not be successful in generating revenues in the future. Failure to generate revenues could cause the Company to go out of business. If the Company raises further funds through equity issuances, the price of its securities could decrease due to the dilution caused by the sale of additional shares. Additional funds raised by the Company through the issuance of equity or convertible debt securities will cause the Companys current shareholders to experience dilution and possibly lower the trading price of its shares.  Such securities may grant rights, preferences or privileges senior to those of the Companys common shareholders. The Company is not profitable and will not be profitable for the foreseeable future under its current development plan. The Company plans to issue further equity to raise funds as necessary to continue operations and fund its program of research and development, patent protection and regulatory approvals. As a result, an indeterminate amount of dilution of the Companys capital stock will occur. The Company has issued only 32,192,404 shares out of its authorized capital of an unlimited number of common shares, which could be dilutive and negatively affect the share price. Having an unlimited number of authorized but unissued common shares could allow the Companys Directors and Officers to issue a large number of shares without shareholder approval, leading to significant dilution of current shareholders and possible lowering of the share price. The Company could enter into debt obligations and not have the funds to repay these obligations. The Company does not have any contractual restrictions on its ability to incur debt and, accordingly, the Company could incur significant amounts of indebtedness to finance its operations. Any such indebtedness could contain covenants, which would restrict the Companys operations. The Company might not be able to repay indebtedness.  The Company does not plan on entering into any debt obligations in the next twelve months.  Alda Pharmaceuticals Corp. 2007 20F/A Page 10------------------------------------------------------------------------------------------------------------------------------------------------  The Company has a history of generating limited revenues and the continuing failure to generate further revenues could cause the Company to cease operations. The Company has no history of pre-tax profit and in the previous three years has had annual revenues for each of the years ended June 30 of $256,243 in 2007 $223,586 in 2006 and $239,271 in 2005. The Company sustained operating losses for each of the fiscal years ended June 30, 2007, 2006 and 2005 of $562,090, $380,026, and $798,028, respectively. The Company has sustained accumulated operating losses in its last audited year of operation in fiscal 2007 of $2,603,791. The continued operation of the Company will be dependent upon its ability to generate operating revenues and to procure additional financing. The Company may not be successful in generating revenues or raising capital in the future. Failure to generate revenues or raise capital could cause the Company to cease operations.  The auditors report to the shareholders, dated October 17, 2007, is expressed in accordance with Canadian reporting standards, which do not require a reference to conditions and events that cast substantial doubt on the Company's ability to continue as a going concern when these are adequately disclosed in the financial statements. In the United States, reporting standards for auditors require the addition of an explanatory paragraph when the financial statements are affected by conditions and events that cast substantial doubt on the Company's ability to continue as a going concern. Had the Companys financial statements been audited by US auditors, the Company may have received a going concern qualification. A going concern qualification, or the existence of a basis for such a qualification, could negatively affect the Companys ability to raise capital. As the Company is a Canadian company, it may be difficult for U.S. shareholders of the Company to effect service on the Company or to realize on judgments obtained in the United States. The Company is a Canadian corporation. A majority of its directors and officers are residents of Canada and a significant part of its assets are, or will be, located outside of the United States. As a result, it may be difficult for shareholders resident in the United States to effect service within the United States upon the Company, directors, officers or experts who are not residents of the United States, or to realize in the United States judgments of courts of the United States predicated upon civil liability of any of the Company, directors or officers under the United States federal securities laws. If a judgment is obtained in the U.S. courts based on civil liability provisions of the U.S. federal securities laws against the Company or its directors or officers, it will be difficult to enforce the judgment in the Canadian courts against the Company and any of the Companys non-U.S. resident executive officers or directors. Accordingly, United States shareholders may be forced to bring actions against the Company and its respective directors and officers under Canadian law and in Canadian courts in order to enforce any claims that they may have against the Company or its directors and officers. Nevertheless, it may be difficult for United States shareholders to bring an original action in the Canadian courts to enforce liabilities based on the U.S. federal securities laws against the Company and any of the Companys non-U.S. resident executive officers or directors. The Companys future performance is dependent on key personnel. The loss of the services of any of the Companys executives or Board of Directors could have a material adverse effect on the Company. The Companys performance is substantially dependent on the performance and continued efforts of the Companys executives and its Board of Directors. Dr. Terrance G. Owen is the President, Chief Executive Officer and a Director. Peter Chen is the Secretary, Chief Financial Office and a Director. Dr. Linda Allison, Dr. Ronald Zokol, Dr. William F. McCoy and Eugene Hodgson are independent Directors. Dr. Allison, Mr. Chen and Mr. Hodgson are members of the Audit Committee. The loss of the services of any of the Companys executives or Board of Directors could have a material adverse effect on the Companys business, results of operations and financial condition. There is no assurance that key personnel can be replaced with people with similar qualifications within a reasonable period of time. The Company currently does not carry any key person insurance on any of the executives or members of the board of directors. There are no contracts in place with any of the employees, officers or directors of the Company. The Company has not declared any dividends since its inception in 2000 and has no present intention of paying any cash dividends on its common shares in the foreseeable future. The Company has not declared any dividends since its inception in 2000, and has no present intention of paying any cash dividends on its common shares in the foreseeable future. The payment by the Company of dividends, if any, in the future, rests in the discretion of the Company's Board of Directors and will depend, among other things, upon the Company's earnings, its capital requirements and financial condition, as well as other relevant factors.  Alda Pharmaceuticals Corp. 2007 20F/A Page 11------------------------------------------------------------------------------------------------------------------------------------------------  The Companys future performance is dependent on key collaborators and a loss of any collaborators could have a material adverse effect on the Company by reducing or eliminating the ability of the Company to manufacture or sell its products.  The Company is dependent on Norwood Packaging Ltd. to manufacture its products to a standard that is accepted by Health Canada (Exhibit 4.b.). Although other manufacturers have been identified, they do not have the same familiarity as Norwood with the manufacturing of the Companys products. If the Company had to switch manufacturers there would be a start-up period in which sales would be lost and revenues would drop. An agreement with Fuzhou Xinmei Biotech Co. Ltd. (Fuzhou), which allowed manufacturing and marketing in Fujian province in China (Exhibit 4.c.)  has been transferred to He-Yi She Ye Limited (He-Yi) and expanded to cover marketing in all of China (Exhibit 4.g.). The relationship with He-Yi is important because registration and manufacturing of T36®Disinfectant in China depends on the successful completion of the required applications by He-Yi and acceptance of the registrations by the Chinese government agencies. At this time, the Company has no other agent working on its behalf in China. If He-Yi were to fail or go out of business, the Company would have to find another agent to represent its interests in China. This would delay the registrations in China and lead to reduced revenue expectations. The loss of  the services of Phigenics, LLC to assist with US product registrations would necessitate finding another collaborator to assist with registrations of the Companys products with the Environmental Protection Agency (EPA) of the US  and with the marketing of the Companys products to the customer base served by Phigenics. There is no assurance that the patent applications filed for theT36® technology or for other products will be approved, and failure to obtain such approvals could leave the Company with no protection for its intellectual property and reduced sales. Patent protection of the T36® technology is very important to the Companys current and future products because the T36® Disinfectant technology is the basis for its products. Although patents have been allowed in the United States, and in China, there is also no assurance that future patent applications will be successful.  A lack of patent protection would significantly alter the competitive environment and possibly allow competitors to infringe on the technology of the Companys business. Reduced revenues and lack of future products could result from such infringement. There is no assurance that the Company will be able to secure the funds needed for future development, and failure to secure such funds could lead to a lack of opportunities for growth. Many of the Companys products require laboratory testing that could cost as much as $100,000 per product or more to establish toxicity, efficacy and analytical methods. This testing is required in order to obtain required regulatory approvals from Health Canada and the EPA in the US.  A lack of funds would impair the ability of the Company to complete such tests.  A lack of funds would also impair the Companys ability to establish marketing and sales plans once the products have been approved for sale.  If adequate financing is not available when required, the Company may be required to delay, scale back or eliminate various activities and may be unable to continue in operation.  The Company may seek such additional financing through debt or equity offerings, but there can be no assurance that such financing will be available on terms acceptable to the Company or at all.  Any equity offering will result in dilution to the ownership interests of the Companys shareholders and may result in dilution to the value of such interests. There is no assurance that research and development being conducted by the Company to create new products will be successful. The Company is conducting research and development on new products, but the outcomes of research and development are never certain. For example, there is no assurance that any new products will be developed or that any new products that do result will have a competitive advantage or market acceptance, will not be superseded by the new products of competitors, will not infringe on the patents of other companies or that other companies will not develop products that infringe on patents obtained by the Company for its new products. The Company has completed the formulations for new products but still needs to conduct the toxicity and efficacy tests and establish the analytical methods required to obtain regulatory approvals from Health Canada and the EPA and FDA in the US.  Alda Pharmaceuticals Corp. 2007 20F/A Page 12------------------------------------------------------------------------------------------------------------------------------------------------  The Company and the Companys products have limited brand awareness which limits the ability of the Company to gain credibility from prospective customers and to sell its products into new markets. Market knowledge of the Companys name is limited. The Company will need to devote considerable resources to educate new markets about the products the Company offers.  In establishing new markets, the Company will be competing with companies that are potentially already entrenched in such markets or may be better funded than the Company. The ability of the Company to raise brand awareness will depend on its ability to raise the money required to undertake such an intensive marketing effort. As noted elsewhere, there is no assurance that the Company can raise funds required for such an investment in marketing.  The Company has limited sales and marketing experience and can provide no assurance that the Company can keep its current customers or gain new ones. The Company has limited experience in marketing and selling its products.  The Company had two sales and marketing people until February 2, 2007, one with just over two years of experience with the Company and no prior sales experience, and the other with three years experience with the Company and no prior sales experience in pharmaceutical or disinfectant products. With the departure of the more experienced sales and marketing person, the Company has one person in sales and marketing. The Company will have to expend substantial funds to promote and develop its products. The Companys success in this regard will depend on the quality of its products and its ability to develop and implement an effective sales and marketing strategy. Current plans call for the expenditure of $ 235,000 over the next 18 months for marketing activities.  Failure to achieve these objectives will have a material adverse effect on the Company and on its results of operations and financial condition. Conflicts of interest may exist for Directors and Officers which may inhibit their ability to act in the best interests of the Company and its shareholders leading to possible impairment of the Companys ability to achieve its business objectives. The directors and officers of the Company will not be devoting all of their time to the affairs of the Company. The directors and officers of the Company are directors and officers of other companies. The directors and officers of the Company will be required by law to act in the best interests of the Company.  They will have the same obligations to the other companies in respect of which they act as directors and officers.  Discharge by the directors and officers of their obligations to the Company may result in a breach of their obligations to the other companies and, in certain circumstances, this could expose the Company to liability to those companies.  Similarly, discharge by the directors and officers of their obligations to the other companies could result in a breach of their obligation to act in the best interests of the Company.  Such conflicting legal obligations may expose the Company to liability to others and impair its ability to achieve its business objectives. Terrance Owen has been the Secretary of Bi-optic Ventures Inc., a company listed on the TSX Venture Exchange, since September, 2002 and a Director of this same company since September, 2006. As a non-management Officer and Director of Bi-Optic Ventures Inc., Terrance Owen spends approximately four hours per month on the business of Bi-Optic Ventures Inc. since Bi-Optics is operationally inactive while seeking acquisition prospects. Terrance Owen controls a company, Duft Enterprises Corp., that owns the building in which the Company is located and the Company pays rent to Duft Enterprises Corp. Peter Chen is not a Director or Officer of any other company nor has Mr. Chen spent any time on other companies or on financial consulting for other companies since the Company completed the Qualifying Transaction in November, 2003. Neither Peter Chen nor Terrance Owen is a Director or Officer of any companies that compete with or provide services that are similar to those of the Company. Management of the Company can, through their stock ownership in the Company, influence all matters requiring approval by the Companys shareholders. Management of the Company as at June 30, 2007, directly own 1,587,500 shares, which was 4.93% of the Company's issued and outstanding common shares at that date. These shareholders, if acting together, will be able to significantly influence all matters requiring approval by the Company's shareholders, including the election of directors and the approval of mergers or other business combination transactions. Management may not make decisions that will maximize shareholder value and may make decisions that will contribute to or cause the entrenchment of management.  Alda Pharmaceuticals Corp. 2007 20F/A Page 13------------------------------------------------------------------------------------------------------------------------------------------------  The value and transferability of the Company shares may be adversely impacted by the limited trading market for the Companys common shares.  No assurance can be given that a market for the Companys common shares will be quoted on an exchange in the U.S. or on the NASD's Over the Counter Bulletin Board. The Companys common shares may be subject to illiquidity and investors may not be able to sell their shares in a timely manner. The value and transferability of the Company shares may be adversely impacted by the penny stock rules. The sale or transfer of the Company common shares by shareholders in the United States may be subject to the so-called "penny stock rules." Under Rule 15g-9 of the Exchange Act, a broker or dealer may not sell a "penny stock" (as defined in Rule 3a51-1) or effect the purchase of a penny stock by any person unless: (a) Such sale or purchase is exempt from Rule 15g-9; (b) Prior to the transaction the broker or dealer has (1) approved the person's account for transaction in penny stocks in accordance with Rule 15g-9, and (2) received from the person a written agreement to the transaction setting forth the identity and quantity of the penny stock to be purchased; and (c) The purchaser has been provided an appropriate disclosure statement as to penny stock investment. The SEC adopted regulations generally define a penny stock to be any equity security other than a security excluded from such definition by Rule 3a51-1. Such exemptions include, but are not limited to (1) an equity security issued by an issuer that has (i) net tangible assets of at least $2,000,000, if such issuer has been in continuous operations for at least three years, (ii) net tangible assets of at least $5,000,000, if such issuer has been in continuous operation for less than three years, or (iii) average revenue of at least $6,000,000 for the preceding three years; (2) except for purposes of Section 7(b) of the Exchange Act and Rule 419, any security that has a price of $5.00 or more; and (3) a security that is authorized or approved for authorization upon notice of issuance for quotation on the NASDAQ Stock Market, Inc.'s Automated Quotation System. It is likely that the Companys common shares, assuming a market were to develop in the US, will be subject to the regulations on penny stocks. Consequently, the market liquidity for the common shares may be adversely affected by such regulations limiting the ability of broker/dealers to sell the Companys common shares and the ability of shareholders to sell their securities in the secondary market in the US. Moreover, the Company shares may only be sold or transferred by the Company shareholders in those jurisdictions in the US in which an exemption for such "secondary trading" exists or in which the shares may have been registered. For example, if trading on the OTC Quality Exchange under a Mergent Manual registration, the Companys shares would not be eligible for trading in all 51 states. There is no market for the Companys common shares in the United States. The Company is not listed on any stock exchange in the United States nor is there any guarantee that the Company will be listed on any stock exchange in the United States in the future. As a result, there is no market for the Companys common shares in the United States and there is no guarantee that there will be a market for the Companys common shares in the United States Risks Pertaining to the Industry Registration of products may not occur in a timely manner which could lead to delays in product introductions, reduced revenue expectations and extra costs to conduct further tests to satisfy regulatory agencies. Government agencies, such as the EPA and the Food and Drug Administration (FDA) in the United States and Health Products and Food Branch in Canada, need to provide approvals of the Companys products prior to any sales of these products.  To obtain such approvals, the Company must submit extensive amounts of information on the efficacy, toxicology, carcinogenicity, mutagenecity and other testing of the products that it is trying to register. After all of the information is provided, the agencies can request supplemental information and further testing. Once all of the requirement for documentation is satisfied, the agencies can take up to 24 months or longer to provide approvals for the Company to market its products.  Significant delays could lead to slower revenue growth than anticipated.  In addition, regulatory delays can allow time for competitors to devise strategies to prevent or reduce market penetration.  There is no assurance that government agencies will accept for registration any of the Companys products.  Alda Pharmaceuticals Corp. 2007 20F/A Page 14------------------------------------------------------------------------------------------------------------------------------------------------  There is a risk that the Companys intellectual property infringes upon the rights of other companies, which could lead to reduced revenues, reduced margins due to sanctions against the Company, outright withdrawal or prohibition of products or trademarks  from the market and significant costs for legal defense against infringement claims, re-branding of products and revised marketing materials. The Company is unaware of any infringement claims being made against the Company or its products or processes, except that JohnsonDiversey, Inc. (JDI) took action against the Company for use of the trademark, Viralex, which JDI claimed infringed on their trademark, Virex.  This action was settled by the Company accepting a one-time payment of US$30,000 and agreeing to cease to use the name.  The Company instead now uses the trademark T36® for its products and this trademark is registered in both Canada and the US. The change of name from Viralex to T36®caused some confusion among the customers of the Company and required additional expenditures to be made for new labels, packaging and marketing materials, as well as mailings to advise customers of the change. There was no noticeable effect on overall sales on a quarterly basis beyond normal fluctuations. There can be no assurances that other third parties will not assert infringement claims in the future or require the Company to obtain a license for the intellectual property rights of such third parties.  There can be no assurance that such a license, if required, will be available on reasonable terms or at all.  If the Company does not obtain such a license, it could encounter delays in the introduction of products or could find that the development, manufacture or sale of products requiring such a license could be prohibited. There is a risk that earlier inventionsmay exist that invalidate the Companys patent applications so that the Company may not be able to sell any infringing products. Since patent applications are maintained in secrecy for a period of time after filing, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, the Company cannot be certain that it was the first creator of inventions covered by pending patent applications, or that it was the first to file patent applications for such inventions. The Company might have to participate in interference proceedings in the U.S. Patent and Trademark Office to determine priority of invention, at substantial cost. There can be no assurance that the Companys patents, if issued, would be held valid or enforceable by a court. The Company has patents allowed in the United States and China and patent applications filed in the European Union, Canada, Australia and Singapore. These patent applications seek intellectual property protection for the basic formulation of the T36®Disinfectant and the method for making it. There may be limited ability to defend the patents if and when they are issued, leading to loss of sales that might otherwise be realized if the Company was in a position to defend its patents. Litigation among pharmaceutical companies can be intense and costly.  The Company might not have the financial ability to defend its patents, if issued, against larger industry players.  Litigation may be necessary to enforce patents issued or assigned to the Company, or to determine the scope and validity of a third party's proprietary rights.  Additionally, there can be no assurances that the Company would prevail in any such action.  An adverse outcome in litigation or as part of an interference or other proceeding in a court or patent office could subject the Company to significant liabilities, require disputed rights to be licensed from other parties or require the Company to cease using certain technology or products, any of which could have a material adverse effect on the Companys business. The market for disinfectant products is competitive and well established with a number of large, multinational, widely recognized companies with significant financial and marketing resources selling, and possibly developing, similar products. Competitors are already well established in the market for disinfectant products.  The introduction of a new product into this existing market could be met with aggressive marketing, price cutting and distribution impediments by competitors.  To obtain market share, the Companys business must penetrate a market with established competitors and obtain sufficient recognition to be able to displace the existing disinfectant products.  Substantial funds will have to be spent on marketing and education to achieve these objectives.  Competitors may be developing new technologies and new products that will offer significant improvements over existing products, including those offered by the Company. There can be no assurance that others will not independently develop similar products, duplicate any of the Companys products or, if patents are issued to the Company, design around such patents.  There can be no assurance that a competitor's technology or product would be found to infringe the Companys patents. Key competitors are Germiphene Corporation, Virox Technologies, Inc., JohnsonDiversey Inc., Advanced Sterilization Products and Metrex Research Corporation. All of these companies are well established and sell disinfection products into the same markets served by the Company.  Alda Pharmaceuticals Corp. 2007 20F/A Page 15------------------------------------------------------------------------------------------------------------------------------------------------  The Companys T36® Disinfectant is composed of various chemicals that may pose risks due to flammability and possible health risks. One of the main components of T36® Disinfectant is ethanol, which is flammable and, at a concentration of 95%, has a flash point (the minimum temperature at which the liquid produces a sufficient concentration of vapour above it that it forms an ignitable mixture with air) of 17 oC. T36® contains 70% ethanol which raises the flash point of T36® Disinfectant to 24oC. The transport and storage of T36® Disinfectant can pose a fire hazard if shipped or stored in sufficient quantities. The Company uses an independent warehousing company to store and ship T36® Disinfectant. The warehouse is fully equipped with fire suppression equipment according to the relevant regulations established by the municipal, provincial and federal governments. T36® Disinfectant is shipped by ground only in cases of 4 bottles holding 4 litres each or 12 bottles holding 0.48 litres. In these quantities, T36® Disinfectant is not classified as a Dangerous Good under Sections 1.15, 1.16 and 1.17 of the Transportation of Dangerous Goods Act administered by Transport Canada. As a result, no special regulations apply to the shipping of T36® Disinfectant by ground within Canada. There is no guarantee that special shipping regulations will not be applied to shipments of T36® Disinfectant in the future or in other jurisdictions, such as the United States.  Two potentially toxic components of T36® Disinfectant are present in low concentrations compared to their LD50 levels (the amount of the substance that kills 50% of the test population of experimental animals when administered as a single dose). O-phenylphenol (OPP) in pure crystalline form is considered to be a possible carcinogen and eye contact can cause severe irritation or burns with possible eye damage (Concentration in T36® Disinfectant = 2,800 ppm, oral LD50 = 2,480 mg/kg in rats). For some individuals, o-phenylphenol can also irritate the skin. Benzalkonium chloride (BZK), supplied as a 50% solution in water, has been reported to cause allergic reactions and the swelling of the mucosa when used as nose sprays on a continuous, long-term basis by sensitive users (Concentration in T36® Disinfectant = 2,000 ppm, oral LD50 = 300 mg/kg in rats). The Company does not directly handle, store, use or dispose of OPP or BZK in pure form but only in their highly diluted form in T36® Disinfectant. Further, because the denatured alcohol that contains Bitrex to prepare T36® Disinfectant, the consumption of significant amounts of T36® Disinfectant is not possible. Therefore, it is unlikely that anyone can be poisoned or otherwise harmed through the proper use of T36® Disinfectant as instructed by the Company.  Toxicology studies conducted for the company by Product Safety Labs (PSL), located in Dayton, New Jersey, have confirmed  that T36® Disinfectant has no harmful effects on animals except as reported below by PSL: · Acute inhalation (rat): LC50 > 2020 mg/m3. Difficulty breathing, irregular respiration, lethargy and discharge from nose and eyes reported. · Acute oral (rat): LD50 > 5000 mg/kg. Lethargy and hunched posture reported. · Acute dermal (rat): LD50 > 2000 mg/kg. No systemic effects observed. · Effects not observed but possible based on individual ingredients may include: ataxia, loss of coordination, drowsiness, intoxication, nausea and vomiting. However, T36® Disinfectant  is classified as a moderate eye irritant.  Although T36® Disinfectant is not measurably toxic if used as directed, it is possible that regulations against these chemicals may become more restrictive and affect the ability of the Company to market its products in certain jurisdictions without additional warning labels. None of the chemicals present in T36® pose a serious threat to the environment and are biodegradable.  However, given the attention that any chemicals may attract from environmental groups, it is possible that negative publicity about these chemicals could affect the ability of the company to market itsproducts in certain jurisdictions. There are persuasive arguments and credible scientific evidence that is available to support the safety of T36® Disinfectant, but such an educational effort on the part of the Company would require funds to be spent and would affect the profitability of the Company.  Alda Pharmaceuticals Corp. 2007 20F/A Page 16------------------------------------------------------------------------------------------------------------------------------------------------  The Company has a limited number of customers and is dependent on a few key accounts to maintain its current levels of sales. The key customers for which sales account for more than 10% of total revenues are: · Esthetics Plus, Inc.: A distributor to the beauty market with a contract (Exhibit 4.h.) that renews on an annual basis. The terms of the contract are summarized below in Section 10.C, Material Contracts. · Sinclair Dental Limited: A distributor to the dental market and a customer of the Company for nearly 4 years, · The Stevens Company Limited: A distributor to the scientific and medical markets and a customer of the Company for nearly 4 years, VWR International: A distributor to the laboratory market and customer of the Company for nearly 4 years and · Product Distribution Centre: A distributor that is owned by the provincial government of BC, supplies the provinces public sector consumers within BC and a customer of the Company for nearly 4 years. The Company currently sells its T36® Disinfectant through these distributors and is also planning on introducing new products, such as the T36® "Ready to Use" Disinfectant Cleaner, T36® Disinfectant Cleaner CONCENTRATE, and the corresponding wipes through these same distributors. The current sales and the plans to introduce the new products through these distributors would be disrupted if any of these distributors stopped representing the Company. The result would be a reduction in the Companys revenues until new distributors could be found. It is possible that new distributors could not be found and the Company would have to try to sell its products directly to the end users, leading to a significant increase in marketing and sales costs even if the sales levels could be regained. ITEM 4. INFORMATION ON THE COMPANY 4.A.   History and Development of the Company  Capital Pool Company  The Company was incorporated by registration of its Memorandum and Articles under the BC Companies Act on May 30, 2000 under the name Duft Biotech Capital Ltd. and was classified as a Capital Pool Company (CPC) on the TSX Venture Exchange. Under the policies of the TSX Venture Exchange, the principal business of a CPC is to identify and evaluate opportunities for acquisition. The completion of such an acquisition is referred to as a Qualifying Transaction. A CPC does not carry on any business other than the identification and evaluation of assets or businesses in connection with potential Qualifying Transactions, does not have business operations or assets other than seed capital and has no written or oral agreements for the acquisition of an asset or business at the time of formation.  A Qualifying Transaction, pursuant to the policies of the TSX Venture Exchange, is a transaction whereby a capital pool company: (a) Issues or proposes to issue, in consideration for the acquisition of significant assets or businesses, common shares or securities convertible, exchangeable or exercisable into common shares, which, if fully converted, exchanged or exercised would represent more than 25 percent of its common shares issued and outstanding immediately prior to the issuance; (b) Enters into an arrangement, amalgamation, merger or reorganization with another issuer with significant assets, whereby the ratio of securities which are distributed to the security holders of the capital pool company and the other issuer results in the security holders of the other issuer acquiring control of the resulting entity; or (c) Otherwise acquires significant assets other than cash.  Alda Pharmaceuticals Corp. 2007 20F/A Page 17------------------------------------------------------------------------------------------------------------------------------------------------   Qualifying Transaction On November 13, 2003, the Company completed its Qualifying Transaction, which was the acquisition of the assets of API, a private company founded in 1996 and since renamed 513947 BC Ltd. (513947). The transaction was approved by the TSX Venture Exchange as a valid Qualifying Transaction. The Company purchased the assets of API with 3,711,263 shares of the Company valued at 20 cents per share, for a total share value of $742,252.60, plus forgiveness of loans and accrued interest of  $57,747.40 advanced to API by the Company prior to completion of the Qualifying Transaction. The total transaction price of the Qualifying Transaction to the Company was therefore $800,000. The Company purchased only the assets and not the liabilities of API except for the trademark litigation undertaken by JohnsonDiversey Inc. against API. This litigation was subsequently settled and is discussed elsewhere. As a result of the asset purchase, API became the registered owner of the shares of the Company. The Company also acquired the intellectual property and $17,500 worth of inventory from API. The intellectual property consisted of one patent application, #PCT/CA2002/001284, A wide spectrum disinfectant, filed on August 20, 2002 under the Patent Cooperation Treaty (PCT), described in more detail below. two Drug Identification Numbers (DINs, i.e.,02245056 for T36® Disinfectant under its previous name, Spritz and 02231344 for the same product renamed, Viralex and subsequently renamed to T36® Disinfectant),  provided to the Company by Health Canada and the pending trademarks for Viralex, T36 and a logo displayed with the name, ALDA Pharmaceuticals. (described under Trademarks in Section 4.B. Business Overview), customer lists and contacts, products under development (also described in 4.B. Business Overview), marketing materials, technical bulletins, and instructions for customers and technical studies. The agreements that still remain in effect as a result of the asset purchase are the appended Voting Agreement and the Non-Competition Agreement.  Voting Agreement (Exhibit 3.)  The parties to the Voting Agreement, dated November 13, 2003 and established as a condition of completing the Qualifying Transaction, are API, Allan Shapiro (Shapiro), Michael Wilby (Wilby), the Company, Terrance Owen (Owen), Peter Chen (Chen) and Bruce Schmidt (Schmidt).  Under the terms of the agreement, API, Shapiro and Wilby will vote their shares of the Company in favour of  the number of directors of the Company not to exceed six directors with one director being independent of API and the election of Owen, Chen and Schmidt as directors of the Company provided they have been nominated by the Company for election to the Board of the Company;  Until termination of this Agreement, the Company will nominate Owen, Chen and Schmidt for election to the Board at each Meeting provided each person consents to continuing as a director of The Company, is not then prohibited by law from serving as a director of The Company and that each nomination and election is acceptable to the TSX Venture Exchange and all other applicable securities regulatory authorities.  Subject to restrictions imposed under applicable securities legislation, API, Shapiro or Wilby may sell shares of the Company through a stock exchange. If any of them proposes to sell in excess of 200,000 shares of the Company in an off-market transaction they will require the purchaser to agree to be bound by the terms of the Voting Agreement.  If a take-over bid or other offer is made to shareholders of the Company by an arms-length third party for all or a portion of the shares of The Company, API, Shapiro and Wilby will be free to tender to such bid or offer any shares owned by them and will not be required to comply with the selling restrictions described above.  The Voting Agreement will terminate with respect to Wilby, at the earlier of: · such time as API, Shapiro and Wilby collectively cease to hold, directly  or indirectly, less than 10% of the issued voting shares of The Company; · such time as Wilby ceases to hold directly or indirectly, or control at least 5% of the issued  voting shares of The Company; and · 5 years from the date of the execution and delivery of this Agreement.  Alda Pharmaceuticals Corp. 2007 20F/A Page 18------------------------------------------------------------------------------------------------------------------------------------------------   The Voting Agreement will not terminate with respect to API and Shapiro, except with the consent of the TSX Venture Exchange. As of June 30, 2007, the Voting Agreement is no longer in effect for Wilby since his personal shareholdings are below 5% of the issued voting shares of the Company.  On November 1, 2004, the Voting Agreement was amended. The parties to the Amendment are API, Shapiro, Wilby, the Company, Owen, Chen and Schmidt.  The Amendment was entered into because of the name changes undertaken by the Company and API after completion of the Qualifying Transaction and the resignation of Schmidt as a director of the Company. The Amendment also changed references to Owen, Chen and Schmidt to Owen Nominee, Chen Nominee and Schmidt Nominee, respectively, so that, if any one of Owen, Chen or Schmidt does not consent to being nominated as a director of APC, another person acceptable to the TSX Venture Exchange and to the other nominees would become a party to the Voting Agreement. On October 4, 2004, Eugene Hodgson was appointed as a director and became the Schmidt nominee on completion of the Amendment.  Escrow Agreement  An Escrow Agreement, dated November 13, 2003, was automatically terminated on November 14, 2006 due to the release of all remaining escrowed securities on that date.  Non-Competition Agreement (Exhibit 4.i.) The parties to the Non-Competition Agreement, dated November 13, 2003 and established as a condition of completing the Qualifying Transaction, are API, Shapiro and the Company.  Under the terms of the Agreement, API and Shapiro agree that neither Shapiro nor API will compete with the Company in any way. In the case of API, the Agreement expired after one year on November 13, 2004. In the case of Shapiro, the Agreement stays in place while Shapiro provides services for the Company in any capacity and for a period of one year after his services for the Company come to an end. Competition, as defined in the Agreement, includes, but is not limited to, the solicitation of customers or the sale of any products or services that are in any way similar to those offered by the Company or inducement of any employees of the Company to leave the Company. Shapiro agrees that any breach of the agreement by him could cause irreparable harm to the Company and that the Company can take any action that it deems necessary to end the breach and be compensated for the breach.  Change of Business. As a consequence of completing the Qualifying Transaction, The Company entered into the business of developing and marketing disinfectant products. On November 26, 2003 the Company changed its name to ALDA Pharmaceuticals Corp. The Company is still a British Columbia, Canada The head office of the Company is located at 635 Columbia Street, New Westminster, British Columbia, Canada, V3M 1A7. The Companys telephone number is (604) 521-8300. The contact person is: Mr. Terrance Owen, President and CEO or Mr. Peter Chen, CFO and Secretary. The Companys common shares have been listed for trading on the TSX Venture Exchange since July, 2001.   Alda Pharmaceuticals Corp. 2007 20F/A Page 19------------------------------------------------------------------------------------------------------------------------------------------------  Financings  The Company has financed its operations since inception through funds raised in a series of private placements of common shares:  Fiscal YearNature of Share IssuanceNumber of SharesAmount ($)Fiscal 2001Private Placement @ $0.0851,176,475$100,000.38Fiscal 2002Canadian Prospectus Offering (IPO) @$0.171,200,000$204,000.00Fiscal 2003Brokers Warrant Shares on Canadian Prospectus Offering (IPO) @ $0.17150,000$25,500.00Fiscal 2004Private Placement @ $0.15346,666$52,000.00Private Placement @ $0.206,200,000$1,240,000.00Fiscal 2005Private Placement @ $0.103,000,000$300,000.00Fiscal 2006Private Placement @$0.053,916,000$195,800.00Private placement @ $0.051,100,000$55,000.00Fiscal 2007Private placement @ $0.051,430,000$ 71,500Private placement @ $0.108,000,000$800,000  4.B. Business Overview  The Company was established in order to develop and commercialize disinfectant products.  The Company has called the disinfectant technology T36® Disinfectant.  T36®Disinfectant is a mixture of ethanol, o-phenylphenol, benzalkonium chloride and other ingredients (including lemon fragrance and water).  All of these component chemicals are bio-degradable. The Company is attempting to patent or secure proprietary protection for the specific combination of these products although the ingredients are all common chemical compounds. During its first five years, Companys primary focus has been on product development. T36® Disinfectant The Companys first product, a surface disinfectant called Viralex and subsequently renamed T36®Disinfectant, was launched in September of 2001. It is being sold primarily to (i) First Responder organizations including ambulance, fire fighters and police forces in Canada, (ii) dental clinics, and (iii) beauty and hair care salons and spas. Based on the efficacy and toxicology studies described below, T36®Disinfectant has been approved by Health Canada for use on any hard, inanimate non-porous surfaces.  This includes, but is not limited to, counter tops, cutting boards, sinks, tubs, walls, floors, windows, mirrors, scissors, nail clippers and other equipment used in beauty salons and spas, dental mirrors and other equipment in dental offices, and equipment used by firefighters, police and paramedics. T36® Disinfectant is also approved by the Canadian Food Inspection Agency (CFIA) for use in restaurants and other facilities where food is prepared. Efficacy studieson T36® Efficacy studies refer to proving a drug's effectiveness (in this case as a disinfectant) in producing a desired result (bactericide, virucide, fungicide or tuberculocide). In studies conducted by independent laboratories in Canada and the United States, T36®Disinfectant has demonstrated efficacy against bacteria, fungi and viruses. The types of surfaces tested were hard, non-porous surfaces unless otherwise noted.  Alda Pharmaceuticals Corp. 2007 20F/A Page 20------------------------------------------------------------------------------------------------------------------------------------------------  An efficacy study, dated February 10, 1997, was conducted by British Columbia Research Inc. (Vancouver, Canada) under the supervision of Dr. Ernie Lee. The  organisms tested were four strains of bacteria (Staphylococcus epidermis, Pseudomonas aeruginosa, Serratia marcescens, and Mycobacterium tuberculosis) one strain of yeast (Candida albicans), spores from one strain of fungus (Aspergillus fumigatus) and two strains of viruses (Herpes Simplex Virus-1 and Poliovirus-1) in compliance with test standards accepted by Health Canadas Therapeutic Product Directorate. Twenty five replicates of each organism at low levels, ranging from 38 to 177 cfus/ml (colony forming units/ml) were dried on microscope cover slips and exposed to T36® Disinfectant for varying times. The studies demonstrated that T36® Disinfectant was 100% effective against all five organisms after 10 minutes or longer contact times. At shorter contact times, the kill rate for all 5 organisms ranged from 95.5% to 97.2% after a 1 minute exposure and 98.7 and 99.0% after a 5 minute exposure. 1. An efficacy study, dated June 6, 1997, was conducted by Dr. Richard Stokes of the University of British Columbia in conjunction with the British Columbia Childrens Hospital.  Twenty replicates of Mycobacterium tuberculosis at approximately 107cfus/ml were dried on microscope cover slips and exposed to T36® Disinfectant for varying times. The studies demonstrated that the kill rate was 99.99997% (a reduction of log10 = 6.46) and 99.99998% (a reduction of log10 = 6.59)  after a 10-minute exposure. The requirement for a disinfectant to be designated as Tuberculocidal by Health Canada is a log10reduction of 6.0 or greater. 2. Efficacy studies were conducted by Viromed Biosafety Laboratories of Minneapolis, Minnesota, and completed on February 23, 2000. The organisms tested were Staphylococcus aureus, Pseumomonas aeruginosa, Salmonella choleraesuis, Human Immunodeficiency Virus Type I, Herpes simplex Virus Type 1, Trichophyton mentagrophytesand Poliovirus Type 1, in compliance with test standards accepted by the Environmental Protection Agency (EPA) of the United States. · For each of the bacteria, Staphylococcus aureus, Pseumomonas aeruginosa, Salmonella choleraesuis, 180 replicates at 6.1 x106 cfu/ml (log10 = 6.79), 1.9 x 106 cfu/ml (log10 = 6.28) and 1.7 x 104 cfu/ml (log10 = 4.23), respectively, were dried on microscope slides and exposed to T36® Disinfectant for 3 minutes. For both Staphylococcus aureusandPseumomonas aeruginosa, growth was observed on only 1 replicate out of 180. For Salmonella choleraesuis, none of the 180 replicates showed any growth. These results met the requirement that no more than 1 replicate out of 60 can show growth and T36® Disinfectant was deemed to demonstrate efficacy against all three bacteria. · For Human Immunodeficiency Virus Type I, six replicates at 1.77 x105 cfu/ml (log10 = 5.25), were dried on the bottom of Petri dishes. After being exposed to T36® Disinfectant for 3 minutes, none of the replicates showed any viral activity and T36® Disinfectant was deemed to demonstrate efficacy against HIV. · ForHerpes simplex Virus Type 1, six replicates at 5.6 x106 cfu/ml (log10 = 6.25), were dried on the bottom of Petri dishes, After being exposed to T36® Disinfectant for 3 minutes, none of the replicates showed any viral activity and T36® Disinfectant was deemed to demonstrate efficacy against the Herpes virus. · ForPoliovirus Type 1, six replicates at 5.6 x105 cfu/ml (log10 = 5.75), were dried on the bottom of Petri dishes. After being exposed to T36® Disinfectant for 3 minutes, none of the replicates showed any viral activity and T36® Disinfectant was deemed to demonstrate efficacy against the Polio virus. · For the fungus, Trichophyton mentagrophytes, twenty replicates at 4.6 x104 cfu/ml (log10 = 4.66), were dried on microscope slides. After being exposed to T36® Disinfectant for 3 minutes, none of the replicates showed any viral activity and T36® Disinfectant was deemed to demonstrate efficacy against Trichophyton mentagrophytes.  The above studies demonstrated that T36®Disinfectant was effective in inactivating polio viruses within 3 minutes and tuberculosis mycobacteria within 5 minutes. Polio and tuberculosis are benchmark micro-organisms because they are among the most difficult to kill with disinfectant products. Efficacy against polio and tuberculosis demonstrates a high level of disinfection capability. In order to make a virucidal claim and a tuberculocidal claim, a disinfectant product must demonstrate its ability to destroy the poliomyelitis type 1 virus, andMycobacterium bovis or tuberculosis mycobacteria within a specified time. This is mandated in Canada by the Canadian General  Alda Pharmaceuticals Corp. 2007 20F/A Page 21------------------------------------------------------------------------------------------------------------------------------------------------  Standards Board, Assessment of Efficacy of Antimicrobial Agents for Use on Environmental Surfaces and Medical Devices, CAN/CGSB -2.161-97, p.4, and the Therapeutic Products Programme Guidelines on Disinfectant Drugs, 1999 Edition, Appendix II on page 23.  In all of the testing described above, controls were used to validate the testing protocols. A positive test result required complete inactivation of the tested viruses and complete efficacy against the fungi and bacteria as required by the U.S. EPA for disinfectant label claims. The results from BCRI demonstrated efficacy in excess of Log10 4.0 (i.e. 10,000 times reduction in micro-organisms) in compliance of the standards required in Canada. The tuberculocidal studies demonstrated results in excess of Log10 6.0 (1,000,000 times reduction in micro-organisms).  Toxicology studies  Toxicology is the study of the adverse effects of chemical, physical or biological agents on living organisms and the ecosystem, including the prevention and amelioration of such adverse effects. The toxicology studies listed below were conducted in the United States by Product Safety Labs in East Brunswick, New Jersey, USA and completed in November, 1999.  · Acute Oral Toxicity Study in Rats - This test determines the amount of a substance that kills 50% of the test population of experimental animals when administered as a single dose. Five thousand milligrams of T36® Disinfectant per kilogram of bodyweight was administered orally to ten healthy rats. The animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days. Bodyweights were recorded prior to administration and again on Days 7 and 14. Necropsies were performed on all animals at terminal sacrifice. All animals survived and gained weight during the study. Following administration, most animals exhibited piloerection (erection of the hair), hunched posture and/or were hypoactive. Apart from one female that exhibited reduced fecal volume between Days 0 and 5, all affected animals recovered from the above symptoms. Based on the results of this study, the single dose acute oral LD50 of T36® Disinfectant is greater than 5,000 mg/kg of bodyweight · Primary Skin Irritation Study in Rabbits -  This test determines the potential for a substance to produce irritation after a single topical application. Five-tenths of a milliliter of T36® Disinfectant was applied to the skin of three healthy rabbits for 4 hours. Following exposure, dermal irritation was evaluated and no dermal irritation was noted at any dose site during the study. Based on the results of this study, T36® Disinfectant is classified as non-irritating to the skin. · Primary Eye Irritation Study in Rabbits - This test determinesthe potential for a substance to produce irritation from a single dose to the eye.One-tenth of a milliliter of T36® Disinfectant was placed into the right eye of six healthy rabbits. The treated eyes of three rabbits were rinsed with physiological saline after instillation. The eyes of the remaining three rabbits were not rinsed. The left eye remained untreated and served as a control. Ocular irritation was evaluated and, based on the results of this study,T36® Disinfectant is classified as moderately irritating to the unrinsed eye and severely irritating to the rinsed eye. · Acute Inhalation Toxicity Study in Rats - This test determinesthe potential for a substance to produce toxicity from a single exposure via the inhalation route. Ten healthy rats were exposed to T36® Disinfectant vapours in a closed chamber at a concentration 2.02 mg/L for 4 hours. The animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days thereafter. Bodyweights were recorded prior to exposure and again on Days 7 and 14. All animals survived exposure to the test atmosphere and gained bodyweight over the 14-day observation period. During the exposure, the rats exhibited ocular and nasal discharge, shortness of breath, irregular respiration, shallow respiration, hunched posture and hypoactivity. With the exception of ocular and nasal discharge and shallow respiration, similar clinical signs persisted in all animals upon removal from the exposure chamber. Some animals also developed noisy breathing, reduced fecal volume and/or a prone posture, but all rats recovered from these symptoms by Day 11 and appeared active and healthy for the remainder of the study. Necropsy findings at terminal sacrifice were unremarkable. Based on the results of this study, the single exposure acute inhalation LC50 of T36® Disinfectant is greater than 2.02 mg/L. · Acute Dermal Toxicity Study in Rats - This test determinesthehealth hazards likely to arise from a short-term exposure to a substance from a single topical application to the skin. Two thousand  Alda Pharmaceuticals Corp. 2007 20F/A Page 22------------------------------------------------------------------------------------------------------------------------------------------------  · milligrams per kilogram of bodyweight of T36® Disinfectant was applied to the skin of ten healthy rats for 24 hours. The animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days. Bodyweights were recorded prior to application and again on Days 7 and 14. Necropsies were performed on all animals at terminal sacrifice. All animals survived, gained weight and appeared active and healthy. There were no signs of gross toxicity, adverse pharmacologic effects or abnormal behavior. Gross necropsy findings at terminal sacrifice were unremarkable. Based on the results of this study, the single dose acute dermal LD50 of T36® Disinfectant is greater than 2,000 mg/kg of bodyweight.  Dermal Sensitization Study in Guinea Pigs - This test determinesthepotential for a substance to produce sensitization after repeated topical applications. T36® Disinfectant was topically applied to twenty healthy test guinea pigs, once each week for a three week induction period. Twenty-seven days after the first induction dose, a challenge dose of T36® Disinfectant at its highest non-irritating concentration (100%) was applied to a new site on each guinea pig. Ten untreated animals were maintained under the same environmental conditions and treated with T36® Disinfectant at challenge only. Approximately 24 and 48 hours after each induction and challenge dose, the animals were scored for erythema (redness of the skin).Based on the results of this study, T36® Disinfectant is not considered to be a contact sensitizer.  There were no p-values nor statistical significance employed in the studies because such measurements are not required by Health Canada or the EPA and, therefore, are not part of the standard protocols. There were no further requirements for the Company to undertake further studies.  T36®Disinfectants Heath Canada Drug Identification Number (DIN) is 02231344. There were no p-values nor statistical significance employed in the studies because such measurements are not required by Health Canada or the EPA and, therefore, are not part of the standard protocols. There were no further requirements for the Company to undertake further studies.  T36®Disinfectants Heath Canada Drug Identification Number (DIN) is 02231344. The studies described above were conducted according to the requirements of the EPA. EPA registration of T36® has not been pursued to date and it is uncertain if EPA registration for T36® will be pursued in the future. However, if  the Company does decide to pursue EPA registration in the future, the following requirements apply. Disinfectant products are classified by the EPA as pesticides under the authority of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Federal law requires that, before selling or distributing a disinfectant in the United States, a registration, or license, must be obtained from the Environmental Protection Agency (EPA). The process of registering a pesticide is a scientific, legal, and administrative procedure through which EPA examines the ingredients of the disinfectant, how it is to be used, the amount, frequency, and timing of its use, storage and disposal practices and potential human health and environmental effects associated with use of the product. In order to accomplish this, potential registrants must generate scientific data necessary to address concerns pertaining to the identity, composition, potential adverse effects and environmental fate of each disinfectant. These data allow the EPA to evaluate whether a pesticide has the potential to cause harmful effects to non-target organisms and the environment including humans, wildlife, plants and surface water or ground water.  The tests required for EPA approval of a disinfectant are described above in the sections above entitled Efficacy studies and Toxicology studies. These tests adhere to the standards established by the AOAC (Association of Analytical Communities) International, an organization that provides over 3,000 analytical methods in its publication Official Methods of Analysis of the AOAC International. For disinfectants, such as T36® Disinfectant, the AOAC standards that apply include the AOAC Use-Dilution Method, the AOAC Germicidal Spray Products Test,  the AOAC Fungicidal Test and the AOAC Tuberculocidal Activity Method. Storage and stability studies and proof that the manufacturing process is reliable must also be provided to the EPA.  Alda Pharmaceuticals Corp. 2007 20F/A Page 23------------------------------------------------------------------------------------------------------------------------------------------------  After completion, the efficacy and toxicology studies are submitted to the EPA according to specific templates that are provided by the EPA and available on the website of the EPA. These templates ensure that the testing results are submitted in standard formats to facilitate the review of the information by the EPA.  A disinfectant can only be used legally according to the directions on the labeling accompanying it at the time of sale. Accordingly, the content of product labels is also subjected to review and must be approved by the EPA to ensure full and accurate disclosure of such matters as the concentrations of ingredients, instructions for use, precautions, any hazards to health or the environment, treatments for exposure, disposal instructions, manufacturer and the registrant.  Most states also conduct a review of the disinfectant label to ensure that it complies with federal labeling requirements and any additional state restrictions of use.  Once all of the tests and the label for a product have been approved by the EPA a "registration" or license that permits a disinfectants manufacture, distribution, sale, and use is granted. A manufacturer must have an EPA Establishment License because the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) requires that production of disinfectants be conducted in a registered Pesticide-Producing Establishment. In this case, Production" includes formulation, packaging, repackaging, and re-labeling. Production in an unregistered establishment is a violation of the law. The EPA assigns a unique number to each establishment that produces any pesticide or device. Each company must submit EPA Form 3540-8 to request an establishment number. FIFRA requires that each producing establishment must place its EPA establishment number on the label or immediate container of each disinfectant, device or active ingredient produced. After a disinfectant is registered by the EPA, the Company, its manufacturers, distributors and independent testing facilities must maintain full and complete records for review by the EPA if an inspection is required. These records include such matters as information on manufacturing, quality control of ingredients and finished goods, inventory, shipping, receiving and disposal. Other products The Company is also in various stages of development of other products including: 1. "Ready to Use" Disinfectant Cleaner: This product has been recognized by Health Canada as being able to kill bacteria, fungi and viruses on hard surfaces within 10 minutes (compared to the 3 to 5 minute time for T36®Disinfectant).  It has also passed internal company efficacy testing.  This product is intended for use in hospitals, cruise lines, airlines and consumer applications that dont require a disinfectant product that is as fast acting as T36®Disinfectant, but need a more economical  product.  The Health Canada DIN for this product is 02272989 The Company has not determined when manufacturing will be started or when revenues will be realized from this product. At the present time, there are no plans to conduct further testing or to register the product in any jurisdiction outside of Canada. 2. Disinfectant Cleaner CONCENTRATE: This product has completed testing and is registered with Health Canada (DIN 02278820). For US sales, EPA registration is required at an estimated cost of  $100,000. Completion of the required US registration is dependent on financing. The EPA registration is projected to be completed 2 years after financing is available. International sales are important to the Company and delays in US registration could have a significant effect on future sales and cash flow, as well as allow competition to penetrate this market. It is not known when manufacturing will be started or when revenues will be realized from this product. At the present time, the Company is considering conducting further testing to satisfy the requirements of the EPA for disinfectant cleaners and applying for registration of the product in the United States. It is not certain when this testing will begin and the decision may be made not to proceed at all if sales in Canada do not seem to warrant the expense of seeking EPA registration. 3. Hand Sanitizer:  In February 2006, the Company started marketing of its hand sanitizer product (Health Canada DIN 02247771) through its current distributors to existing customers.  Up to June 30, 2007, there have been sales of approximately $50,000 of this product. No further testing or registrations are planned. 4. T36® Personal Disinfectant, T36® Disinfectant Wipes and "Ready to Use" Disinfectant Cleaner Wipes: These products have been designed for use by general public for cleaning and disinfecting their hands or hard surfaces. Development has been completed and both products are registered with Health Canada (DINs  02231344 and  02272989, respectively). No further testing or registrations are planned and no final  Alda Pharmaceuticals Corp. 2007 20F/A Page 24------------------------------------------------------------------------------------------------------------------------------------------------  5. product has been manufactured or marketed up to June 2007. It is not known when manufacturing will be started or when revenues will be realized from these products. Delays may cause reductions in anticipated revenue generation. 6. Anti-viral Soap: The Company has developed an anti-viral, anti-bacterial soap.  As at June 30, 2007, no application has been filed for a Health Canada DIN and no product release date has been set. Testing for Health Canada or FDA approval will not occur until further progress has been made on other projects or, possibly, not at all. Further, completion of product registration and initiation of marketing activities is dependent on financing. Completion of these tasks is estimated to require at least within 3 years after financing.  This delay could allow competition to penetrate this market, which could reduce the revenue potential for this product. 7. Microbicide Gel: This product has been formulated and now requires testing for efficacy and toxicity. It was developed as a personal lubricant to prevent the transmission of sexually transmitted infections (STIs). The testing required to attain FDA approval of this product would be beyond the financial capabilities of the Company. Therefore, the Company intends to undertake some initial testing on its own after a suitable delivery system has been identified and the rights to that delivery system acquired. If initial testing is successful, it is most likely that the Company will need to identify a licensee or joint venture partner working in the area of STI prevention that can undertake further testing and market development. It is not known when the Company will start the initial testing, how much time it would take to complete the required testing for STI prevention, what costs would be involved or even if there are companies that would be interested in conducting this testing. Delays may allow competition to develop comparable products, which will make market penetration more difficult which would lead to reduced revenues from this product. 8. Topical infection treatment: The body normally hosts a variety of microorganisms, including bacteria and fungi. Some of these are useful to the body. Others may multiply rapidly and form infections. Approximately sixty percent of microbial infections are systemic meaning that the infections are spread throughout the body, leaving 40% of microbial infections that are topical, i.e., occur on the surface of the body. Topical fungal infections include mold-like fungi that cause athlete's foot, jock itch and ringworm, and yeast-like fungi that can cause diaper rash, oral thrush, cutaneous candidiasis and some cases of genital rashes. Bacterial infections, such as Staphylococcus can also infect the skin, particularly if a patient has a preceding skin condition, such as eczema. The Companys T36® formulation can be used to treat such topical infections and anecdotal evidence has shown that it can be used to treat such conditions as athletes foot and toenail infections. This application of the T36® formulation must be tested against such conditions according to the requirements of the FDA, Health Canada and the European Medicines Agency and the Company intends to conduct such testing as soon as possible. Once the testing is completed, the results must be submitted to these regulatory agencies and be approved for marketing by the company. However, the testing required to attain the approval of this product are beyond the financial capabilities of the Company at this time it is not known when the Company may be able to start such testing. It is not known how much time it would take to complete the required testing for the topical infection treatment, what costs would be involved or how long it will take to conduct this testing. There are active competitors that are already well established in this market. Delays may allow even more competition to develop comparable products, which will make market penetration more difficult which would lead to reduced revenues. 9. Hand hygiene products: The Company is planning on providing the T36® formulation in spray form and in gel form for hospital use as a hand sanitizer in nursing stations, patient rooms, hallways, washrooms, etc. and for sale to consumers through retail outlets. These applications of the T36® formulation must be tested for their ability to kill microorganisms on the skin of humans according to the requirements of the FDA, Health Canada and the European Medicines Agency. Once the testing is completed, the results must be submitted to these regulatory agencies and be approved for marketing by the company. The testing required to attain the approval of this product are beyond the financial capabilities of the Company at this time it is not known when the Company may be able to start such testing. It is not known how much time it would take to complete the required testing for the hand hygiene products, what costs would be involved or how long it will take to conduct this testing. There are active competitors that are already well established in this market. Delays may allow even more competition to develop comparable products, which will make market penetration more difficult which would lead to reduced revenues.  Alda Pharmaceuticals Corp. 2007 20F/A Page 25------------------------------------------------------------------------------------------------------------------------------------------------  10. Skin antiseptic and first-aid ointment: The Company is planning on providing the T36® formulation in liquid form with a biological dye in a suitable delivery system for use as pre-operative and pre-injection antiseptic in hospitals and clinics and in gel and spray form, without biological dye, as a first-aid ointment for use on cuts and scrapes to prevent infections. These applications of the T36® formulations must be tested for their ability to kill microorganisms on the skin of humans and in cuts and scrapes according to the requirements of the FDA, Health Canada and the European Medicines Agency. Once the testing is completed, the results must be submitted to these regulatory agencies and be approved for marketing by the company. The testing required to attain the approval of this product are beyond the financial capabilities of the Company at this time it is not known when the Company may be able to start such testing. It is not known how much time it would take to complete the required testing for the topical infection treatment, what costs would be involved or how long it will take to conduct this testing. There are active competitors that are already well established in this market. Delays may allow even more competition to develop comparable products, which will make market penetration more difficult which would lead to reduced revenues. 11. Vulvovaginal infections (VVIs): The Company is planning on providing the T36® formulation in a form suitable for the treatment of all vulvovaginal infections including fungi, bacteria and, possibly, parasites and combinations of all fungal and bacterial infections. This application of the T36® formulation must be tested for its ability to resolve VVIs according to the requirements of the FDA, Health Canada and the European Medicines Agency. Once the testing is completed, the results must be submitted to these regulatory agencies and be approved for marketing by the company. The testing required to attain the approval of this product are beyond the financial capabilities of the Company at this time it is not known when the Company may be able to start such testing. It is not known how much time it would take to complete the required testing for the topical infection treatment, what costs would be involved or how long it will take to conduct this testing. There are active competitors that are already well established in this market. Delays may allow even more competition to develop comparable products, which will make market penetration more difficult which would lead to reduced revenues. The Company does not keep separate records of the cost of the development and registration for each product for a number of reasons. First, much of the development had already been done on the products before the Company acquired the assets of API in November, 2003 and API did not keep such records. Second, the Companys expenditures after completing the acquisition of the assets of API have mostly involved registration, intellectual property protection and some testing. These expenses are recorded in separate categories from research and development in the financial statements. Third, the level of expenditures by the Company would be relatively small if they were allocated to individual products and would not be considered to be material if expenditures on each product were considered on their own. Finally, the cost of accounting for such a variety of expenditures on such a number of products is not considered to be financially justified. Limited information has been provided on the estimated time of completion for individual products and for the estimated time of material net cash inflows for a number of reasons. Testing in the US for applications to the FDA or the EPA, in Canada for Health Canada and in Europe for the European Medicines Agency, is dependent on financing to support these tasks. The timing of financing and even the availability of financing is uncertain, which mean that completion dates and the time required to achieve material net cash flows are also uncertain. Even when the financing is available to complete testing and prepare the required submissions to the regulatory bodies, the time taken by the regulatory agencies to review the submissions is unpredictable. Further, the regulatory agencies may identify deficiencies in the submission and request more documentation or possibly even more testing before providing an approval for a product, if such approval is granted at all. Since the timing to secure product registration and market approval is uncertain and delays can lead to the entrenchment of competitors and make the penetration of markets more difficult, even more uncertainty is added to the estimates of time required to time to arrive at material net cash flows. For these reasons, the Company believes that it is more prudent to not project the times or costs of market approval for individual products.  Plan Of Operations  Anticipated Changes to Facilities/Employees Management of the Company anticipates no changes to either its facilities or personnel, including number of employees, in Fiscal 2008. As distribution and sales are done on a wholesale price basis, sales revenue changes do not result in changes in the number of personnel or the Companys facilities.  Alda Pharmaceuticals Corp. 2007 20F/A Page 26------------------------------------------------------------------------------------------------------------------------------------------------  As production is being performed on a contract basis with Norwood Packaging Ltd. (see Exhibit 4.b.) changes in product sales do not result in changes to the Companys facilities or personnel.  United States vs. Foreign Sales/Assets All of the Companys assets are located in Canada. All of the Companys sales to date have been in Canada.  Material Effects of Government Regulations At this time, our sales are primarily in Canada and, as a result, government regulations in Canada affect the Company most significantly.  However, the Company hopes to commence sales in the United States, China, Europe and other jurisdictions in the future and, as a result, we have summarized the government regulations in these markets that may affect the Company in the future. The Companys products and future planned products can be categorized either as disinfectant products or therapeutic products, depending on the intended use. A summary is provided on the government regulations for both of these product categories. 1. Canada: In order to market and sell a disinfectant, which is classified as a drug in Canada, the product must be approved by Health Canada, a federal government department responsible for the oversight of drugs and certain other medical products. The Therapeutics Product Directorate (TPD) is the department of Health Canada that issues the DIN (Drug Identification Number) for registered products.  A company can apply for a DIN by submitting the appropriate fee, a draft label and, in most cases, copies of completed efficacy and safety studies to support the claims made on the label. The descriptions of the tests required for Health Canada approval of a disinfectant are described above in the sections entitled Efficacy studies and Toxicology studies. The TPD generally takes up to 12 months for review and completion prior to the issuance of a DIN. However, if further documentation or studies are required, the time taken to obtain approval for a new product can be longer. T36®Disinfectant has received approval from Health Canada as a disinfectant, disinfectant cleaner, sanitizer and deodorizer. The DIN for T36 Disinfectant is 02231344, which permits its sale in Canada for these applications.  T36®Disinfectant has also been approved in Canada by the Canadian Food Inspection Agency for use in Registered Establishments, which include meat processing plants, restaurants, breweries, wineries and other commercial food processing establishments. Production facilities that manufacture an approved product must have an Establishment License that verifies its adherence to Good Manufacturing Practices (GMP) as set out by a division of Health Canada.  Norwood Packaging Ltd. (Norwood), which produces the Companys products under contract (see Exhibit 4.b.), has an Establishment License. The Companys agreement with Norwood, dated September 29, 2005 (Exhibit 4.b.), requires Norwood to manufacture and store T36®Disinfectant for the Company in exchange for a percentage of sales made by the Company. The percentage paid to Norwood varies with the size of the order and for certain customers. Norwood also has a Right of First Refusal to manufacture other products for the Company under similar terms. The termination provisions of the agreement are standard commercial terms that include uncorrected breaches of the agreement, any form of insolvency on the part of Norwood or the Company, or 90 days written notice by either party. There is no specified expiry date for this agreement. United States:In order to market and sell a disinfectant in the US, the product must be approved by either the US Food & Drug Administration (FDA) or the US Environmental Protection Agency (EPA), depending on the intended use.  Disinfectant products, such as hard surface disinfectants, are regulated by the EPA. The descriptions of the tests required for EPA approval of a disinfectant are described above in the sections entitled Efficacy studies and Toxicology studies. Any products with therapeutic claims or intended for use on humans are regulated by the FDA.  It is illegal to market and sell therapeutic products in the United States without an FDA or EPA registration. At some point in the future, the Company intends to undertake the processes in the United States to obtain FDA or EPA registration numbers.  Alda Pharmaceuticals Corp. 2007 20F/A Page 27------------------------------------------------------------------------------------------------------------------------------------------------  The Company cannot say when, or even if, the proposed submissions to the EPA and the FDA will be completed.  The Company cannot predict the timing of FDA or EPA approval, if such approval can be obtained. FDA product registrations may require the following tests for a topical therapeutic test substance, such as T36® Disinfectant. 2. United States:In order to market and sell a disinfectant in the US, the product must be approved by either the US Food & Drug Administration (FDA) or the US Environmental Protection Agency (EPA), depending on the intended use.  EPA  Disinfectant products, such as hard surface disinfectants, are regulated by the EPA. The procedures and tests required for EPA approval of a disinfectant are described above in the sections entitled Efficacy studies and Toxicology studies  in the section entitled T36® Disinfectant under 4.B.Company Development  FDA Any products with therapeutic claims or intended for use on humans are regulated by the FDA.  It is illegal to market and sell therapeutic products in the United States without an FDA or EPA registration. At some point in the future, the Company intends to undertake the processes in the United States to obtain FDA or EPA registration numbers. The Company cannot say when, or even if, the proposed submissions to the EPA and the FDA will be completed.  The Company cannot predict the timing of FDA or EPA approval, if such approval can be obtained. FDA product registrations may require the following tests for a topical therapeutic test substance, such as T36® Disinfectant. · Time kill Evaluation  In these tests, dozens of different species of infectious micro-organisms are exposed to each of the active ingredients of a test substance and the complete test substance formula for periods of time ranging from 15 seconds to 30 minutes to determine the time required for each ingredient of a test substance and the complete test substance formulation to completely kill the selected species. The objectives of the testing are to determine the effective exposure times required for the test substance to be effective and if the individual ingredients have an additive, subtractive or synergistic effect. · MIC (Minimum Inhibitory Concentration) Evaluation  Each ingredient of a test substance, the complete test substance formula and a known antiseptic product are tested against hundreds of micro-organisms. The objectives of the tests are to quantify the minimum concentration that is required for each of the test substances to have a measurable effect on the tested species, compare those results to the known antiseptic product and determine if the individual ingredients have an additive, subtractive or synergistic effect. · In-vitro dermal test  This testing involves in-vitro preparation and contamination of pig skin that has been harvested from carcasses with bacteria to evaluate the methods of application of a test substance and the time of exposure to achieve the best anti-microbial results. The objective of the testing is to determine the methods that would be proposed for subsequent human trials. · Pilot Clinical Evaluation - This study evaluates the antimicrobial efficacy of a disinfectant in two different applications when used as patient preoperative skin preparation on 10 subjects.  A disinfectant must achieve a log10 microbial reduction of 3 or greater on skin of the groin and a log10microbial reduction of 2 or greater on skin of the abdomen at ten minutes post-application. The objective of the testing is to obtain an preliminary evaluation of the efficacy of the test substance when used on humans. · Full pre-operative clinical evaluation - The study evaluates the immediate and persistent antimicrobial properties of a disinfectant when used as a preoperative skin preparation.  A known active control, e.g., 4% chlorhexidine, and a placebo, e.g., sterile saline, are also evaluated.  All treatments are  Alda Pharmaceuticals Corp. 2007 20F/A Page 28------------------------------------------------------------------------------------------------------------------------------------------------  · assessed for their potential to cause skin irritation.  One-hundred  subjects are screened in order to obtain at least forty subjects having sufficient number of resident bacterial flora to permit evaluation of the efficacy of the test products. The objective of this test is to further evaluate the efficacy of a test substance when used on humans.  · Pharmacokinetics describes how the body affects a specific drug after administration and examines the extent and rate of Absorption, Distribution, Metabolism and Excretion, commonly referred to as the ADME scheme. Absorption is the process of a substance entering the body. Distribution is the dispersion or dissemination of substances throughout the fluids and tissues of the body. Metabolism is the irreversible transformation of parent compounds into daughter metabolites. Excretion is the elimination of the substances from the body. In rare cases, some drugs irreversibly accumulate in a tissue in the body. The pharmacokinetic properties of drugs may be affected by elements such as the site of administration and the concentration in which the drug is administered. These may affect the absorption rate. The objective of the ADME studies are to determine if the test substance or any of its components are absorbed and if any absorbed components are metabolized into harmful chemicals that may or may not accumulate in the body. · Insult patch test  The objective of this test is to evaluate the effect, if any, of prolonged and repeated exposure of the skin to the test substance. The Induction Phase of this study incorporates the test substance into a series of patches that are applied to the skin of 50 subjects repeatedly for periods of time and then removed. After a rest period, new patches are applied. This process is repeated over a period of time with a number of new patches and after completion of this phase, the reaction of the skin is evaluated. The Challenge Phase takes place some time after application of the final induction patch. Challenge patches are applied to previously untested sites, adjacent to the original induction patch sites. The reaction of the skin is evaluated 24 to 48 hours after application and the subjects are asked to report any delayed reactions which might occur after the final challenge patch reading.21-day Cumulative irritation test  The objective of this test is similar to that of the insult patch test but assesses the irritation caused by topical products and chemicals over 21 days of continuous exposure of the skin. The test substance is incorporated into patches that remain on the skin for a period of time and are replaced from time to time to maintain continuous exposure to the skin. These tests would typically require 12-18 months to complete and must be conducted by FDA certified labs. The FDA review and approval of this data can take up to 24 months. Once approved, then human clinical trials (if required) would need to be completed.  These trials are normally conducted in 3 phases, with a detailed protocol for each phase provided to the FDA for approval to proceed. At the end of each phase, the results are analyzed and submitted to the FDA and, if acceptable, the trial continues to the next phase: Phase I Clinical Trials: This is the first stage of testing of a new therapeutic in human subjects, normally with a small group (20-60) of healthy volunteers. The objective is to assess the safety and tolerability of the product as a therapeutic, as well as to determine the effects of various doses of the product.  For externally administered agents, the testing is simpler than for injected or internally administered agents. However, Phase 1 trials can require up to 2 years to complete, including analysis of the collected data, preparation of the Phase I report for submission to the FDA and the time until a response is received. If these results of Phase I are accepted by the FDA, then the clinical trial can proceed to Phase II. Phase II Clinical Trials: This second phase tests the therapeutic on a larger group and evaluates both the required dose (i.e. different quantities of the therapeutic) and efficacy (i.e. how well the therapeutic works for the specified indication). Phase II trials can take up to 3 years. However, some trials can combine Phase I and Phase II, which can reduce the total time required. Phase III Clinical Trials: This third phase of clinical trial depends on the indications for which the therapeutic is being tested. For most agents Phase III trials are a randomized, controlled, multi-center trial with large patient groups (often more than 300), with the objective of  confirming that the therapeutic is as effective or more effective than the current gold standard for the same application.  Phase III trials can take up to 5 years or more to complete.  If the results of the Phase III trial are approved by the FDA, then product is approved for marketing for the specific indications that were tested.  Alda Pharmaceuticals Corp. 2007 20F/A Page 29------------------------------------------------------------------------------------------------------------------------------------------------  The three phases of clinical trials can require as long as 5-10 years to complete even for topical products. The total time required is dependant on the nature of the therapeutic, the condition being treated, the design of the protocols, the time to recruit patients and the review process conducted by the FDA. The registration time for products taken internally can take much longer than for topical agents. The costs of a complete clinical trial can be significant, depending on the intended application.  The Company may not conduct any clinical trials itself, but may enter into strategic alliances or licensing agreements with larger companies, which can support the costs of such trials,  3. China: In the Peoples Republic of China (China), the Company must have its products tested for toxicology and efficacy at the Centers for Disease Control (CDC).  The CDC should not be confused with the CDC in Atlanta, Georgia, although both organizations share the same name. The studies required by the CDC include the following tests.  · Kill tests against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa  In a suspension test, the disinfectant must provide a log10 reduction in bacterial population of 5.0 or more within a test time designated by the supplier of the disinfectant. A suspension test involves adding the bacteria to the disinfectant, usually at a ratio of 0.1 to 2 parts bacterial suspension to 9.9 to 8 parts disinfectant, respectively. · Field disinfecting test on general hard surfaces  General bacterial counts are first determined on table surfaces and the window frame surfaces, maintained at 19 to21 oC, by taking sample swabs and culturing the bacteria. The same surfaces are then wiped with the disinfectant and sampled after a test time designated by the supplier of the disinfectant. The disinfectant must provide a average log10 reduction in bacterial population of 2.0 or more in this test. · Metal corrosion test - Metal plates made of  stainless steel, carbon steel, copper and aluminum are immersed continuously for 72 hors in the disinfectant. The corrosion rate, measured in millimeters per annum, is then determined for each metal. · Acute oral toxicity test - Four dosage groups receive 1,000, 2,150, 4,640, and 10,000 mg/kg of disinfectant administered orally with 10 animals in each group and comprised of half females and half males. After exposure to the disinfectant, the general conditions, symptoms of toxicity, and deaths of animals are observed over a period of 2 weeks.  After the tests are finished, all animals are dissected and gross pathological changes of animals are recorded.  Acute toxicities are measured in terms of the LD50, the dose at which 50% of the animals die. · Bone marrow erythrocyte micronucleus test - Rats are given a dose of 500, 2,000, and 5,000 mg/kg of disinfectant by gastric lavage. Each group consists of 5 females and 5 males. Thirty hours later, the rats are given a second dose that is identical to the first. Six hours later, the rats are killed and dissected. Bone marrow from the sternum is removed, smeared on microscope slides, stained and examined for signs of chromosomal mutations. · Skin irritation test - Twenty-four hours before testing, a 3 cm x 3 cm area beside both sides of spinal cords on the backs of three New Zealand rabbits is shaved. On the next day, a testing area of 2.5 cm x 2.5 cm on the shaved skin on the left side is marked and 0.5 ml of disinfectant is smeared evenly on the test area, covered by 2 to 4 layers of gauze the same size as the test area and one layer of cellophane which is a little bigger than testing area for each animal. The test area is directly exposed to the disinfectant in this way for 4 hours. The shaved area on the right side is exposed to saline as a negative control using the same procedure. After the 4 hour exposure, the dressings are removed and shaved areas are washed using warm water to remove any residual saline or disinfectant.  After 1, 24, and 48 hrs the level of skin irritation is observed and recorded.  Upon completion of successful testing at the CDC, products can be registered for sale within China.  On May 25, 2007, an Agreement with Fuzhou Xinmei Biotech Co. Ltd. (Fuzhou), which allowed manufacturing and marketing in Fujian province in China (Exhibit 4.c.), was transferred to He-Yi She Ye Limited (He-Yi) and expanded to cover marketing in all of China (Exhibit 4.g.).On August 31, 2006, He-Yi received its certificate of approval from the Fujian Centre of  Disease Control for T36® Disinfectant after  Alda Pharmaceuticals Corp. 2007 20F/A Page 30------------------------------------------------------------------------------------------------------------------------------------------------  passing all of the required tests. This certificate allowed He-Yi to apply to the Chinese National Centre for Health Inspection and Supervision for approval to manufacture T36® Disinfectant for sale in China and for export. The registration of T36® Disinfectant in China was expanded beyond disinfection of inanimate objects, such as hospital equipment and instruments, to also allow external use on humans, including use as a first-aid antiseptic and hand sanitizer. Approval for the manufacturing of T36® Disinfectant was obtained from the Ministry of Health in The Peoples Republic of China. On April 19, 2007, a manufacturing certificate (Certificate of Approval (Health ID. No. 0109) was granted to He-Yi for a period of four years from April 19, 2007 to April 18, 2011 and is renewable by filing an application for renewal 6 months before the expiry date.  The Company cannot guarantee that He-Yi will be able to construct a manufacturing facility, that products manufactured by He-Yi will pass the quality control standards established by the Company or the Chinese government, that He-Yi will be able to obtain approvals to market the Companys products in other provinces of China or that He-Yi will be able to sell any of the Companys products at all in China or elsewhere.  Seasonality The only seasonality observed with respect to T36® Disinfectant marketing is that sales slow down in the summer and during the Christmas period due to a general business slowdown as a result of customers being on holidays. Dependency upon Patents/Licenses/Contracts/Processes If the Company is able to further commercialize and increase sales of its T36®products, the Company may be dependent on patent and trademark protection to protect future potential revenues and growth.  Patents The Patent Cooperation Treaty (PCT) is an international patent law treaty established in 1970. It provides a unified procedure for filing patent applications to protect inventions in each of its Contracting States, which includes each jurisdiction specified below. A patent application filed under the PCT is called an international application or PCT application. A single filing of an international application is made with a Receiving Office (RO) in one language. It then results in a search being performed by an International Searching Authority (ISA), accompanied with a written opinion regarding the patentability of the invention which is the subject of the application. Optionally, this is followed by a preliminary examination, performed by an International Preliminary Examining Authority (IPEA). The PCT does not lead to the grant of an "international patent", which does not exist, but rather, national patent examinations that are handled by each relevant national or regional authority. For example, in Canada, the US, China, Australia and Singapore, there are national patent offices whereas, in Europe, the European Patent Office handles the national phase for its member states.  API filed patent application #PCT/CA2002/001284, A wide spectrum disinfectant, on August 20, 2002. All rights to the patent application were transferred from API to the Company on completion of the Qualifying Transaction on November 13, 2003. A summary of subsequent events is presented below. Canada: On February 18, 2005 the Canadian Intellectual Property Office received the PCT patent application and assigned it Patent Application Number 2,495,938. European Union: On March 30, 2005 the PCT application was accepted for national examination by the European Patent Office (EPO) and assigned it Patent Application Number 02754054.1-2113. The countries covered by the European patent application are Austria, Belgium, Bulgaria, Switzerland, Cyprus, the Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Great Britain (the UK), Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Portugal, Sweden, the Slovak Republic and Turkey. On May 18, 2005, the bibliographic data of the above-noted application was published in the European Patent Bulletin, under Publication No. 1530485. The resulting effect of such publication is that any possible infringer is deemed to have knowledge of the patent application without the Company having to formally inform them of this applications existence. On October 18, 2006 the EPO provided the Company with an  Alda Pharmaceuticals Corp. 2007 20F/A Page 31------------------------------------------------------------------------------------------------------------------------------------------------  Office Action requesting further information on the patent application. The Company responded to the questions and received a second Office Action, dated September 5, 2007 from the EPO. This second Office Action requested that the Company provide certain additional information to support the claims that were made in the application. China: On June 25, 2005 the Company was notified that the PCT application was accepted for national examination by the Patent Office of the Peoples Republic or China (Chinese Patent Office) and assigned Patent Application Number 02829642.7. On August 11, 2005, the Chinese Patent Office accepted a Request for Substantive Examination from the Company. The application was published in the Chinese Patent Gazette on October 19, 2005, under Publication No. CN1684711A and entered into Substantive Examination. On February 5, 2006, the Company filed a Voluntary Amendment to the original patent application to correct certain minor errors in the original application. On June 2, 2006, the Chinese Patent Office provided an Office Action which requested certain additional amendments to the patent application. On December 18, 2006, the Company filed its response to the Office Action. The Company was notified by the Chinese Patent Office that the Chinese patent had been allowed, effective June 8, 2007. United States: On February 18, 2005, the US Patent and Trademark Office (USPTO) received the PCT patent application and assigned it Patent Application Number 10/525,110. The patent application was published by the USPTO on December 22, 2005, under Publication Number US 2005/0282727. On July 27, 2006, the Company received that first Office Action from the USPTO which required clarification or modification of certain claims made in the patent application. The Company was required to respond to the Office Action by October 27, 2006 and did so on October 26, 2006 with amendments to the claims that required clarification or modification. On February 7, 2007 the USPTO provided the Company with a Notice of Allowance for the US patent with all claims made by the Company accepted  by the USPTO. A Notice of Allowance is not a grant of a patent and is subject to withdrawal by the USPTO or on petition by the Company. The Company then filed certain minor, voluntary amendments to the patent application and a second Notice of Allowance, dated June 8, 2007 was provided by the USPTO.   Singapore:On February 18, 2005, the Singapore Patent Office accepted the PCT patent application and assigned it Patent Application Number 200500987-3. Australia: On March 15, 2005 the PCT application was accepted for national examination by the Australian patent office on March 15, 2005 and assigned with Patent Application Number 2002322916. On October 24, 2006, the Australian patent office provided the Company with a Direction to Request Examination. Under Australian Patent law, such examination must be requested within five years of the filing date or within six months of receiving a direction from the Australian Patent Office, whichever is sooner.  The subject matter of all of these pending patents is the composition of T36®Disinfectant which contains five active ingredients, four of which are in relatively low concentrations that act synergistically to disrupt the physical structure of all types of micro-organisms. The pending patents also provide for the method of manufacturing T36®Disinfectant. As of June 30, 2007 none of these patents has yet been finally granted.  The Company cannot estimate when, if at all, the patents will be granted. Trademarks: The Company successfully trademarked T36 in Canada on April 22, 2004 and in the United States on November 2, 2004.  The trademark in the United States is a Principal Register mark. The Principal Register of the US Patent and Trademark Office (USPTO) conveys the important substantive rights that most people associate with federal registration and, as a result, it is the preferred method of federal trademark protection. Probably the most important benefit of placing a mark on the Principal Register is that anybody who later initiates use of the same or a confusingly similar trademark may be presumed by the courts to be a "willful infringer" and therefore liable for damages.  Alda Pharmaceuticals Corp. 2007 20F/A Page 32------------------------------------------------------------------------------------------------------------------------------------------------  The Company also successfully trademarked the Companys logo in Canada on July 16, 2004 and in the United States on January 18, 2005, also as a Principal Register mark. Impairment of intellectual property The Company purchased substantially all of the assets and undertakings of API, principally comprised of certain intellectual property rights of API related to T36 Disinfectant developed by API including certain drug identification numbers, trademark and patent applications, inventory, capital assets, the shares of ALDA Institute For Preventative Health Care Inc., a non-competition agreement, and certain contracts. The value placed on these assets was $540,000. In the financial statements, the intangible assets balance represents the carrying amount for the intellectual property and these assets were determined to have an indefinite life. An impairment loss of $179,000 was charged against earnings for fiscal 2004 and an impairment loss of $245,000 was charged against earnings for fiscal 2005. This impairment loss was considered necessary due to sales of the T36®Disinfectant being lower than the $540,000 valuation could support and also because the Company's progress towards securing legal protections for its proprietary product and development of a market for its product were significantly slower than had been anticipated at the time of the purchase of the business assets.  At June 30, 2005, the carrying cost of the intangible assets was written down to the estimated net recoverable amount of $116,000. The carrying amount of Intangible Assets was determined as follows: Original purchase cost (Note 9) $540,000 Impairment loss in 2004 (179,000) Balance at June 30, 2004 361,000 Impairment loss in 2005 (245,000) Balance at June 30, 2005 116,000 Balance at June 30, 2006 $116,000  Effective July 1, 2006, the Company changed its estimate of the useful life of the intangible assets from an infinite life to a finite of 20 years.  The impact of this change in estimate was to increase amortization by $5,800 for the year ended June 30, 2007. Opening balance as at July 1, 2006 $116,000 Accumulated amortization (   5,800) Balance as at June 30, 2007 $110,200  Sources/Availability of Raw Materials and Production T36®is comprised of ethanol, o-phenyl phenol, benzalkonium chloride and other ingredients, including lemon fragrance and water.  All of these chemical raw materials are commonly produced in industrialized countries by a number of manufacturers and are generally considered safe to transport. However, they have a low value to weight ratio which means it is likely cheaper to source raw materials from local producers than shipping raw materials from other markets. As a result, the Company does not believe that it is vulnerable to raw materials shortages or to loss of access to supply from any one producer. The Company has entered into a production contract with Norwood Packaging Ltd. (see Exhibit 4.b.) and anticipates entering into production contracts for each area in which the Company would market and sell the T36®Disinfectant or other products. The Company does not have production facilities or anticipate leasing, building or acquiring production facilities.  Alda Pharmaceuticals Corp. 2007 20F/A Page 33------------------------------------------------------------------------------------------------------------------------------------------------  Principal markets and Potential Product Markets At this time, the Companys sales have principally been to: First Responder organizations, including ambulance, fire fighters and police forces in Canada; 1. Dental clinics; and 2. Beauty and hair care salons and spas. There are no reliable market estimates of the size of the disinfectant or disinfectant cleaner market in these segments. The Company hopes to expand its product sales to hospital and related consumers in the future. In addition, the Company hopes to expand its product sales to the United States and China.  However, as detailed in Item 4B Material Effects of Government Regulation, the Companys products must first receive regulatory approval in any new sales jurisdiction and obtaining this approval can be costly and time consuming. There is no available estimate of the size of the Canadian market for disinfectant products or products similar to those of the Company. Also, no estimates are available for the US or overseas markets. Disinfectant Products are a very broad category of products and, where estimates are available of market size, the data appears to include many products dissimilar to those of the Company and often includes consumer products (e.g. widely marketed consumer brand name hand soaps).  As well, particularly in the market niches where the Companys sales have been to date (as described above), there are a number of private company producers of disinfectant products whose sales figures are not publicly available.  No industry trade organization exists which could provide estimates of disinfectant sales, in product categories, for Canada or the United States. Marketing, Distribution and Sales Channels The Company does not directly market its products to end consumers.  The Companys marketing, distribution and sales model is to market its products to wholesalers of similar products who then market the products to end consumers. The wholesale industry for disinfectants, cleaners, cleaning and hospital supplies and similar consumer products is fragmented into a large number of wholesalers.  As a result, no competitor of the Company exercises significant control over distribution.  However, the Company must convince each new wholesaler that it targets both to carry its products, often in place of other existing products, and also to make the Companys products available to the wholesalers customers. The Companys products and name are not immediately recognizable to end consumers and, as a result, wholesalers have to make some additional effort to generate sales, as compared to the effort associated with a product familiar to end consumers. This difficulty, which all new companies face in marketing their products, is probably the greatest challenge for the Company (i.e. how to get end consumers to recognize and request its products from wholesalers), given the Companys limited budget for incentives or advertising. The Company markets it products to wholesalers through one inside sales and marketing representative, trade shows, lectures to end users and product promotional materials and flyers. The current key accounts are described below. With one exception, there are no contracts or oral agreements in place. Customers and distributors place orders for products from the Company, the shipper receives instructions from the Company and the shipper sends the products from its warehouse via carriers specified by the Company or the customer. All product shipments are made FOB from the Companys shipper and title passes to the customer upon the Companys or customers carrier taking delivery of the product from the shipper.  The Company may prepay all costs of transportation and insurance and the customer reimburses the Company for such expenses.  The payment terms for products delivered to the customer by the Company are net cash in Canadian currency within 30 days. 1. Esthetics Plus, Inc. (EP) is a distributor to the beauty market and is the only distributor with a formal agreement with the Company dated February 1, 2005 (Exhibit 4.h.). EP has exclusive distribution rights in the beauty industry across Canada, except that the agreement is not exclusive within the province of BC. The material terms of the agreement between the Company and EP are described below under Item 10.C. Material Contracts.  Alda Pharmaceuticals Corp. 2007 20F/A Page 34------------------------------------------------------------------------------------------------------------------------------------------------  2. Sinclair Dental Limited is a distributor to the dental market and has been a customer of the Company for nearly 4 years. 3. Product Distribution Centre (PDC) is a Crown Corporation of the Province of British Columbia, Canada, a distributor to the first responder market and has been a customer of the Company for nearly 4 years. 4. The Stevens Company Limited is a distributor to the scientific and medical markets and a customer of the Company for nearly 4 years. 5. VWR International is a distributor to the laboratory market and has been a customer of the Company  for nearly 4 years. The Company currently sells its T36® Disinfectant through these distributors and is also planning on introducing its new products, such as the T36® "Ready to Use" Disinfectant Cleaner, T36® Disinfectant Cleaner CONCENTRATE and the corresponding wipes, through these distributors. The current sales and plans to introduce the new products through these distributors would be disrupted if any of these distributors stopped representing the Company. The result would be a reduction in the Companys revenues until new distributors could be found. It is possible that new distributors might not be found and the Company would have to try to sell its products directly to the end users, leading to a significant increase in marketing and sales costs, even if the sales levels could be regained. 4.C.  Organization structure The Company is not part of a group and has only one wholly owned subsidiary, Sirona Therapeutics Corp. (Sirona), formerly the ALDA Institute for Preventative Health Care Inc., a Company incorporated in British Columbia. On January 12, 2005 the Company entered into a license agreement with Sirona.  Under this agreement, the Company can choose to transfer the rights to certain therapeutic applications of its T36®Disinfectant to Sirona if financing is directed into Sirona rather then into the Company. The Company will retain ownership of the technologies if Sirona undertakes any financing and completes the patenting and registration of any therapeutic products developed and based on the T36®Disinfectant. At the present time, Sirona is an inactive company, but is in a position to become active if Sirona secures investment funding in the future. If such an investment is not made directly into Sirona, it will remain inactive or may undertake unrelated business activities. 4.D. Property, Plant and Equipment The Company has executive offices at 635 Columbia Street, New Westminster, British Columbia, V3M 1A7 which consist of 1,975 square feet. The Company leases its offices on a month-by-month basis at CDN$ 2,401.98 per month (see Exhibit 4.d. for original lease agreement). The Company contracts out its manufacturing and has no present intention of leasing or acquiring manufacturing facilities (see Exhibit 4.b. for production contract with Norwood Packaging Ltd.). Item 4A Unresolved Staff Comments No disclosure necessary. ITEM 5.  OPERATING AND FINANCIAL REVIEW AND PROSPECTS This discussion should be read in conjunction with the audited financial statements of the Company and related notes included therein. 5.A.  Operating Results of The Company Overview Over the course of the Companys operating history, the Company has successfully secured the required government and regulatory approvals to market and sell its T36®Disinfectant products in Canada.  This has resulted in sales as described in Results of Operations below and, to date, all of the Companys sales have been in Canada. Canada, however, while it is a developed industrial economy, is not a particularly large market relative to economies such as the United States or China. To achieve profitability and increase sales substantially, the  Alda Pharmaceuticals Corp. 2007 20F/A Page 35------------------------------------------------------------------------------------------------------------------------------------------------  Company must first secure government and regulatory approval of its products in markets outside of Canada or secure registrations for additional products within Canada Although sales in Canada have grown over the Companys operating history, the Company has not yet secured the required government and regulatory approvals for the sales of its products outside of Canada.  Each government or regulatory jurisdiction tends to require efficacy studies or safety studies of differing content or quality.  The regulatory approval process to date has been costly both in terms of working capital and in terms of management time and attention. Results of Operations The Company has been actively marketing its T36®Disinfectant product since the acquisition of API was completed. The Companys sales, over the last three financial years, have been$239,271 in the year ended in June, 2005, $223,586 in the year ended June 30, 2006 and $256,243 in the year ended June 30, 2007.  The unit cost of sales has stabilized as a percentage of sales in the years ended June, 2006 and 2007. However, the Company is still operating overall with a significant loss from operations.  This reflects, to a great extent, the costs associated with trying to register its products for sale in jurisdictions other than Canada and ongoing administrative, management and intellectual property protection costs. To generate a net profit, the Company believes that it must register its products for sale in another major market, such as the United States or China or both, to achieve sales economies or achieve significant sales of its newer products such as the hand sanitizer and disinfectant cleaners. Sales For the year ended June 30, 2007, sales were $256,342 compared to $223,586 for the year ended on June 30, 2006, and $239,271 for the year ended on June 30, 2005. Sales were generated in 2005, 2006 and 2007 from the Companys surface disinfectant, T36® Disinfectant, through its distributors to the first responders, dental and beauty markets.  In 2006, the Company introduced the T36® Hand Sanitizer, which is also being sold through the same distributors. Some seasonality is observed with sales slowing down in the summer and over the Christmas period. No other factors seem to significantly affect sales on a quarterly basis. No new competitors have appeared in the market nor have any withdrawn from the market. Company Average Monthly Sales for the year ended June 30, 2007 were $ 21,353 compared to $18,632 per month for the year ended June 30, 2006 and $19,939 per month for the year ended June 30, 2005. The 7% drop in average sales in 2006 compared to 2005 was likely due to the timing of purchases by customers and the 15% increase in average sales per month in 2007 compared to 2006 was likely due to the timing of purchases and the addition of a Hand Sanitizer to the product line. Cost of Sales The cost of sales for the year ended June 30, 2007 was $165,920 compared to $142,379 for the year ended on June 30, 2006, and $150,075 for the year ended on June 30, 2005. Cost of sales includes the direct costs of the inventory sold during the period plus warehousing costs and handling charges. Gross Profit (Loss) In 2007, a gross profit of $90,323 was retained, which was in line with the gross profit of $81,207 in 2006 and $89,196 in 2005. Advertising and Promotion Advertising and promotion costs for the year ended June 30, 2007 were $12,766 compared to $12,169 and $27,685 for the year ended June 30, 2006 and 2005, respectively. Costs in this category were reduced significantly as the Company did not allocate as many resources to advertising in 2006 and 2007 as in the 2005 fiscal year.  The Company has put new efforts into attracting new customers by providing lectures, sending samples of T36® Disinfectant and literature to potential new customers and distributors rather than paying for journal advertising.  Alda Pharmaceuticals Corp. 2007 20F/A Page 36------------------------------------------------------------------------------------------------------------------------------------------------  Amortization In 2007, patent costs incurred during the year were capitalized with an amortization period of 20 years resulting in $2,131 in amortization expense being recognized.  In addition, the Company changed its estimate of the useful life of the intangible assets from an infinite life to a finite life of 20 years; as a result of such change, amortization of $5,800 was recognized in the statements of operations and deficit.  Amortization of $8,217 for the year ended June, 2005, $8,281 for the year ended June, 2006 and $8,350 for the year ended June, 2007 were being recognized. Conferences Expenses for conferences were $12,035 for the year ended June, 2005 due to the Companys representatives attending trade shows for purposes of marketing the Companys products.  . These expenses dropped dramatically to $666 for the year ended June, 2006 and $20 for the year ended June, 2007 because the Companys management made the decision that the return from attending the conferences was not sufficient.. Consulting & Management Services Fees Consulting fees for the year ended June 30, 2007 were $308,600 as compared to $183,218, and $210,561 for the year ended June 30, 2006, and 2005 respectively.  The consulting fees primarily represent remuneration for management services provided to the Company by management services companies controlled by the Companys President, Terrance Owen; its CFO and Peter Chen. The consulting fees were higher for the fiscal year ended June 30, 2007 because of increased product registration activities compared to 2005 and 2006 and $82,000 of stock-based compensation expenses being recognized in 2007 from the issuance of 3,530,000 stock options to consultants officers, directors and employees in 2007 compared to 300,000 options granted in 2005 and no options granted in 2006.Filing Fees Filing fees were $21,544 for the year ended June, 2005, $22,834 for the year ended June, 2006 and $24,570 for the year ended June, 2007 due to the need for the Company to pay the regulatory bodies for such matters as the completion of private placements, the issuance of options, the filing of financial documents and the payment of annual listing fees. Investor Relations Investor relations costs were $90,779 for the year ended June 30, 2005, decreased to $52,808 for the year ended June 30, 2006 due to fewer investor relations activities taking place and increased again to $65,039 for the year ended June 30, 2007 due to the Company retaining Rhone Alternative Marketing Partners (RAMP) to raise funds in Europe for the testing and registration of the topical therapeutic applications of the Companys T36® technology. Legal and Accounting Legal and accounting was $57,833 for the year ended June, 2005, $63,178 for the year ended June 30, 2006 and $53,697 for the year ended June 30, 2007. Accounting fees consist primarily of the cost of the year-end audits and for reviewing the quarterly statements. As announced in a news release issued by the Company on September 13, 2007, Berris Mangan resigned as the Companys external auditor due to a decision by Berris Mangan to focus its practice on TSX-listed companies with Canadian reporting responsibilities.  The Company appointed HLB Cinnamon Jang Willoughby, Charted Accountant (CJW) to conduct the year-end audit.   Legal fees included costs for preparing materials for the AGM, closing of a private placement by way of an Offering Memorandum, preparing the agreement between the Company and JohnsonDiversey, Inc. that settled the trademark dispute as announced in a press release dated May 30, 2005 and continuing legal action seeking damages from a competitor as announced in a news release issued by the Company on June 30, 2004. In the 2004 fiscal year, legal costs were incurred for closing the Qualifying Transaction, the Financing associated with the Qualifying Transaction, required regulatory filings and litigation involving a competitor as announced in new releases issued by the Company on May 14, 2004 and June 30, 2005. Office and Miscellaneous Office and Miscellaneous expenses were $30,426 for the year ended June, 2005, $25,450 for the year ended June, 2006 and $24,008 for the year ended June, 2007 due to the need for the Company to undertake sales of its acquired product and to maintain its administrative functions for day-to-day operations. Office and miscellaneous expenses have steadily declined due to greater efficiency and fewer purchases of office supplies after the initial need to stock up on such supplies.  Alda Pharmaceuticals Corp. 2007 20F/A Page 37------------------------------------------------------------------------------------------------------------------------------------------------  Product Development and Product Registration Costs in these two categories are combined for purposes of this discussion. Costs in this category were $54,293 for the year ended June, 2005 and $18,377 for June 30, 2006.  In 2007, total costs incurred in this category were $42,617 and capitalized under patent application and development costs. Patent costs incurred during the year were capitalized with an amortization period of 20 years rather than expensed.  A new category has been added to the Balance Sheet to reflect this change in accounting practices.  Costs in this category include the fees paid to the regulatory consultants in Canada and the US to pursue the registration of the Companys products in the United Kingdom and the United States. Costs spent on laboratory testing and intellectual property protection are also included in this category. Product registration refers to the registration of the Companys products with Health Canada and to the patenting activities undertaken by the Company. The level of these activities varies from year to year as funds become available from external sources and may not be consistent. Rent Rent was $25,265 for the year ended June, 2005, $30,912 for the year ended June, 2006 and $28,371 for the year ended June, 2007. Travel Travel expenses were, $4,512 for the year ended June, 2005, $3,252 for the year ended June, 2006 and $10,259 for the year ended June, 2007. The travel expenses were higher in 2007 due to the President & CEO of the Company attending meetings arranged by RAMP in Europe for the purpose of raising funds.. Wages and Benefits Wages and benefits were $97,389 for the year ended June, 2005, $75,903 for the year ended June, 2006 and $116,633 for the year ended June, 2007. Costs in this category include the wages paid for accounting and administrative assistance.  Expenses were higher for the year ended June, 2007 because of the stock-based compensation expense of $62,500 as result of 3,530,000 stock options to consultants officers, directors and employees. Loss from Operations The loss from operations was $562,090 as compared to $380,026 for the year end June 30, 2006, and $553,028 for the year ended June 30, 2005. The losses were due, in large part, not due to a loss on sales (see Gross Profit (Loss) above) but to the many costs incurred to establish a basis for further growth of the Company, such as costs associated with patenting the Companys products, costs associated with attempting to secure US and foreign regulatory approval of the Companys products and producing prototypes of products (such as disinfectant wipes, which contain the Companys T36®Disinfectant or similar active ingredients).  The loss for the year ended June 2007 was higher than June, 2007 because of the non-cash stock-based compensation expense of $148,100. Other Income (Loss) Under this category, the impairment loss on intangible assets and the loss on legal settlement have been described elsewhere. 5.B. Liquidity and capital resources The Company had working capital of approximately $627,730 as of June 30, 2007.  As described below, the Company believes that it requires $337,270 in additional working capital to complete its planned business activities over the 18 month period ending on December 31, 2008.  Source of Funds for Fiscal 2008 and for Fiscal 2009 The Companys primary source of funds since incorporation has been and continues to be through the issuance of common shares since sales revenues are not yet rising. As of June 30, 2007, the Company had a deficit of $2,603,791.  Alda Pharmaceuticals Corp. 2007 20F/A Page 38------------------------------------------------------------------------------------------------------------------------------------------------  Use of Funds for Fiscal 2008/2009  For the 18 months ending December 31, 2008 the Company estimates that it will require the following to fund planned operations:  General Office and Administrative Expenses: $   700,000 New Products Research and Development: $   100,000 US securities fees and expenses (related to Form 20F filing): $     30,000 Sales and Marketing: $   235,000 Patenting activities: $     30,000 Regulatory activities (1): $   150,000 New Product Sample Inventory / Production (2): $     20,000 Total: $1,265,000 Less Anticipated Revenue: $   300,000 Additional Funds required: $   965,000 Working Capital (as of June 30, 2007): $   627,730 TOTAL ADDITIONAL FUNDS REQUIRED: $   337,270  (1) Regulatory Activities refers to performance of toxicology, efficacy and other studies required to secure FDA, EPA and other regulatory approvals so that the Company can sell in markets outside of Canada and also refer to securing Health Canada Drug Identification Numbers for Canadian approvals for the Companys new products. (2) New Product Sample Inventory / Production refers to the costs of producing samples for market and consumer testing of those products the Company is developing.  It is the intention of management to undertake private placements as needed to secure sufficient working capital to maintain its operational and development plans. For example, the Company closed a brokered private placement of 8,000,000 Units of the Company at a price per share of $0.10 for gross proceeds of $800,000 as announced on June 7, 2007. Management will undertake further such private placements as required. While the Company has (as described above in Results of Operations) experienced sales revenues growth, these revenues are not sufficient, at this time, to enable the Company to expand its activities in seeking regulatory approval in markets outside of Canada or to enable it to develop and market new products. If it is unable to secure additional equity financing, the Company may not be able to continue as an operating business.  The Company is operating at a loss and its sales revenues do not currently cover even its general and administrative expenses. Critical Accounting Policies Please refer to the Notes to the audited financial statements Recent Accounting Pronouncements  1. Stock-based compensation Effective July 1, 2001, the Company adopted the new recommendations of the Canadian Institute of Chartered Accountants Accounting Handbook Section 3870, Stock-based Compensation and Other Stock-based Payments ("CICA 3870").  The new recommendations were applied prospectively to all stock-based payments to employees and non-employees granted on or after July 1, 2001. Under CICA 3870, prior to July 1, 2003, the Company was not required to record compensation expense for stock-based compensation awards granted to employees, except for employee awards that were direct awards of stock, called for settlement in cash or other assets, or were stock appreciation rights that called for settlement by the issuance of equity instruments.  Consequently the adoption of the standard had no impact on the figures presented other than the pro forma disclosure contained in Note 8(d).  Alda Pharmaceuticals Corp. 2007 20F/A Page 39------------------------------------------------------------------------------------------------------------------------------------------------  During the year ended June 30, 2004, CICA 3870 was amended to require the use of the fair value-based method to account for stock options granted to employees.  In accordance with the revised recommendations, the Company has prospectively applied the fair value-based method to all stock options granted to employees on or after July 1, 2003, whereby compensation cost is measured at fair value at the date of grant and is expensed over the vesting period. 2. Impairment of long-lived assets Effective July 1, 2003, the Company adopted the recommendations of the Canadian Institute of Chartered Accountants Handbook Section 3063, Impairment of long-lived assets.  The new recommendations were applied prospectively to all long-lived assets held for use by the Company after July 1, 2003. 5.C.  Research and development, patents and licenses etc. The Company expects to spend approximately $100,000 on research and development of its products in Fiscal 2008 in total.  Some of these funds will, it is anticipated, by expended in preparing submissions to the FDA and the EPA under the Phigenics, LLC contract (see Exhibit 4.a.) which provides that Phigenics will seek FDA and EPA approval of the Companys products. Because it is impossible to predict if the EPA or FDA will request further studies or reviews of the Companys products, or what cost such studies or reviews would incur, it is not possible to say if this budget will suffice to allow Phigenics to complete submissions on the Companys behalf. The Company does not presently have the working capital to fund its Research and Development expenditures described above and will need to undertake further financings to secure the funds required.. 5.D.   Trend information There are no markets or other trends, other than as disclosed below, which the Company believes materially affect its business prospects. The Companys existing customers and the general public are becoming more aware of disinfectant products. The continuing spread of antibiotic resistant bacteria is contributing to this awareness and a perception that there is a growing need or demand for products similar to those the Company produces. This has resulted in growth in the market for disinfectant products, in particular consumer products which provide antibacterial soaps and lotions.  No reliable quantification of the growth these product sales have experienced is available and no growth or future growth can be reliably predicted. The Company believes that the demand for its T36®Disinfectant product, or at least for similar products, will increase. 5.E.  Off-balance sheet arrangements The Company does not have any off-balance sheet arrangements. 5.F.  Tabular disclosure of contractual obligations The Company does not have any long-term debt obligations, capital (finance) lease obligations, operating lease obligations, purchase obligations or other long-term liabilities reflected on the Companys balance sheet. 5.G.  Safe Harbor This Annual Report on Form 20-F contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, principally in ITEM #4, Information on the Company and ITEM #5.  These statements may be identified by the use of words like plan, expect, aim, believe, project, anticipate, intend, estimate, will, should, could and similar expressions in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends.  In particular, these include statements about the Companys strategy for growth, future performance or results of current sales and production, interest rates, foreign exchange rates, and the outcome of contingencies, such as acquisitions and/or legal proceedings and intellectual property issues.   Alda Pharmaceuticals Corp. 2007 20F/A Page 40------------------------------------------------------------------------------------------------------------------------------------------------  Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties.  Actual future results and trends may differ materially from historical results or those projected in any such forward-looking statements depending on a variety of factors, including, among other things, the factors discussed in this Annual Report under ITEM #3, Key Information, Risk Factors and factors described in documents that the Company may furnish from time to time to the Securities and Exchange Commission.  The Company undertakes no obligation to update publicly or revise any forward-looking statements because of new information. ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES A. Directors and Senior Management The following table sets forth certain information as of June 30, 2007 about the Companys current directors and senior management.  There have been no subsequent changes to the Companys current directors and senior management: Table No. 6: Directors and Senior Management: NameAgePositionOther Reporting Companies in Canada or the United StatesCompanyPositionTerrance Owen61President, CEO and DirectorBi-optic Ventures Inc.Secretary and DirectorPeter Chen45Secretary, CFO and DirectorNonen/aEugene Hodgson51DirectorGrandfield Pacific Inc.
Timmins Gold Corp.Director
DirectorLinda Allison60DirectorNonen/aRonald Zokol58DirectorNonen/aWilliam McCoy52DirectorNonen/a o Terrance Owen  President, CEO and Director:President & Chief Executive Officer of Duft Biotech since May 2000; President of Helix Biotech ULC, a laboratory providing DNA testing services for paternity, immigration and forensic cases, from December 1980 to April 2002; President of Helix BioPharma Corp., a biopharmaceutical company focused on drug delivery, drug discovery, drug development, drug distribution and drug licensing, from July 1995 to June 1998. Since September, 2002, Secretary of Bi-optic Ventures Inc. a company listed on the TSX Venture Exchange and since  September, 2006, a Director of Bi-Optic Ventures Inc. o Peter Chen  Secretary, CFO and Director:Self-employed financial consultant since 1994; financial consultant with Whitaker Consulting Ltd., an internet consultant group involved in web design and generating internet traffic to client sites, from February 2000 to August 2001; President of CME Managing Consultants Inc., a consulting firm offering financial analysis and due diligence services to the mining industry, from January 1997 to January 2000; Financial Officer of CME Consulting Ltd. from February 1994 to January 2000. o Eugene Hodgson  Director: Received a Bachelor of Arts degree from the University of Calgary in 1978; Director, Corporate Development, Intrawest Corporation, 1990-1996. President of E.A. Hodgson & Associates, a private management consulting firm, since 1996; Vice President Western Region of Corpfinance International Ltd., a firm that provides specialized term financing to mid-sized and large companies since December, 2006; Director of the publicly-traded companies Timmins Gold Corp. since , Grandfield Pacific Inc. since 2005; Vice President of Sea Breeze Power Inc. from 2003-2007, co-founder of the "Families for School Seismic Safety" in B.C. in 2004, Director of the Independent Power Producers of B.C. since 2006; Director of the Vancouver Board of Trade from 1995 to 1997,President of the Quadra Liberal Riding Association since 2007 and Area Commissioner, Scouts Canada-Pacific Spirit Area since 2007.  Alda Pharmaceuticals Corp. 2007 20F/A Page 41------------------------------------------------------------------------------------------------------------------------------------------------  o Linda Allison - Director:President of Snowdon & Associates Management Consultants Ltd., a management consulting company that has provided professional services to pharmaceutical, biotechnology, medical device and high technology companies, since 1984; President, CEO & a director of MDX Medical Inc., a biomedical company that develops medical imaging technologies for the improved diagnosis and treatment of cancer, from 2003 to 2004; President, CEO & a director of Genesis Bioventures Inc., a biomedical holding company that invested in companies developing novel diagnostics and therapeutics in the areas of cancer and neurological disorders, from August 2000 to February 2001. o Ron Zokol  Director: Dr. Zokol graduated from the Faculty of Dentistry at the University of British Columbia in 1974 and has been practicing dentistry for the last 26 years. He is the director of the Pacific Institute for Implant Dentistry and a Diplomat of the American Board of Oral Implantology, lecturing internationally in the fields of implant surgery and prosthodontics. In 1986, Dr. Zokol was elected President of the Vancouver and District Dental Society. Currently he also teaches advanced reconstructive dentistry. o William McCoy  Director:Dr. McCoy is Chief Technology Officer for Phigenics, LLC, a life sciences technology company based in Chicago, Illinois. He serves on the World Health Organization (WHO) committee. Dr. McCoy received the Intellectual Property Law Association 2001 Inventor of the Year award and has commissioned to write a book for The International Water Association. The Directors have served in their respective capacities since their election and/or appointment and will serve until the next Annual General Meeting or until a successor is duly elected, unless the office is vacated in accordance with the Articles/By-Laws of the Company. The senior management serves at the pleasure of the Board of Directors. No Director and/or member of senior management had been the subject of any order, judgment, or decree of any governmental agency or administrator or of any court or competent jurisdiction, revoking or suspending for cause any license, permit or other authority of such person or of any corporation of which he is a Director and/or member of senior management, to engage in the securities business or in the sale of a particular security or temporarily or permanently restraining or enjoining any such person or any corporation of which he is an officer or director from engaging in or continuing any conduct/practice/employment in connection with the purchase or sale of securities, or convicting such person of any felony or misdemeanor involving a security or any aspect of the securities business or of theft or of any felony. There are no family relationships between any two or more Directors or members of senior management. There are no arrangements or understandings with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a Director or member of senior management. 6.B.  Compensation Cash Compensation Total compensation accrued and/or paid (directly and/or indirectly) to all Directors/Senior Management during the year ended June 30, 2007 and previous years are detailed in Table No. 7 below:  Alda Pharmaceuticals Corp. 2007 20F/A Page 42------------------------------------------------------------------------------------------------------------------------------------------------  Table No. 7 Annual Compensation of Senior Management _____________________________________________________________________________________  Annual CompensationLong Term CompensationAwardsPayoutsName and
Principal PositionYearSalary
($)Bonus
($)Other 
Annual 
Compen-
sation ($)Securities Under 
Option/
SAR's Granted
(#)Shares/
Units 
Subject to 
Resale 
Restrictions
($)LTIP 
Pay-
outs ($)All Other 
Compen-sation 
($)Terrance G. Owen, Chief Executive Officer (1)2007
2006
2005
2004Nil
Nil
Nil
NilNil
Nil
Nil
Nil$60,000
$60,000
$70,000
$75,000550,000
Nil
32,363
NilNil
Nil
Nil
NilNil
Nil
Nil
NilNil
Nil
Nil
NilPeter Chen, Chief Financial Officer (2)2007
2006
2005
2004Nil
Nil
Nil
NilNil
Nil
Nil
Nil$60,000
$60,000
$64,000
$58,000550,000
Nil
120,000
NilNil
Nil
Nil
NilNil
Nil
Nil
NilNil
Nil
Nil
Nil (1) Consulting/management fees (other annual compensation of $60,000, $60,000, $70,000 and $75,000) were paid to a management consulting company owned by Terrance Owen; (2) Consulting/management fees (other annual compensation of $60,000, 60,000, $64,000 and $58,000) were paid to a management consulting company owned by Peter Chen. _____________________________________________________________________________________ Table No. 8 Stock Option Grants to directors and officers in Fiscal 2006 Ended June 30, 2006 and Fiscal 2007 Ended June 30, 2007 _____________________________________________________________________________________  NameNumber of Options Granted% Of Total Options GrantedExercise Price per ShareGrant DateExpiration DateMkt. Value of Securities Underlying Options on Date of GrantTerrance Owen250,000
300,0007.34%
8.88%$0.10
$0.1208/02/2006
05/04/200708/02/2008
05/03/2009$5,000
$21,000Peter Chen250,000
300,0007.34%
8.88%$0.10
$0.1208/02/2006
05/04/200708/02/2008
05/03/2009$5,000
$21,000Linda Allison150,000
200,0004.44%
5.92%$0.10
$0.1208/02/2006
05/04/200708/02/2008
05/03/2009$3,000
$14,000William McCoy50,000
200,0001.48%
5.92%$0.10
$0.1108/02/2006
04/12/200708/02/2008
04/12/2009$1,000
$14,000Eugene Hodgson50,000
200,0001.48%
5.92%$0.10
$0.1108/02/2006
04/12/200708/02/2008
04/12/2009$1,000
$14,000Ron Zokol150,000
50,0004.44%
1.48%$0.10
$0.1208/02/2006
05/04/200708/02/2008
05/03/2009$3,000
$3,500   Alda Pharmaceuticals Corp. 2007 20F/A Page 43------------------------------------------------------------------------------------------------------------------------------------------------  The following table gives certain information concerning stock option exercises during Fiscal 2007 by our Senior Management and Directors.  It also gives information concerning stock option values.  Table No. 9 Aggregated Stock Options Exercises in Fiscal 2007 Fiscal Year-end Unexercised Stock Options Fiscal Year-end Stock Option Values Senior Management/Directors  NameNumber of Shares Acquired on ExerciseAggregate Value RealizedValue of Unexercised In-the-Money Options at Fiscal Year-End Exercisable/UnexercisableTerrance Owen250,00013,750$9,000/$0William McCoy00$10,500/$0Peter Chen250,00010,675$9,000/$0Ron Zokol00$9,000/$0Linda Allison150,0008,250$6,000/$0Eugene Hodgson00$10,500/$0  Director Compensation:  The Company has no formal plan for compensating its Directors for their service in their capacity as Directors.  Directors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of the Board of Directors. The Board of Directors may award special remuneration to any Director undertaking any special services on behalf of the Company other than services ordinarily required of a Director.  Other than indicated below no Director received any compensation for his services as a Director, including committee participation and/or special assignments. Stock Options:  The Company may grant stock options to Directors, Senior Management and employees. 3,380,000 stock options were granted during fiscal year ended 2007 and 650,000 were exercised during Fiscal 2007. Refer to ITEM #6.E., "Share Ownership" and Table No. 8 for information about stock option grants.  Table 8 excludes 350,000 share purchase options granted to non-officer and non-director employees, which were granted on August 2, 2006 and April 12, 2007 at an exercise price of $0.10 to $0.11 and have a term of 2 years from the date of grant.   In 2007, 150,000 options to acquire common shares of the Company were cancelled due to the employees departure. Change of Control Remuneration:  The Company had no plans or arrangements in respect of remuneration received or that may be received by Executive Officers of the Company in Fiscal 2007 to compensate such officers in the event of termination of employment (as a result of resignation, retirement, change of control) or a change of responsibilities following a change of control, where the value of such compensation exceeds US$60,000 per Senior Management. It is possible that the Company may institute such plans in the future. Other Compensation:  No Senior Manager or Director received other compensation in excess of the lesser of US$25,000 or 10% of such officer's cash compensation, and all Senior Managers or Directors as a group did not receive other compensation which exceeded US$25,000 times the number of persons in the group or 10% of the compensation. Bonus/Profit Sharing/Non-Cash Compensation:  Except for the stock option program discussed in ITEM #6.E., the Company had no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to the Company's Directors or Senior Management. Pension/Retirement Benefits: No funds were set aside or accrued by the Company during Fiscal 2007 to provide pension, retirement or similar benefits for Directors or Senior Management.  Alda Pharmaceuticals Corp. 2007 20F/A Page 44------------------------------------------------------------------------------------------------------------------------------------------------  6.C.  Board Practices 6.C.1.  Terms of Office. Refer to ITEM 6.A.1. 6.C.2.  Directors Service Contracts. --- No Disclosure Necessary ---  6.C.3.  Board of Director Committees. The Company has an Audit Committee, which recommends to the Board of Directors the engagement of the independent auditors of the Company and reviews with the independent auditors the scope and results of the Companys audits, the Companys internal accounting controls, and the professional services furnished by the independent auditors to the Company.  The current members of the Audit Committee are: Peter Chen (the Companys CFO), Eugene Hodgson (non-management Director) and Linda Allison (non-management Director).  The Audit Committee met four times during the year ended June 30, 2007 to discuss and approve the Companys audited and quarterly financial statements.  The Audit Committee also met subsequent to the Companys last Annual General Meeting of shareholders.  6.D.  Employees As of June 30, 2007 and as of the date of filing of this Annual Report, the Company had 1 full-time sales and marketing employee, and two Officers (its President, Terrance Owen and its CFO, Peter Chen), employed full-time.  The Company does not have any part-time employees. The Company has no plans to increase its numbers of employees unless sales revenues increase and permit hirings.  6.E.  Share Ownership Table No. 10 lists, as of June 30, 2007, Directors and Senior Management who beneficially own the Company's voting securities, consisting solely of common shares, and the amount of the Company's voting securities owned by the Directors and Senior Management as a group.  Table No. 10 Shareholdings of Directors and Senior Management _____________________________________________________________________________________  Title of ClassName of Beneficial OwnerAmount and Nature of Beneficial OwnershipPercent of Class(1)Options exercisable in 60 daysCommonTerrance Owen (2)1,514,0004.70%300,000CommonLinda Allison25,0630.08%200,000CommonPeter Chen137,5000.43%300,000CommonEugene Hodgson00.00%250,000CommonRonald Zokol205,7480.64%200,000CommonWilliam McCoy00.00%250,000Total Directors/Management1,882,3115.85%1,500,000 (1) Based on 32,192,404 outstanding as of June 30, 2007 (2) Includes 64,000 shares owned by Patricia Genereaux, the spouse of Terrance Owen _____________________________________________________________________________________  Alda Pharmaceuticals Corp. 2007 20F/A Page 45------------------------------------------------------------------------------------------------------------------------------------------------  Stock Options:  The terms of incentive options grantable by the Company are done in accordance with the rules and policies of the TSX Venture Exchange and the British Columbia Securities Commission, including the number of common shares under option, the exercise price and expiry date of such options, and any amendments thereto.  The Company adopted a formal written stock option plan (the "Plan") on December 13, 2005. (A copy of the Companys Stock Option Plan is included with this document as Exhibit 4.e.) At every Annual General Meeting of the Company, the Plan is presented to and voted on by the shareholders of the Company. If approved, the terms and conditions of the Plan remain in force for the subsequent year.  Such terms and conditions, including the pricing of the options, expiry and the eligibility of personnel for such stock options; and are described below. The principal purposes of the Companys stock option program are to (a) assist the Company in attracting, retaining, and motivating directors, officers and employees of the Company and, (b) to closely align the personal interests of such directors, officers and employees with the interests of the Company and its shareholders. The Plan provides that stock options may be granted to service providers for the Company.  The term service providers means: (a) Any full or part-time employee or Officer, or insider of the Company or any of its subsidiaries; (b) Any other person employed by a company or individual providing management services to the Company; (c) Any other person or company engaged to provide ongoing consulting services for the Company or any entity controlled by the Company or (d) Any individual engaged to provide services that promote the purchase or sale of the issued securities (any person in (a), (b), (c) or (d) hereinafter referred to as an Eligible Person); and (e) Any registered retirement savings plan established by such Eligible Person, or any corporation controlled by such Eligible Person, the issued and outstanding voting shares of which are, and will continue to be, beneficially owned, directly or indirectly, by such Eligible Person and/or spouse, children and/or grandchildren of such Eligible Person. For stock options to Employees, Consultants or Management Company Employees, the Company must represent that the optionee is a bona fide Employee, Consultant or Management Company Employee as the case may be.  The terms insider Controlled and subsidiary shall have the meanings ascribed thereto in the Securities Act (Ontario) from time to time.  Subject to the foregoing, the board of directors or Committee, as applicable, shall have full and final authority to determine the persons who are to be granted options under the Plan and the number of shares subject to each option. The Plan shall be administered by the board of directors of the Company or a committee established by the board of directors for that purpose.  Subject to approval of the granting of options by the board of directors or Committee, as applicable, the Company shall grant options under the Plan. The Plan provides that the aggregate number of shares of the Company, which may be issued and sold under the Plan, will not exceed 10% of the issued shares of the Company.  The Company shall not, upon the exercise of any option, be required to issue or deliver any shares prior to (a) the admission of such shares to listing on any stock exchange on which the Companys shares may them be listed, and (b) the completion of such registration or other qualification of such shares under any law, rules or regulation as the Company shall determine to be necessary or advisable.  If any shares cannot be issued to any optionee for whatever reason, the obligation of the Company to issue such shares shall terminate and any option exercise price paid to the Company shall be returned to the optionee. If a stock option expires or otherwise terminates for any reason without having been exercised in full, the number of common shares reserved for issuance under that expired or terminated stock option shall again be available for the purposes of the Plan.  Any stock option outstanding when the Plan is terminated will remain in effect until it is exercised or it expires.  The Plan provides that it is solely within the discretion of the Board to determine who should receive stock options and in what amounts, subject to the following conditions: (a) Options will be non-assignable and non-transferable except that they will be exercisable by the personal representative of the option holder in the event of the option holders death;  Alda Pharmaceuticals Corp. 2007 20F/A Page 46------------------------------------------------------------------------------------------------------------------------------------------------  (b) Options may be exercisable for a maximum of five years from grant date; (c) Options to acquire no more than 5% of the issued shares of the Company may be granted to any one individual in any 12-month period; (d) Options to acquire no more than 2% of the issued shares of the Company may be granted to any one consultant in any 12-month period; (e) Options to acquire no more than an aggregate of 2% of the issued shares of  the Company may be granted to an employee conducting investor relations activities (as defined in TSX Venture Exchange Policy 1.1), in any 12 month period; (f) Options to acquire no more than 10% of the issued shares of the Company may be granted to any insiders in any 12-month period; (g) Options held by an option holder who is a director, employee, consultant or management company employee must expire within 90 days after the option holder ceases to be a director, employee, consultant or management company employee; (h) Options held by an option holder who is engaged in investor relations activities must expire within 30 days after the option holder ceases to be employed by the Company to provide investor relations activities; and (i) In the event of an option holders death, the option holders personal representative may exercise any portion of the option holders vested outstanding options for a period of one year following the option holders death. The Plan provides that other terms and conditions may be attached to a particular stock option, such terms and conditions to be referred to in a schedule attached to the option certificate.  Stock options granted to directors, senior officers, employees or consultants will vest when granted unless otherwise determined by the Board on a case by case basis, other than stock options granted to consultants performing investor relations activities, which will vest in stages over 12 months with no more than one-fourth of the options vesting in any three month period. The price at which an option holder may purchase a common share upon the exercise of a stock option will be as set forth in the option certificate issued in respect of such option and in any event will not be less than the discounted market price of the Companys common shares as of the date of the grant of the stock option (the Award Date).  The market price of the Companys common shares for a particular Award Date will typically be the closing trading price of the Companys common shares on the day immediately preceding the Award Date, or otherwise in accordance with the terms of the Plan.  Where there is no such closing price or trade on the prior trading day market price shall mean the average of the most recent bid and ask of the shares of the Company on any stock exchange on which the shares are listed or dealing network on which the shares of the Company trade. In no case will a stock option be exercisable at a price less than the minimum prescribed by each of the organized trading facilities or the applicable regulatory authorities that would apply to the award of the stock option in question. Common shares will not be issued pursuant to stock options granted under the Plan until they have been fully paid for by the option holder.  The Company will not provide financial assistance or loans to option holders to assist them in exercising their stock options. The names and titles of the Directors/Executive Officers/Employees of the Company to whom outstanding stock options have been granted and the number of common shares subject to such options are set forth in Table No. 11 as of June 30, 2007, as well as the number of options granted to them.  There are outstanding stock options granted to consultants, scientific advisors and investor relations.  Alda Pharmaceuticals Corp. 2007 20F/A Page 47------------------------------------------------------------------------------------------------------------------------------------------------   Table No. 11 Stock Options Outstanding ________________________________________________________________________________  Number of Options GrantedExercise Price per ShareGrant DateExpiration DateTerrance Owen300,000$0.1205/04/200705/03/2009Peter Chen300,000$0.1205/04/200705/03/2009Linda Allison200,000$0.1205/04/200705/03/2009Eric Lam100,000
100,000$0.10
$0.1108/02/2006
04/12/200708/02/2008
04/12/2009Eugene Hodgson50,000
200,000$0.10
$0.1108/02/2006
04/12/200708/02/2008
04/12/2009William F. McCoy50,000
200,000$0.10
$0.1108/02/2006
04/12/200708/02/2008
04/12/2009Ron Zokol150,000
50,000$0.10
$0.1208/02/2006
05/04/200708/02/2008
05/03/2009TOTAL1,700,000Allan Shapiro300,000$0.1205/04/200705/03/2009Brian Conway40,000$0.1008/02/200608/02/2008Mike Wilby40,000$0.1008/02/200608/02/2008Freeform Communications100,000$0.1008/02/200608/02/2008John Mooney300,000$0.1008/02/200608/02/2011Total Consultants, scientific advisors and
Investor relations780,000Total Outstanding2,480,000 ________________________________________________________________________________   Alda Pharmaceuticals Corp. 2007 20F/A Page 48------------------------------------------------------------------------------------------------------------------------------------------------  ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 7.A. Major Shareholders As of June 30, 2007, all shareholders have the same voting rights attached thereto as all other common shares of the Company except that, under the terms of the Voting Agreement described above and attached as Exhibit 3. only Allan Shapiro has restrictions on the voting rights of his shares. NameNumber of Common
Shares and Options (exercisable within 60 days) HeldPercentage of Common
Shares Held (calculated as a percentage of issued and outstanding on June 30, 2007)Options exercisable in 60 days2007
Allan Shapiro(1)4,269,19213.26%1,650,00Terrance Owen(2)2,589,0008.04%1,075,000 (1) Shares held by Allan Shapiro include 98,356 shares held by his spouse, Margaret Shapiro. (2) Shares held by Terrance Owen include 64,000 shares held by his spouse, Patricia Genereaux.  The share ownership of both Allan Shapiro and Terrance Owen increased compared to 2005 and 2006 due to the issuance of 300,000 options each to both individuals during the 2007 fiscal year and the acquisition of 775,000 warrants by Terrance Owen and 1,650,000 warrants by Allan Shapiro pursuant to the private placement completed on June 7, 2007. Other than as disclosed above the Company is not aware of any other company, any foreign government or any other person, jointly or severally, that directly or indirectly controls the Company. The Company is not aware of any arrangements the operation of which may at a future date result in a change in control of the Company.  7.A.1.a.  Holdings By Major Shareholders.  Refer to ITEM #6.E and Table No. 10.  7.A.1.b.  Significant Changes in Major Shareholders Holdings. ---No Disclosure Required---  7.A.1.c.  Different Voting Rights.  The Companys major shareholders do not have different voting rights except as described in the Voting Agreement (Exhibit 3.a.) which is disclosed in Section 4.A., History and Development of the Company.  7.A.2.  Canadian Share Ownership. On June 30, 2007, the Companys shareholders list showed 32,192,404 common shares outstanding and 56 registered shareholders.  The Company has researched the indirect holding by depository institutions and other financial institutions estimates that there are: 54 holders of record  resident in Canada, holding 19,685,055 common shares; 0 holders of record resident in the USA, holding  0 common shares; and, 1 holder of record resident elsewhere holding 15,439 common shares.  7.A.3.  Control of the Company  The Company is a publicly owned Canadian corporation, the shares of which are owned primarily Canadian residents and other foreign residents.  The Company is not controlled by any foreign government or other person(s) except as described in ITEM #4.A., History and Growth of the Company, and ITEM #6.E., Share Ownership.  Alda Pharmaceuticals Corp. 2007 20F/A Page 49------------------------------------------------------------------------------------------------------------------------------------------------  7.A.4.  Change of Control of Company Arrangements ---No Disclosure Necessary---  7.B.  Related Party Transactions  During the 2007 year, the Company incurred consulting fees of $120,000 (2006: $120,000; 2005: $134,000) to companies controlled by Terrance Owen, President & CEO and Peter Chen, CFO, both Directors of the Company. During the 2007 year, the Company incurred premises rent of $28,371 (2006: $$30,912; 2005: $25,265) to a company controlled by Terrance Owen, President & CEO and a director of the Company. As at June 30, 2007, of the $293,600 Subscriptions Receivable (2006: $nil; 2005: $nil) for the private placement that closed on June 7, 2007,  $55,000 (2006: $nil; 2005: $nil) was owing from Terrance Owen, President & CEO and $50,000 (2006: $nil; 2005: $nil) from Linda Allison, both Directors of the Company. Subsequent to the year ended June 30, 2007, both amounts were paid in full. The Company entered into an agreement with Phigenics, LLC on July 21, 2005 (see 10.C. Material Contracts for a summary of the agreement and Exhibit 4.a. for details of the agreement). William McCoy, a Director of the Company, is the Chief Technical Officer of Phigenics.  On January 1, 2004 the Company advanced $7,998 to API (now named 513947 BC Ltd. and controlled by Allan Shapiro) at an interest rate of 8% per annum and secured by 40,000 shares of the Company owned by API. On September 30, 2005, API repaid $7,000 to the Company.  At December 31, 2005, the Company received repayment of the remaining balance of $988. Interest of $1,137.31 was also paid on December 31, 2005.  Other than as disclosed above, there were no related party transactions of the Company for the previous three fiscal years except that during the 2006 fiscal year, the Company incurred consulting fees of $60,000 (2005: $70,000) to Allan Shapiro, a major shareholder of the Company. Accounting Fees For the annual statements dated June 30, 2007, the Company paid accounting fees of $25,000 to HLB Cinnamon Jang Willoughby, Charted Accountants and $2,950 to Berris Mangan, Charted Accountants.  The Company paid accounting fees of $23,100, and $25,750 to Berris Mangan, Chartered Accountants during the years ended June 30, 2005 and June 30, 2006, respectively.  Indirect Payments ---No Disclosure Required---  Shareholder Loans ---No Disclosure Required---  Amounts Owing to Senior Management/Directors There is no money owing to members of senior management of members of the Board of Directors. There have been no transactions since June 30, 2005, or proposed transactions, which have materially affected or will materially affect the Company in which any director, executive officer, or beneficial holder of more than 5% of the outstanding common shares, or any of their respective relatives, spouses, associates or affiliates has had or will have any direct or material indirect interest.  7.C.  Interests of Experts and Counsel ---No Disclosure Required---    Alda Pharmaceuticals Corp. 2007 20F/A Page 50------------------------------------------------------------------------------------------------------------------------------------------------  ITEM 8.  FINANCIAL INFORMATION  8.A.  Consolidated Statements and Other Financial Information The Company's financial statements are stated in Canadian Dollars (CDN$) and are prepared in accordance with Canadian Generally Accepted Accounting Principles (GAAP), the application of which, in the case of the Company, conforms in all material respects for the periods presented with United States GAAP, except as discussed in footnotes to the financial statements. The financial statements as required under ITEM #17 are attached hereto and found immediately following the text of this Annual Report.  The audit reports of HLB Cinnamon Jang Willoughby, Charted Accountants (former auditor, Berris Mangan, Chartered Accountants), are included herein immediately preceding the financial statements.  Audited Financial Statements: Fiscal 2006/2007 ended June 30, 2007 and Fiscal 2005/2006 ended June 30, 2007.   8.A.7.  Legal/Arbitration Proceedings The Directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation, other than as described below: On May 14, 2004, the Company announced that certain documents which had been published and disseminated by CIBRON Corporation, a company which had been retained by the Company as a   manufacturers representative, together with presentation materials presented at a conference by a consultant to the Company contained certain comparisons and information with respect to the safety and efficacy of products manufactured and sold by Virox Technologies Inc. that were untrue, and potentially misleading in the context in which they were presented. On June 14, 2004, the Company received a release from Virox Technologies, Inc. and paid an amount of $10,000 to settle a legal claim made by Virox Technologies, Inc. Subsequently On June 18, 2004, the management of the Company discovered that Virox had posted damaging, misleading, libelous and possibly fraudulent statements on Viroxs website about the Company. The Company also suspected that Virox had infringed on the Companys trademark and copyright. The Company filed an action (No. S043563) for defamation in the Vancouver Court Registry of the Province of British Columbia on June 25, 2004., naming the defendants as Virox Technologies Inc. and one of its principals, Randy Pilon. This claim was settled effective July 12, 2006, by an agreement under which the Company received an amount of $15,000 from the competitor. The proceeds of the settlement, net of associated legal costs in the amount of $4,455, have been recognized in the Statement of Operations and Deficit for the period ended June 30, 2007.  .Prior to the completion of the Qualifying Transaction, a company, JohnsonDiversey Inc., opposed a trademark application made in Canada by API and commenced legal proceedings during 2003 claiming damages in respect to alleged infringement of trademark. API had filed a Statement of Defence prior to the completion of the Qualifying Transaction. The Statement of Claim was subsequently amended to add the Company as a defendant in the action. On May 23, 2005, the Company entered into a settlement agreement with that company, whereby the Company agreed to terminate the use, and application for registration of, the trademark "Viralex". The Company must discontinue the use of that trademark in advertising and other promotional disclosures, liquidate its inventory of goods bearing the trademark "Viralex", and rename the Viralex product within twelve months from the date of the agreement, in consideration for payment of $30,000 (US). These funds were held in escrow by the Company's lawyer until the Company issued a press release regarding the settlement of the trademark dispute, and withdrew its application for the "Viralex" trademark, which occurred on May 30, 2005. The proceeds of the settlement, net of associated costs, as well as the costs associated with establishment of a new trademark, are recognized for accounting purposes in the 2006 year, when the Company's obligations under the settlement agreement are fulfilled. The Company has since renamed its lead product and it is now referred to as T36® Disinfectant  Alda Pharmaceuticals Corp. 2007 20F/A Page 51------------------------------------------------------------------------------------------------------------------------------------------------  The Directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.  8.B.  Significant Changes  ----No Disclosure Required----  ITEM 9.  THE OFFER AND LISTING  9.A.  Common Share Trading Information The Company's common shares trade on the TSX Venture Exchange in Toronto, Ontario, Canada, under the symbol "APH".  The Company applied for listing on the TSX Venture Exchange and began trading on the TSX Venture Exchange on July 31, 2001 under its former name, Duft Biotech Capital Ltd. and under its former symbol, DUF. Table No. 12 lists the high, low and closing sales prices on the TSX Venture Exchange for the last six months, last ten fiscal quarters, and last five fiscal years.  Alda Pharmaceuticals Corp. 2007 20F/A Page 52------------------------------------------------------------------------------------------------------------------------------------------------    Table No. 12 TSX Venture Exchange Common Shares Trading Activity ____________________________________________________________________________________  Sale - Canadian Dollars Period AverageHighLowMonth ended 06/30/070.1550.145Month ended 05/31/070.150.14Month ended 04/30/070.150.125Month ended 03/31/070.100.095Month ended 02/28/070.100.10Month Ended 01/31/070.080.08Fiscal Year Ended 06/30/20070.1550.145Fiscal Year Ended 06/30/20060.0750.075Fiscal Year Ended 06/30/20050.180.06Fiscal Year Ended 06/30/20040.150.24Fiscal Year Ended 06/30/20030.270.15Fiscal Quarter Ended 06/30/20070.1550.145Fiscal Quarter Ended 03/31/20070.100.095Fiscal Quarter Ended 12/31/20060.060.06Fiscal Quarter Ended 09/30/20060.050.05Fiscal Quarter Ended 06/30/20060.0750.075Fiscal Quarter Ended 03/31/20060.0850.08Fiscal Quarter Ended 12/31/20050.0950.055Fiscal Quarter Ended 09/30/20050.0950.04Fiscal Quarter Ended 06/30/20050.1150.06Fiscal Quarter Ended 03/31/20050.140.09 ______________________________________________________________________________  9.A.5.  Common Share Description  Registrar/Common Shares Outstanding/Shareholders Effective August 19, 2005, the authorized share capital of the Company was increased to an unlimited number of common shares without par value due to changes in the British Columbia Company Act which permitted this action. There are no Indentures or Agreements limiting the payment of dividends and there are no conversion rights, special liquidation rights, pre-emptive rights or subscription rights.  Alda Pharmaceuticals Corp. 2007 20F/A Page 53------------------------------------------------------------------------------------------------------------------------------------------------  Pacific Corporate Trust Company of Canada, a wholly owned division of Computershare Trust Company of Canada (located at 2nd Floor, 510 Burrard Street, Vancouver, British Columbia Canada V5K 1A1) is the registrar and transfer agent for the common shares.  Stock Options Refer to ITEM 6.E., Table No. 9 (Aggregate Option Exercises) and Table No. 11 (Stock Options Outstanding) for additional information regarding the Companys stock options. Table No. 13 lists, as of June 30, 2007, share purchase warrants (options to purchase common shares) outstanding, the date the share purchase warrants were issued, the exercise price, and the expiration date of the share purchase warrants.   These warrants were issued in conjunction with private placements of the Companys securities and all holders of the Companys warrants are resident in Canada.  Table No. 13 Share Purchase Warrants Outstanding ____________________________________________________________________________________  Effective Date of IssuanceNumber of Share Purchase Warrants Originally IssuedNumber of Share Purchase Warrants Still OutstandingExercise PriceExpiration Date of Share Purchase WarrantsSeptember 12, 20061,430,000(1)1,430,000$0.10September 12, 2007December 21, 20053,916,000(2)2,934,000$0.10December 22, 2007June 7, 20078,000,000(3)8,000,000$0.20
$0.30June 7, 2008
June 7, 2009 (1) Issued pursuant to a private placement which closed in September of 2006 (2) Issued pursuant to a private placement which closed in December of 2005.  Terms of warrants were amended to extend the exercisable period of the warrants to December 22, 2007 at the exercise price of $0.10 per share. (3) Issued pursuant to a private placement which closed in June of 2007.  Exercisable at a price of $0.20 per share until June 7, 2008 and, thereafter at a price of $0.30 until June 7, 2009. ______________________________________________________________________________   9.A.6.  Differing Rights ---No Disclosure Necessary--- 9.A.7.a.  Subscription Warrants/Right ---No Disclosure Necessary--- 9.A.7.b.  Convertible Securities/Warrants ---No Disclosure Necessary---  9.C.  Stock Exchanges Identified The common shares trade on the TSX Venture Exchange headquartered in Toronto, Ontario.  Alda Pharmaceuticals Corp. 2007 20F/A Page 54------------------------------------------------------------------------------------------------------------------------------------------------  Refer to ITEM #9.A.4 for trading information and history. At this time, the Company is not seeking a listing on any other stock exchange except that a listing on a US exchange will be sought once this filing is completed and the company is accepted for trading on a US exchange.   ITEM 10.  ADDITIONAL INFORMATION  10.A.  Share Capital  10.A.1.  Authorized/Issued Capital. Effective August 19, 2005, the authorized share capital of the Company was increased to an unlimited number of common shares without par value due to changes in the British Columbia Company Act which permitted this action. At June 30, 2007, there were 32,192,404 common shares issued and outstanding. At June 30, 2006, there were 20,800,404 common shares issued and outstanding. As of June 30, 2005, there were 100,000,000 common shares authorized. At June 30, 2005 there were 15,784,404 common shares issued. As of June 30, 2004, there were 100,000,000 common shares authorized.   At June 30, 2004 there were 12,784,404 common shares issued. As of June 30, 2003, there were 100,000,000 common shares authorized.   At June 30, 2003 there were 2,451,475 common shares issued. As of June 30, 2002, there were 100,000,000 common shares authorized.   At June 30, 2002 there were 2,376,475 common shares issued. As of June 30, 2001, there were 100,000,000 common shares authorized.   At June 30, 2001 there were 1,176,475 common shares issued. During the last five years, less than 1% of the capital has been paid for with assets other than cash.  10.A.2.  Shares Not Representing Capital. ---No Disclosure Necessary---  10.A.3.  Shares Held By Company. ---No Disclosure Necessary---  10.A.4.  Stock Options/Share Purchase Warrants 10.A.5.  Stock Options/Share Purchase Warrants ---Refer to Table No. 11 and Table No. 13.--- Check tables for correct reference  10.A.6.  History of Share Capital The Company has financed its operations through funds raised in public and private placements of common shares and warrants:  Alda Pharmaceuticals Corp. 2007 20F/A Page 55------------------------------------------------------------------------------------------------------------------------------------------------    Fiscal YearNature of Share IssuanceNumber of SharesAmount ($)Fiscal 2001Private Placement @ $0.0851,176,475$100,000.38Fiscal 2002Canadian Prospectus Offering (IPO) @$0.171,200,000$204,000.00Fiscal 2003Brokers Warrant Shares on Canadian Prospectus Offering (IPO) @ $0.17150,000$25,500.00Fiscal 2004Private Placement @ $0.15346,666$52,000.00Private Placement @ $0.206,200,000$1,240,000Fiscal 2005Private Placement @ $0.103,000,000$300,000  Fiscal YearNature of Share IssuanceNumber of SharesAmount ($)Fiscal 2006Private Placement @$0.05
Private Placement @$0.053,916,000
1,100,000$195,800
$55,000Fiscal 2007Private Placement @$0.05
Private Placement @$0.101,430,000
8,000,000$71,500
$800,000 (1) At June 30, 2007, there were no common shares held in escrow, During the 2007 year, 733,163 common shares were released from escrow (2006: 1,466,324; 2005: 1,466,318)  10.A.7.  Resolutions/Authorizations/Approvals ---No Disclosure Necessary---  10.B.  Memorandum and Articles of Association  The Companys corporate constituting documents comprising the Notice of Articles and Articles are registered with the British Columbia Registrar of Companies under Incorporation No. BC0607937.  A copy of the Articles was filed as an Exhibit 1 with the Companys initial registration statement on Form 20-F.  The following is a summary of certain  provisions of the Company's  Notice of Articles and Articles and certain provisions of the British Columbia Business Corporations Act (the BCA), applicable to the Company: Objects and Purposes The Articles do not specify objects or purposes.  Under both the BCA, a British Columbia corporation generally has all the legal powers of a natural person.  British Columbia corporations may not undertake certain limited business activities such as operating as a trust company or railroad without alterations to its form of articles and specific government consent. Share Capital The authorized capital of the Company consists of an unlimited number of common shares without par value.  All of the common shares must be fully paid and are not subject to any future call or assessment.  All of the common shares of the Company rank equally as to voting rights, participation in a distribution of the assets of the Company on a liquidation, dissolution or winding-up of the Company and the entitlement to dividends.  The holders of the common shares are entitled to receive notice of all shareholder meetings and to attend and vote at such meetings.  Shareholders are not entitled to cumulative voting.  Each common share carries with it the right  Alda Pharmaceuticals Corp. 2007 20F/A Page 56------------------------------------------------------------------------------------------------------------------------------------------------  to one vote.  The common shares do not have preemptive or conversion rights.  In addition, there are no sinking fund or redemption provisions applicable to the common shares or any provisions discriminating against any existing or prospective holders of such securities as a result of a shareholder owning a substantial number of shares. Share Certificates Under the Articles, a shareholder is entitled to a share certificate representing the number of shares of the Company held or a written acknowledgement of the shareholders right to obtain such a share certificate. No Limitation on Foreign Ownership There are no limitations under the Companys Articles or in the BCA on the right of persons who are not citizens of Canada to hold or vote common shares. Dividends Dividends may be declared by the Board out of available assets and are paid rateably to holders of common shares.  No dividend may be paid if the Company is, or would thereby become, insolvent. Voting Rights Each of the Companys common share is entitled to one vote on matters to which common shares ordinarily vote including the annual election of directors, appointment of auditors and approval of corporate changes.  There are no cumulative voting rights applicable to the Company. Borrowing Powers The Company, if authorized by the directors, may: (a) borrow money in the manner and amount, on the security, from the sources and on the terms and conditions that they consider appropriate; (b) issue bonds, debentures and other debt obligations either outright or as security for any liability or obligation of the Company or any other person and at such discounts or premiums and on such other terms as they consider appropriate; (c) guarantee the repayment of money by any other person or the performance of any obligation of any other person; and (d)mortgage, charge, whether by way of specific or floating charge, grant a security interest in, or give other security on, the whole or any part of the present and future assets and undertaking of the Company. Indemnity Provisions Under the Articles and the BCA, the Company is now permitted (and is, in some circumstances, required) to indemnify a past or present director or officer of the Company or an associated corporation without obtaining prior court approval in respect of an eligible proceeding. An eligible proceeding includes any legal proceeding relating to the activities of the individual as a director or officer of the Company. However, under the BCA, the Company will be prohibited from paying an indemnity if: (a) the party did not act honestly and in good faith with a view to the best interests of the Company; (b) the proceeding was not a civil proceeding and the party did not have reasonable grounds for believing that his or her conduct was lawful; and (c) the proceeding is brought against the party by the Company or an associated corporation. Directors  Number and Qualification The Companys Articles do not specify a maximum number of directors.  The minimum under British Columbia law for a public company is three.  The number of directors shall be the number of directors fixed by  Alda Pharmaceuticals Corp. 2007 20F/A Page 57------------------------------------------------------------------------------------------------------------------------------------------------  the directors annually or the number that are actually elected at a general shareholders meeting under the Existing Articles. The number of directors is determined, annually, by shareholders at the annual shareholders meeting and all directors are elected at that time. Under the Articles the directors are entitled between successive annual general meetings to appoint one or more additional directors but not more than one-third of the number of directors fixed at a shareholders or actually elected at the preceding annual shareholders meeting.  Directors automatically retire at the commencement of each annual meeting but may be re-elected thereat. Directors must be of the age of majority (18), and meet eligibility criteria including being mentally competent, not an un-discharged bankrupt, no fraud related convictions in the previous five years. There are residency requirements and there is no mandatory retirement age either under the Articles or under the BCA.  Directors need not own any shares of the Company in order to qualify as directors. Directors - Powers and Limitations Directors must manage or supervise the management of the business and affairs of the Company and have the authority to exercise all such powers which are not required to be exercised by the shareholders as governed by the BCA.  Directors may, by resolution, create and appoint an executive committee consisting of the director or directors that they deem appropriate.  This executive committee has, during the intervals between meetings of the Board, all of the directors powers, except the power to fill vacancies in the Board, the power to remove a Director, the power to change the membership of, or fill vacancies in, any committee of the Board and any such other powers as may be set out in the resolution or any subsequent directors resolution.  Directors may also by resolution appoint one or more committees other than the executive committee.  These committees may be delegated any of the directors powers except the power to fill vacancies on the board of directors, the power to remove a director, the power to change the membership or fill vacancies on any committee of the directors, and the power to appoint or remove officers appointed by the directors. Under the BCA, directors are obligated to abstain from voting on matters in which they may be financially interested after disclosing in writing such interest.  Directors compensation is not a matter on which they must abstain.  Directors borrowing powers are not generally restricted where the borrowing is in the Companys best interests, but the directors may not authorize the Company to provide financial assistance for any reason where the Company is insolvent or the providing of the guarantee would render it insolvent. Amendment of Articles and Notice of Articles; Special Transactions The Articles provide that the general authority required to amend all provisions of the Companys Articles and the Notice of Articles relating to the authorized share structure is a resolution of the directors and the attachment of special rights and restrictions thereto, including any changes therein, an ordinary resolution.  If the amendment prejudices or interferes with the rights or special rights attached to any class of issued shares, by the provisions of the BCA, the consent of the holders of that class of shares by a special separate resolution is also required. Certain corporate changes or proposed transactions including amalgamation with another company, sale of substantially all of the Companys assets, re-domiciling out of the jurisdiction of British Columbia, creation of new classes of shares not only require the consent of the holders of common shares by a special separate resolution but generally also give rise to a dissent right which is the right to be paid the fair value of the stockholders shares in cash if the required special resolution is actually passed and the Company elects to proceed with the matter notwithstanding receipt of dissent notices.  A notice of a shareholders meeting at which such a change or proposed transaction is intended to be considered must include a prominent notice of the dissent right.  Dissent provisions are governed by the BCA and not by the Articles of the Company. Under the Articles, a special separate resolution requires a majority of three-quarters of the votes cast.  Alda Pharmaceuticals Corp. 2007 20F/A Page 58------------------------------------------------------------------------------------------------------------------------------------------------  Shareholders Meetings In addition to reflecting the present notice and other provisions of the BCA relating to shareholders meetings, the Articles provide that shareholders meetings may be held at such place as is determined by the directors.  Shareholders meetings are governed by the Articles of the Company but many important protections and procedures are contained within the BCA and the Securities Act (British Columbia) and the Securities Act (Alberta) and the respective regulations and rules thereto and the policy statements, notices and blanket orders of the respective commissions of each of British Columbia and Alberta, together with the national policy statements, and national instruments applied by the such commissions (collectively, Applicable Canadian Securities Law).  The Articles provide that the Company will hold an annual shareholders meeting, will provide at least 21 days notice and will provide for certain procedural matters and rules of order with respect to conduct of the meeting.  The BCA and Applicable Canadian Securities Law superimpose requirements that generally provide that shareholders meetings require not less than a 60 day notice period from initial public notice and that the Company makes a thorough advanced search of intermediary and brokerage registered shareholdings to facilitate communication with beneficial shareholders so that meeting proxy and information materials can be sent via the brokerages to unregistered but beneficial shareholders.  The form and content of information circulars and proxies and like matters are governed by Applicable Canadian Securities Law and includes the specifies relating to disclosure requirements for the proxy materials and various corporate actions, background information on the nominees for election for director, executive compensation paid in the previous year and full details of any unusual matters or related party transactions.  The Company must hold an annual shareholders meeting open to all shareholders for personal attendance or by proxy at each shareholders determination.  The meeting must be held within 13 months of the previous annual shareholders meeting and must present audited statements which are dated no more than six months prior to such meeting. Change in Control The Company has not implemented any shareholders rights or other poison pill protection against possible take-overs. The Company does not have any agreements which are triggered by a take-over or other change of control.  There are no provisions in its articles triggered by or affected by a change in outstanding shares which gives rise to a change in control.  There are no provisions in the Companys material agreements giving special rights to any person on a change in control. Insider Share Ownership Reporting The Articles of the Company do not require disclosure of share ownership.  Share ownership of director nominees must be reported annually in proxy materials sent to the Companys shareholders.  There are no requirements under the BCA to report ownership of shares of the Company but Applicable Canadian Securities Law requires disclosure of trading by insiders (generally officers, directors and holders of 10% of voting shares) within 10 days of the trade.  Controlling shareholders (generally those in excess of 20% of outstanding shares) must provide seven days advance notice of share sales. Applicable Canadian Securities Law Applicable Canadian Securities Law governs matters typically pertaining to public companies such as continuous quarterly financial reporting, immediate disclosure of material changes, insider trade reporting, take-over protections to ensure fair and equal treatment of all shareholders, exemption and resale rules pertaining to non-prospectus securities issuances as well as civil liability for certain misrepresentations, disciplinary, appeal and discretionary ruling matters.  All of the Companys shareholders regardless of residence have equal rights under this legislation except as provided for in the Voting Agreement (Exhibit 3.a.).  Alda Pharmaceuticals Corp. 2007 20F/A Page 59------------------------------------------------------------------------------------------------------------------------------------------------  10.C.  Material Contracts    Linns (Exhibit 4.f.) The Company assigned a five year licensing and distribution agreement with Linns Corporation Sdn Bhd (Linns) (see Exhibit 4.f.) with an effective date of August 1, 2004.  The Territory is defined as Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, subject to Linns submitting the required applications required for regulatory approval of T36®Disinfectant in each part of the Territory. As of June 30, 2007, no registrations or sales have occurred through Linns and the Company considers the agreement to be inactive. The Company is no longer pursuing any registrations either directly or through agents, except in China through He-Yi , as noted below and in Exhibit 4.g. Esthetics Plus (Exhibit 4.h.) The material terms of the Agreement between the Company and Esthetics Plus (EP), dated February 1st, 2005, are as follows. The Company appointed EP as its exclusive distributor to the beauty industry throughout all the provinces and territories within Canada except for the province of British Columbia, in which the distributorship is non-exclusive (the Territory). The initial term is three years. Thereafter, the Agreement is automatically renewed on each anniversary date for another year unless either party provides the other with written notice, not later than one hundred twenty (120) days prior to the expiration of the term still in effect, of its desire to end the Agreement upon the expiration of the term. In the event that the Company chooses to terminate the Agreement at any time, other than for cause, the Company  will repurchase, within thirty days, all unsold Products in EPs inventory sold to EP by the Company in the previous six  months period at EPS original cost from the Company, plus 10% of the value of the last 6 months product purchased to compensate EP for efforts promoting the Company Products in the Territory, financing costs and inventory warehousing. The agreement is still in effect and in good standing. EP shall use its best efforts to promote the sale of the products, refrain from the sale or distribution of any competing products, stay within the Territory, unless agreed to by the Company in writing; actively prospect the Territory, undertake marketing activities such as exhibitions, conventions, advertising, training and teaching, supply the Company with all market information, comply with all legal requirements relating to the storage, promotion and sale of the products, refrain from using the Companys name or trademarks except as needed to identify EP as a distributor of the Company and respect the confidential nature of the Companys intellectual property and technical information. The Company shall promptly deliver products to EP, refrain from selling any products to the beauty industry in the Territory, refer to EP all leads, prospects, and potential purchasers in the  beauty industry, provide EP with reasonable quantities of marketing materials, provide training in the use and application of the Companys products, provide suitably qualified representatives to assist in the marketing of the products and warranty the products that are purchased by EP.  The Company and EP indemnify each other against harm caused to either one by the actions of the other.  All product shipments are made FOB from the Companys or EPs shipper and title passes to EP upon the Companys or EPs carrier taking delivery of the product from the shipper.  The Company may prepay all costs of transportation and insurance and EP reimburses the Company for such expenses. Starting on February 1, 2007, EP has agreed to minimum sales levels of 144 cases of products per quarter in Year 1, 180 cases per quarter in Year 2 and 216 cases per quarter in Year 3. Details on the amount of products per case are disclosed in Exhibit 4.h. EP has agreed to minimum sales levels that are confidential. The payment terms for products delivered to EP by the Company are net cash in Canadian currency within 35 days  with interest at a rate of 2% per month charged on late payments. The exclusivity of the Agreement may be terminated EP fails to pay the Company according to the terms of the agreement and fails to correct the default within 30 days of receiving written notice from the Company that the exclusivity will be terminated or if EP fails to meet the minimum sales obligations.  Alda Pharmaceuticals Corp. 2007 20F/A Page 60------------------------------------------------------------------------------------------------------------------------------------------------   The Company may terminate the exclusivity of this agreement if EP fails to pay for orders from the Company according to the terms of this agreement, upon giving EP at least 30 days written notice of the failure and its intention to terminate the exclusivity.  If EP cures the failure within thirty (30) days after receiving such notice, then EP's exclusivity shall not terminate. In the event EP's exclusivity terminates in accordance with the provisions above and as long as EP is not in default of any other provision of this Agreement, then this Agreement shall continue in full effect except that EP's rights shall not be exclusive within the Territory. The Company may terminate the exclusivity of this agreement if EP fails to meet the minimum sales goals, upon giving EP at least 30 days written notice of failure and its intention to terminate exclusivity.  IF EP cures the failure within 30 days after receiving such notice, then EPs exclusivity shall not terminate.  This Agreement may be terminated by either party if the other is in default in the performance of any material obligation under the Agreement and fails to cures any such default within 30 days after receiving notice of the default or immediately upon either partys cessation of business, dissolution, insolvency, bankruptcy, general assignment for the benefit of creditors, or filing of any petition in bankruptcy or for relief under the provisions of applicable bankruptcy laws.  Phigenics (Exhibit 4.a.): On August 9, 2005 the Company signed an agreement  appointing Phigenics, LLC to manage the registration of its products with the EPA Registration and assist with U.S. sales. Dr. William F. McCoy, Director is the Chief Technical Officer of Phigenics LLC.  Under the terms of the agreement, Phigenics LLC will provide a contribution in kind of up to $33,000 at a mutually agreeable per diem rate.. The Company will: provide up to $32,000 (US) for registration fees and pay royalties to Phigenics LLC ranging from 7% in the first year to 1% in the 6th and 7th years and a finders fee of 5% of sales to new clients for the first year after the first sale and 3% for the next year. Neither the term nor the termination provisions of the agreement are defined. Norwood: (Exhibit 4.b.) On October 4, 2005 the Company signed a manufacturing agreement with Norwood Packaging Ltd. of Surrey British Columbia, Canada to manufacture its T36®Disinfectant antibacterial product.  See Exhibit 4.B. The agreement requires Norwood to manufacture and store T36®Disinfectant for the Company in exchange for a varying percentage of sales by the Company being paid to Norwood. The percentage of sales paid to Norwood varies with the order size and for certain customers. Norwood also has a Right of First Refusal to manufacture other products for the Company under similar terms. There is no term specified for the agreement. The termination provisions of the agreement are standard commercial terms that include uncorrected breaches of the agreement, any form of insolvency on the part of Norwood or the Company or 90 days written notice by either party. He-Yi (Exhibit 4.g.)  On May 25, 2007, the Agreement with Fuzhou Xinmei Biotech Co. Ltd. (Fuzhou), which allowed manufacturing and marketing in Fujian province in China (Exhibit 4.c.), was transferred to He-Yi She Ye Limited (He-Yi) and expanded to cover marketing in all of China (Exhibit 4.g.).   Alda Pharmaceuticals Corp. 2007 20F/A Page 61------------------------------------------------------------------------------------------------------------------------------------------------  The agreement with He-Yi provides that:  · the Company will: · provide He-Yi with all information that ALDA has at its disposal to assist with the registration of the Companys products in China, · provide He-Yi with the specifications required for He-Yi to provide a manufacturing facility. · He-Yi will: · procure all necessary government approvals for the Companys products, · provide quarterly reports on the progress of the approvals to the Company with extensions to be granted by the Company if He-Yi is employing its best efforts to achieve registrations · provide a manufacturing facility according to the specifications provided by the Company · distribute the Companys products in China, subject to the Companys approval of each distributorship and · sell its products to the Company as requested by the Company and · ship products to customers of the Company located in other countries.  The Agreement is effective until April 18, 2011 (the Initial Term).  Upon expiration of the Initial Term, the Agreement may be renewed periods of time equal to the renewal times for the Certificate of Approval provided that the Company and He-Yi have each met all of their obligations.  Six months after production starts and for period of three years, the Company and He-Yi will establish minimum sales levels and, thereafter, after each new distributorship is established.  He-Yi will pay the Company royalties based on the gross revenues received by He-Yi for all of the Companys products sold in China equal to 5% during Years 1 and 2, 8% during Year 3 and 6% after the sales achieved in Year 2 are doubled and 10% for sales outside of China.  10.D.  Exchange Controls Canada has no system of exchange controls.  There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors.  There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of the Companys securities, except as discussed in ITEM 10, Taxation" below. Restrictions on Share Ownership by Non-Canadians:  There are no limitations under the laws of Canada or in the organizing documents of the Company on the right of foreigners to hold or vote securities of the Company, except that the Investment Canada Act may require review and approval by the Minister of Industry (Canada) of certain acquisitions of "control" of the Company by a "non-Canadian". The threshold for acquisitions of control is generally defined as being one-third or more of the voting shares of the Company. "Non-Canadian" generally means an individual who is not a Canadian citizen, or a corporation, partnership, trust or joint venture that is ultimately controlled by non-Canadians.  If a non-Canadian (for example, a US resident acquirer) were to acquire such a control position, they would not be required to do any filings or provide any notices to the Ministry of Industry (Canada) unless notified first by that Ministry that their acquisition of control was under review. Canada has, as does the United States, competition laws designed to promote competition in industry and markets.  The Competition Act (Canada) provides Canadas federal government with the power to review or prevent business transactions, such as acquiring a controlling interest in a company similar to the Company , if it is found that the acquisition of control would reduce competition in a given market or industry.  Since the market that the Company competes in is extremely competitive, no single company, including the Company, seems to have significant market power. Acquisition of the Company, therefore, would not lead to reduced competition.  Alda Pharmaceuticals Corp. 2007 20F/A Page 62------------------------------------------------------------------------------------------------------------------------------------------------  10.E.  Taxation  Canadian Federal Income Tax Considerations: The following is a brief summary of some of the principal Canadian federal income tax consequences to a holder of common shares of the Company (a "U.S. Holder") who deals at arm's length with the Company, holds the shares as capital property and who, for the purposes of the Income Tax Act (Canada) (the "Act") and the Canada  United States Income Tax Convention (the "Treaty"), is at all relevant times resident in the United States, is not and is not deemed to be resident in Canada and does not use or hold and is not deemed to use or hold the shares in carrying on a business in Canada.  Special rules, which are not discussed below, may apply to a U.S. Holder that is an insurer that carries on business in Canada and elsewhere. Under the Act and the Treaty, a U.S. Holder of common shares will generally be subject to a 5% withholding tax on dividends paid or credited or deemed by the Act to have been paid or credited on such shares.  The withholding tax rate is 5% where the U.S. Holder is a corporation that beneficially owns at least 10% of the voting shares of the Company and the dividends may be exempt from such withholding in the case of some U.S. Holders such as qualifying pension funds and charities. In general, a U.S. Holder will not be subject to Canadian income tax on capital gains arising on the disposition of shares of the Company unless (i) at any time in the five-year period immediately preceding the disposition, 25% or more of the shares of any class or series of the capital stock of the Company was owned by (or was under option of or subject to an interest of) the U.S. holder or persons with whom the U.S. holder did not deal at arm's length, and (ii) the value of the common shares of the Company at the time of the disposition derives principally from real property (as defined in the Treaty) situated in Canada. For this purpose, the Treaty defines real property situated in Canada to include rights to explore for or exploit mineral deposits and other natural resources situated in Canada, rights to amounts computed by reference to the amount or value of production from such resources, certain other rights in respect of natural resources situated in Canada and shares of a corporation the value of whose shares is derived principally from real property situated in Canada. The US Internal Revenue Code provides special anti-deferral rules regarding certain distributions received by US persons with respect to, and sales and other dispositions (including pledges) of stock of, a passive foreign investment company. A foreign corporation, such as the Company, will be treated as a passive foreign investment company if 75% or more of its gross income is passive income for a taxable year or if the average percentage of its assets (by value) that produce, or are held for the production of, passive income is at least 50% for a taxable year. The Company believes that it was not a passive foreign investment company for the taxable year ended December 31, 2007 and, furthermore, expects to conduct its affairs in such a manner so that it will not meet the criteria to be considered passive foreign investment company in the foreseeable future. Dividends: A Holder will be subject to Canadian withholding tax ("Part XIII Tax") equal to 25%, or such lower rate as may be available under an applicable tax treaty, of the gross amount of any dividend paid or deemed to be paid on common shares.  Under the Canada-U.S. Income Tax Convention (1980) as amended by the Protocols signed on 6/14/1983, 3/28/1984, 3/17/1995, and 7/29/1997 (the "Treaty"), the rate of Part XIII Tax applicable to a dividend on common shares paid to a Holder who is a resident of the United States and who is the beneficial owner of the dividend, is 5%.  If the Holder is a company that owns at least 10% of the voting stock of the Company paying the dividend, and, in all other cases, the tax rate is 15% of the gross amount of the dividend.  The Company will be required to withhold the applicable amount of Part XIII Tax from each dividend so paid and remit the withheld amount directly to the Receiver General for Canada for the account of the Holder. Disposition of Common Shares: A Holder who disposes of a common share, including by deemed disposition on death, will not normally be subject to Canadian tax on any capital gain (or capital loss) thereby realized unless the common share constituted "taxable Canadian property" as defined by the Tax Act.  Generally, a common share of a public corporation will not constitute taxable Canadian property of a Holder if the share is listed on a prescribed stock exchange unless the Holder or persons with whom the Holder did not deal at arm's length alone or together held or held options to acquire, at any time within the five years preceding the disposition, 25% or more of the shares  Alda Pharmaceuticals Corp. 2007 20F/A Page 63------------------------------------------------------------------------------------------------------------------------------------------------  of any class of the capital stock of the Company.  The Canadian Venture Exchange is a prescribed stock exchange under the Tax Act.  A Holder who is a resident of the United States and realizes a capital gain on a disposition of a common share that was taxable Canadian property will nevertheless, by virtue of the Treaty, generally be exempt from Canadian tax thereon unless: (a) More than 50% of the value of the common shares is derived from, or from an interest in, Canadian real  estate, including Canadian mineral resource properties, (b) The common share formed part of the business property of a permanent establishment that the Holder has or had in Canada within the 12 month period preceding the disposition, or (c) The Holder is an individual who (i) was a resident of Canada at any time during the 10 years immediately preceding the disposition, and for a total of 120 months during any period of 20 consecutive years, preceding the disposition, and (ii) owned the common share when he ceased to be resident in Canada. A Holder who is subject to Canadian tax in respect of a capital gain realized on a disposition of a common share must include three quarters of the capital gain (taxable capital gain) in computing the Holder's taxable income earned in Canada.  The Holder may, subject to certain limitations, deduct three-quarters of any capital loss (allowable capital loss) arising on a disposition of taxable Canadian property from taxable capital gains realized in the year of disposition in respect to taxable Canadian property and, to the extent not so deductible, from such taxable capital gains realized in any of the three preceding years or any subsequent year. United States Taxation: For federal income tax purposes, an individual who is a citizen or resident of the United States or a domestic corporation ("U.S. Taxpayer") will recognize a gain or loss on the sale of the Company's common shares equal to the difference between the proceeds from such sale and the adjusted tax basis of the common shares.  The gain or loss will be a capital gain or capital loss if the Company's common shares are a capital asset in U.S. Taxpayer's hands. For federal income tax purposes, a U.S. Taxpayer will be required to include in gross income dividends received on the Company's common shares.  A U.S. Taxpayer who pays Canadian tax on a dividend on common shares will be entitled, subject to certain limitations, to a credit (or alternatively, a deduction) against federal income tax liability.  A domestic corporation that owns at least 10% of the voting shares should consult its tax advisor as to applicability of the deemed paid foreign tax credit with respect to dividends paid on the Company's common shares. Under a number of circumstances, United States Investor acquiring shares of the Company may be required to file an information return with the Internal Revenue Service Center where they are required to file their tax returns with a duplicate copy to the Internal Revenue Service Center, Philadelphia, PA 19255.  In particular, any United States Investor who becomes the owner, directly or indirectly, of 10% or more of the shares of the Company will be required to file such a return.  Other filing requirements may apply, and United States Investors should consult their own tax advisors concerning these requirements. The US Internal Revenue Code provides special anti-deferral rules regarding certain distributions received by US persons with respect to, and sales and other dispositions (including pledges) of stock of, a passive foreign investment company.  A foreign corporation, such as the Company, will be treated as a passive foreign investment company if 75% or more of its gross income is passive income for a taxable year or if the average percentage of its assets (by value) that produce, or are held for the production of, passive income is at least 50% for a taxable year.  The Company believes that it was not a passive foreign investment company for the taxable year ended December 31, 2007 and, furthermore, expects to conduct its affairs in such a manner so that it will not meet the criteria to be considered passive foreign investment company in the foreseeable future.  10.F.  Dividends and Paying Agents The Company has not declared any dividends on its common shares for the last five years and does not anticipate that it will do so in the foreseeable future.  The present policy of the Company is to retain future earnings for use in its operations and the expansion of its business. Notwithstanding the aforementioned: the Company is unaware of any dividend restrictions; has no specific procedure for the setting of the date of dividend entitlement; but might expect to set a record date for stock  Alda Pharmaceuticals Corp. 2007 20F/A Page 64------------------------------------------------------------------------------------------------------------------------------------------------  ownership to determine entitlement; has no specific procedures for non-resident holders to claim dividends, but might expect to mail their dividends in the same manner as resident holders.  The Company has not nominated any financial institutions to be the potential paying agents for dividends in the United States.  10.G.  Statement by Experts The Companys auditor for its financial statements for fiscal year ended 2007 was HLB Cinnamon Jang Willoughby, Chartered Accountants.  Their audit report for Fiscal 2006/2007 is included with the related financial statements in this Annual Report with their consent attached hereto as an exhibit. For the preceding two years the auditor was Berris Mangan, Chartered Accountants (formerly BME & Partners, Chartered Accountants).  Their audit report for Fiscal 2005/2006 is included below.  10.H.  Document on Display --- No Disclosure Necessary ---  ITEM 11.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK --- No Disclosure Necessary ---  ITEM 12.  DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 12.A.  Debt Securities --- No Disclosure Necessary ---  12.B.  Warrants and Rights --- No Disclosure Necessary ---  12.C.  Other Securities --- No Disclosure Necessary ---  12.D.  American Depository Shares -- No Disclosure Necessary ---   PART II ITEM 13.  DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES --- No Disclosure Necessary --- ITEM 14.  MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS --- No Disclosure Necessary --- ITEM 15.  CONTROLS AND PROCEDURES The Company carried out an evaluation, under the supervision and with the participation of the Companys management, including the Companys President, of the effectiveness of the design and operation of the Companys disclosure controls and procedures (as defined in the Exchange Act Rule 13a-15(e)) as of the end of the period covered by this report.  Based upon that evaluation, the President concluded that the Companys disclosure controls and procedures are effective in timely alerting them to material information relating to the Company required to be included in the Companys periodic SEC filings, and that information is recorded, processed, summarized and reported as and when required.  Alda Pharmaceuticals Corp. 2007 20F/A Page 65------------------------------------------------------------------------------------------------------------------------------------------------  There was no significant change in the Companys internal control over financial reporting that occurred during the Companys most recently completed fiscal year ended June 30, 2007 that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting.  Nor were there any significant deficiencies or material weaknesses in the Company's internal controls requiring corrective actions. ITEM 16.  RESERVED  ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERTS Linda Allison, Eugene Hodgson and Peter Chenare members of the Companys Audit Committee. Linda Allison and Eugene Hodgson are considered independent and all three members are consideredfinancially literate, as those terms are defined in applicable securities legislation. Dr. Allison received a BSc (Honours) from Simon Fraser University, Vancouver, BC, Canada in 1969, a MSc from the University of London, UK and a Diploma of Imperial College (DIC) from the Imperial College of Science and Technology, London, UK in 1972.  She received her PhD from Simon Fraser University in 1978 based on research in the areas of neurophysiology, molecular biology and biophysics.  From 1980 to 1995, she was President of Groberman Computer Engineering Ltd., a computer technology company developing custom systems for scientific and industrial applications. In 1985, she founded Snowdon & Associates Management Consultants Ltd., a management consulting company that provides professional services to medical device, biotechnology, pharmaceutical, and high technology companies. From 1992 to 1998, Dr. Allison worked in the corporate finance departments of two investment banking and brokerage firms, during which time she assisted the financing of biomedical and high technology companies in both North America and Europe. From 1998 to 2001, she was President & CEO of Ondine Biopharma Corp., a biomedical company developing photo-activated drugs. From 2000 to 2001, she was the President & CEO of Genesis Bioventures Inc., a biomedical holding company that invested in companies developing novel diagnostics and therapeutics in the areas of cancer and neurological disorders. From 2003 to 2005, she served as President & CEO and a Director of MDX Medical Inc., a biomedical company developing medical imaging technologies for the improved diagnosis and treatment of cancer. From 2006 to present, she has been on the ForeFront Committee of the Alberta Heritage Foundation for Medical Research.  Eugene Hodgson received a Bachelor of Arts degree from the University of Calgary in 1978. He was Director of Corporate Development for Intrawest Corporation from 1990 till 1996 and has been the President of E.A. Hodgson & Associates, a private management consulting firm, since 1996.  He currently serves as a Vice President Western Region of Corpfinance International Limited., a firm that provides specialized term financing to mid-sized and large companies and is a Director of Timmins Gold Corp., and Grandfield Pacific Inc. all publicly-traded companies.  Mr. Hodgson was previously a CFO and Director of Sea Breeze Power Inc.  He is a co-founder of the "Families for School Seismic Safety" in B.C. and a past Director of the Independent Power Producers of B.C.  He is a former Director of the Vancouver Board of Trade and current Area Commissioner of the Pacific Spirit Area for the Boy Scouts of Canada. Peter Chen obtained a Diploma in Accounting from Douglas College in 1993. On graduation, he became a self-employed financial consultant. From November 2000 to October 2003, Mr. Chen was the Chief Financial Officer of Prospect Point Exploration & Management Services Ltd., a private company that provides mineral exploration consulting services. He was the President of Canadian Mineral Exploration Managing Consultants Inc., a private company that provides mineral exploration services to publicly listed companies that have projects in Africa and South East Asia, from January 1997 to January 2000 and Chief Financial Officer from February 1994 to January 2000. Mr. Chen is currently a director of the Douglas College Foundation.  Mr. Chen is a founder of the Company and began working with the Company full time in November, 2003.  Peter Chen is considered to be an audit committee financial expert. Mr. Chen obtained a Diploma in Accounting from Douglas College in 1993. On graduation, he became a self-employed financial consultant. From November 2000 to October 2003, Mr. Chen was the Chief Financial Officer of Prospect Point Exploration & Management Services Ltd., a private company that provides mineral exploration consulting services. He was the President of Canadian Mineral Exploration Managing Consultants Inc., a private company that provides mineral exploration services to publicly listed companies that have projects in Africa and South East Asia, from January 1997 to January 2000 and Chief Financial Officer from February 1994 to January 2000. Mr. Chen is  Alda Pharmaceuticals Corp. 2007 20F/A Page 66------------------------------------------------------------------------------------------------------------------------------------------------  currently a director of the Douglas College Foundation.  Mr. Chen is a founder of the Company, has been its CFO since its inception in May, 2000 and began working with the Company full time in that capacity in November, 2003  ITEM 16B. CODE OF ETHICS The company has not adopted a formal code of ethics because, as a TSX Venture Exchange issuer, the Company is only required have an audit committee. The audit committee is composed of a majority of independent members as discussed above under the heading Item 16.B. Audit Committee Financial Experts. In lieu of a code of ethics, the company has adopted the following methodology with respect to corporate governance. The management of ALDA is responsible for establishing and maintaining disclosure controls and procedures for information relating to the Company, including its consolidated subsidiaries. The Companys management is also responsible for establishing and maintaining adequate internal control over financial reporting. ALDAs Board of Directors facilitates its exercise of independent supervision over management by ensuring that the Board is composed of a majority of independent directors.  The Board, at present, is composed of six directors, all of which are considered to be independent except for Mr. Owen and Mr. Chen who are also senior officers.  In determining whether a director is independent, the Board considers, for example, whether the director has a relationship, which could, or could be perceived to, interfere with the director's ability to objectively assess the performance of management. The Board monitors the ethical conduct of ALDA and its management and ensures that it complies with applicable legal and regulatory requirements, such as those of relevant securities commissions and stock exchanges.  The Board has found that the fiduciary duties placed on individual directors by the Companys governing corporate legislation and the common law, as well as the restrictions placed by applicable corporate legislation on the individual directors participation in decisions of the Board in which the director has an interest, have been sufficient to ensure that the Board operates independently of management and in the best interests of the Company. The Board is specifically responsible for approving long-term strategic plans and annual operating plans and budgets recommended by management.  Board consideration and approval is also required for all material contracts, business transactions and all debt and equity financing proposals.  The independent directors on the Board are also responsible for approving senior executive compensation and retirement plans. The Board delegates to management, through the offices of President and Chief Executive Officer and Chief Financial Officer, responsibility for meeting defined corporate objectives, implementing approved strategic and operating plans, carrying on the Companys business in the ordinary course, managing the Companys cash flow, evaluating new business opportunities, recruiting staff and complying with applicable regulatory requirements.  The Board also looks to management to furnish recommendations respecting corporate objectives, long-term strategic plans and annual operating plans. Given the relatively static composition of the Board of Directors and the Companys management over the last several years, the Board has not appointed a corporate governance committee and these functions are currently performed by the Board as a whole.  ITEM 16C. PRINCIPAL ACCOUNTING FEES AND SERVICES  External Auditor Service Fees  The following table sets out the aggregate fees billed by Berris Mangan, Chartered Accountants, our external auditor, in each of the last two fiscal years.  Year Audit Fees Audit Related Fees(1) Tax Fees(2) All Other Fees   2007 $25,000 (91%) $2,480 (9%) Nil (0%) Nil (0%) 2006 $17,500 (68%) $8,250 (32%) Nil (0%) Nil  (0%)  (1) Related to assurance and related services that are reasonably related to the performance of the audit and review of our financial statements and not included in the amounts noted under Audit Fees.  Alda Pharmaceuticals Corp. 2007 20F/A Page 67------------------------------------------------------------------------------------------------------------------------------------------------  (2)Related to fees billed by our external auditor for professional services rendered for tax compliance, tax advice and tax planning.  Pre-Approval Policies and Procedures  The Audit Committee has adopted an Audit Committee Charter (Exhibit 11) governing the provision of audit and non-audit services by the external auditor. This charter requires the Audit Committee to:  1. recommend to the Board of Directors the external auditor to be nominated by the Board of Directors and  the compensation of the external auditor (see 4.1.(a) and (b), Exhibit 11) and  2. to pre-approve all non-audit services provided by the external auditor (see 4.1.(n), Exhibit 11).   ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES ---Not applicable---  ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE COMPANY/AFFILIATED PURCHASERS ---Not Applicable--- PART III ITEM 17.  FINANCIAL STATEMENTS The Company's financial statements are stated in Canadian Dollars (CDN$) and are prepared in accordance with Canadian Generally Accepted Accounting Principles (GAAP), the application of which, in the case of the Company, conforms in all material respects for the periods presented with United States GAAP, except as discussed in footnotes to the financial statements. The financial statements as required under ITEM #17 are attached hereto and found immediately following the text of this Annual Report.  The audit report of HLB Cinnamon Jang Willoughby, Charted Accountants, is included herein immediately preceding the audited financial statements. Audited Financial Statements -- see exhibits ITEM 18.  FINANCIAL STATEMENTS The Company has elected to provide financial statements pursuant to ITEM #17. ITEM 19.  EXHIBITS The financial statements thereto as required under ITEM #17 are attached hereto and found immediately following the text of this Annual Report.  The report of the Companys independent auditors for the audited financial statements are included herein immediately preceding the audited financial statements. (i) Audited Consolidated Financial Statements for the fiscal years ending June 30, 2007,and 2006and 2005. 1. Auditors Reports, dated October 17, 2007. 2. Consolidated Balance Sheets at June 30, 2007 and June 30, 2006. 3. Consolidated Statements of Operations and Deficit for the fiscal years ending June 30, 2007, and 2006and 2005.  Alda Pharmaceuticals Corp. 2007 20F/A Page 68------------------------------------------------------------------------------------------------------------------------------------------------  4. Consolidated Statements of Cash Flows for the fiscal years ending June 30, 2007, and 2006and 2005. 5. Notes to Consolidated Financial Statements. (ii)Audited Consolidated Financial Statements for the fiscal years ending June 30, 2006, 2005 and 2004. 1. Auditors Reports, dated September 15, 2006. 2. Consolidated Balance Sheets at June 30, 2006 and June 30, 2005. 3. Consolidated Statements of Operations and Deficit for the fiscal years ending June 30, 2006, 2005 and 2004 4. Consolidated Statements of Cash Flows for the fiscal years ending June 30, 2006, 2005 and 2004. 5. Notes to Consolidated Financial Statements.  Documents pertaining to the Change of Auditors 1. Consent Resolution of the Directors to accept the resignation of Berris Mangan, Chartered Accountants and to accept the appointment of HLB Cinnamon Jang Willoughby (CJW), Chartered Accountants as auditors. 2. A Notice to Shareholders of Change of Auditor stating that there has been no reportable events as defined in National Instrument 51-102 of the Canadian Securities Administration; 3. A letter of Berris Mangan, Chartered Accountants confirming, to the best of their knowledge, the statements contained in the Companys Notice to Shareholders of Change of Auditors; and 4. A letter of HLB Cinnamon Jang Willoughby (CJW), Chartered Accountants confirming, to the best of their knowledge, the statements contained in the Companys Notice to Shareholders of Change of Auditor. (B)  Index to Exhibits:  1.
Certificate of Incorporation, Certificates of Name Change, Articles of Incorporation, previously filed with the 2005 Form 20F as Exhibit 1.2.
Instruments defining the rights of holders of the securities being registered
- See Exhibit Number 1  3.
Voting Trust Agreement- dated November 13, 2003 between API, Allan Shapiro and Michael Wilby and an amendment to the agreement dated November 1, 2004.  Alda Pharmaceuticals Corp. 2007 20F/A Page 69------------------------------------------------------------------------------------------------------------------------------------------------   4.
Material Contracts
a.
Letter of Agreement with Phigenics LLC regarding US registration and distribution of the Companys products dated July 21, 2005, previously filed with the 2005 Form 20F as Exhibit 4.a.;
b.
Production Agreement with Norwood Packaging Ltd., previously filed with the 2005 Form 20F as Exhibit 4.b.;c.  Product licensing and distribution agreement dated October 26, 2004 with Fuzhou Xinmei Biotech Co. Ltd., previously filed with the 2005 Form 20F as Exhibit 4.c.;
d.
Office Premises Lease Agreement, previously filed with the 2005 Form 20F as Exhibit 4.d.;
e.
Stock Option Plan, previously filed with the 2005 Form 20F as Exhibit 4.e.;
f.
Product licensing and distribution agreement dated August 1, 2004 with Linns Corporation Sdn Bhd of Malaysia, previously filed with the 2005 Form 20F as Exhibit 4.f.;
g.
Product licensing and distribution agreement dated October 26, 2004 with He-Yi She Ye Limited;
h.
Distribution agreement dated February 1, 2005 with Esthetics Plus, Inc, originally filed on December 3, 2008 and amended and re-filed on February 17, 2009
i.
Non-competition agreement dated November 13, 2003 with 513947 BC Ltd., Allan Shapiro and Michael Wilby.5.
List of Foreign Patents  N/A6.
Calculation of earnings per share  N/A7.
Explanation of calculation of ratios  N/A8.
List of Subsidiaries  N/A (the Company has only one subsidiary, Sirona Therapeutics Corp.)9.
Statement pursuant to the instructions to Item 8.A.4, regarding the financial statements filed in registration statements for initial public offerings of securities  N/A10.
Documents pertaining to the Change of Auditors11.
Audit Committee Charter  99.1
Certification of Chief Executive Officer pursuant to Section 302 of SarbanesOxley Act of 200299.2
Certification of Chief Financial Officer pursuant to Section 302 of SarbanesOxley Act of 200299.3
Certification of Chief Executive Officer pursuant to Section 906 of SarbanesOxley Act of 200299.4
Certification of Chief Financial Officer pursuant to Section 906 of SarbanesOxley Act of 2002    Alda Pharmaceuticals Corp. 2007 20F/A Page 70------------------------------------------------------------------------------------------------------------------------------------------------   [alda200720famend2002.gif]ALDA Pharmaceuticals Corp.
635 Columbia Street, New Westminster, British Columbia,   V3M 1A7
Telephone: 604-521-8300; Facsimile: 604-521-8322 CONSOLIDATED FINANCIAL STATEMENTS   For the years ended June 30, 2007 and 2006              Alda Pharmaceuticals Corp. 2007 20F/A Page 71------------------------------------------------------------------------------------------------------------------------------------------------   [alda200720famend2003.jpg] AUDITORS' REPORT  To the Shareholders of Alda Pharmaceuticals Corp.:  We have audited the consolidated balance sheets of Alda Pharmaceuticals Corp. as at June 30, 2007 and the consolidated statements of operations and deficit, and cash flows for the year then ended.  These consolidated financial statements are the responsibility of the company's management.  Our responsibility is to express an opinion on these consolidated financial statements based on our audit.  We conducted our audit in accordance with Canadian generally accepted auditing standards and with the standards of the Public Company Accounting Oversight Board (''PCAOB'') (United States).  Those standards require that we plan and perform an audit to obtain reasonable assurance whether the consolidated financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the company as at June 30, 2007 and the results of its operations and its cash flows for the years then ended in accordance with Canadian generally accepted accounting principles.  The consolidated balance sheet as at June 30, 2006, the consolidated statement of operations and deficit, and cash flows for the years ended June 30, 2006 and 2005 were audited by predecessor auditors who expressed an opinion without reservation on these statements in their report dated September 15, 2006.  Comments by Auditors for U.S. Readers on Canada - United States Reporting Differences  United States reporting standards of the Public Company Accounting Oversight Board (United States) for auditors require the addition of an explanatory paragraph (following the opinion paragraph) when the financial statements are affect by conditions and events that cast substantial doubt on the Company's ability to continue as a going concern, such as those described in Note 1 to the financial statements.  Our report to the shareholders dated October 17, 2007 is expressed in accordance with Canadian reporting standards which do not permit reference to such conditions and events in the auditors' report when these are adequately disclosed in the financial statements.  Burnaby, BC, Canada
October 17, 2007''Cinnamon Jang Willoughby & Company''
Chartered Accountants [alda200720famend2004.jpg]  Alda Pharmaceuticals Corp. 2007 20F/A Page 72------------------------------------------------------------------------------------------------------------------------------------------------   ALDAPHARMACEUTICALS CORP. CONSOLIDATED BALANCE SHEETS AS AT JUNE 30 EXPRESSED IN CANADIAN DOLLARS20072006ASSETSCurrent AssetsCash and Equivalents$  356,127$  28,480Accounts Receivable24,89729,056Subscriptions Receivable (Note 12 (d))293,600-Inventory19,91631,280Prepaids7,4583,857701,99892,673Furniture and Equipment (Note 4)1,4828,199Patent Application and Development Costs(Note 5)40,486-Intangible Assets (Note 6)110,200116,000$ 854,166$  216,872LIABILITIESCurrent LiabilitiesAccounts Payable and Accrued Liabilities$ 74,268$59,504SHAREHOLDERS' EQUITYShare Subscriptions Received (Note 7 (a))-25,000Share Capital (Note 7 (b)2,658,8681,969,562Contributed Surplus  Warrants(Note 7 (f))553,627163,413Contributed Surplus  Options(Note 7 (f))171,19441,094Deficit(2,603,791)(2,041,701)779,898157,368$ 854,166$   216,872 Commitments(Note 10) Going concern(Note 1) Approved by the Directors "Terrance Owen" Director "Peter Chen" Director  See accompanying notes to the financial statements  Alda Pharmaceuticals Corp. 2007 20F/A Page 73------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT FOR THE YEARS ENDED JUNE 30  EXPRESSED IN CANADIAN DOLLARS200720062005Sales$       256,243$       223,586$         239,271Cost of Sales( 165,920)( 142,379)(150,075)Gross Profit90,32381,20789,196General & Administration ExpensesAdvertising and Promotion12,76612,16927,685Amortization  Furniture and Equipment8,3508,2818,217  Patent Application and Development Costs2,131--  Intangible Assets5,800--Conference2066612,035Consulting308,600183,218210,561Dues and Filing Fees24,57022,83421,544Interest and Bank Charges2,7141,5681,685Investor Relations65,03952,80890,779Legal and Accounting53,69763,17857,833Office and Miscellaneous24,00825,45030,426Product Registration & Development-18,37754,293Rent28,37130,91225,265Travel10,2593,2524,512Wages and Benefits116,63375,90397,389Total General & Administration Expenses662,958498,616642,224Loss Before Other Items( 572,635)(417,409)(553,028)Impairment loss on intangible assets (Note 6)--(245,000)Net Gain on Legal Settlement (Note 8)10,54537,383-Loss from Operations( 562,090)(380,026)(798,301)Interest Income-1,7251,727Loss For The Year( 562,090)(378,301)(796,301)Deficit, Beginning of Year(2,041,701)( 1,663,400)(867,099)Deficit, End of Year$ (2,603,791)$ ( 2,041,701)$ (1,663,400)Basic Loss Per Share0.020.020.06Diluted Loss Per Share0.020.020.06Weighted Average of Shares Outstanding22,582,02617,857,70913,663,856 *See accompanying notes to the consolidated financial statements  Alda Pharmaceuticals Corp. 2007 20F/A Page 74------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED JUNE 30  EXPRESSED IN CANADIAN DOLLARS200720062005Operating Activities:Loss for the Year$ ( 562,090)$ ( 378,301)$       (796,301)Items Not Involving CashAmortization  Furniture and Equipment8,3508,2818,217  Patent Application and Development Costs2,131--  Intangible Assets5,800-Stock-Based Compensation148,1001,15616,237Impairment loss on intangible assets--245,000(  397,709)(  368,864)(526,847)Changes in Non-Cash Working Capital ItemsDecrease/ (Increase) in Accounts Receivable4,1593,04922,544Decrease/ (Increase) in Inventory11,36412,388101,248Decrease/ (Increase) in Prepaid Expenses(   3,601)9,132(984)(Decrease)/ Increase in Accounts Payable and Accrued Liabilities14,76429,639(677)(  371,023)(314,656)(404,716)Investing Activities:Patent Application and Development Costs( 42,617)--Purchase of Furniture and Equipment(  1,633)-(642)Repayment of Note Receivable-7,988-(44,250)7,988(642)Financing Activities:Share Subscriptions Received-25,000-Net Proceeds on Issuance of Shares546,720238,485250,870Warrants/Options Exercised196,200--742,920263,485250,870Increase/ (Decrease) in Cash and Equivalents327,647( 43,183)(154,488)Cash and Equivalents, Beginning of Year28,48071,663226,151Cash and Equivalents, End of Year$    356,127$   28,480$   71,663 *See accompanying notes to the consolidated financial statements Supplementary information (Note 14)  Alda Pharmaceuticals Corp. 2007 20F/A Page 75------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007AND 2006   1. BASIS OF PRESENTATION  These consolidated financial statements include the accounts of ALDA Pharmaceuticals Corp. (the Company) and its wholly-owned subsidiary, Sirona Therapeutics Corp. (Sirona).  The name of the subsidiary was changed on January 10, 2006 from ALDA Institute For Preventative Health Care Inc.  Sirona is an inactive company, the shares of which were acquired pursuant to an asset purchase agreement.  These financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of the business. The Company has yet to achieve a level of revenues adequate to achieve profitability. The application of the going concern assumption is dependent on the ability of the Company to secure sufficient financing, and to develop profitable operations.  Management of the Company believes that it will succeed in meeting those objectives, allowing the continued operation of the company.  20072006Deficit$    2,603,791$    2,041,701Working capital627,73033,169   2. DESCRIPTION OF OPERATIONS  The Company was incorporated under the Company Act of British Columbia on May 30, 2000 and was classified as a Capital Pool Company as defined by the policies of the TSX Venture Exchange (the Exchange).  The Company completed its required Qualifying Transaction on November 13, 2003.   As a result of the Company completing the Qualifying Transaction, it ceased to be a Capital Pool Company, and its shares resumed trading on the Exchange effective November 19, 2003.  The Companys main business activity is the development, production and marketing of infection control agent products, principally a product marketed as T36® Disinfectant.  Effective November 26, 2003, the name of the Company was changed from Duft Biotech Capital Ltd. to ALDA Pharmaceuticals Corp.   3. SIGNIFICANT ACCOUNTING POLICIES  a) Cash and equivalents  Cash and equivalents include cash and highly liquid market instruments with original terms to maturity of less than ninety days at the time of acquisition.  b) Accounts receivable  Accounts receivable is presented net of allowance for doubtful accounts.  The allowance for doubtful accounts reflects estimates of probable losses in accounts receivable.  The allowance is determined based on balances outstanding for over 90 days from the invoice date, historical experience and other current information.  The Company extends credit to customers and distributors; credit checks are required for all new distributors.  Alda Pharmaceuticals Corp. 2007 20F/A Page 76------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007AND 2006  3. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)  c) Inventory  Inventory of the Companys finished goods and related raw materials is reported at the lesser of cost and estimated net realizable value, and is determined using the first in, first out cost flow assumption.  d) Furniture and equipment  Furniture and equipment are recorded at cost and are amortized using the following annual rates:  Furniture and fixtures 20% Straight line Computer equipment 30% Straight line  e) Impairment of long-lived assets  The Company reviews for the impairment of long-lived assets, including furniture and equipment, whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable from expected future cash flows.  The assessment of recoverability is made based on projected undiscounted future net cash flows that are directly associated with the assets use and eventual disposition.  The amount of the impairment, if any, is measured as the difference between the carrying value and the fair value of the impaired assets and is presented as an impairment loss in the current period.  f) Patent Application and Development Costs  Patent application and development costs include all expenditures attributable to efforts by the Company to develop, and bring to commercial production a new product as well as to acquire legal protections for its proprietary products, such as trademarks and patents.  Such amounts are charged as an expense in the period incurred except in circumstances where the market and technical feasibility of the product have been established, recovery of these costs can reasonably be regarded as assured, and future values can be realized, in which case such costs are capitalized.  In the latter case, patent application and development costs are amortized on a systematic basis over the patent life of 20 years.  g) Intangible assets  The carrying value of intangible assets which are determined to have a finite useful life are amortized on a systematic basis over the useful life of 20 years.  Intangible assets are subject to an impairment test on an annual basis, based on a comparison of the fair value of the intangible asset to its carrying value.  The carrying value is adjusted for impairment as necessary and any excess of the carrying amount over the fair value of the intangible asset is charged to earnings in the period occurred.  h) Revenue recognition  The revenue of the Company is primarily derived from the sale of the Companys T36® product.  Revenue is recognized at the time of shipment, and invoicing, provided that collection of the amount billed to the customer is reasonably assured.  Revenue is recognized net of any expected sales return.  Credit will be granted to customer for damaged goods.  Alda Pharmaceuticals Corp. 2007 20F/A Page 77------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007AND 2006  3. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)  i) Income taxes  Income taxes are recorded using the asset and liability method whereby future tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Future tax assets and liabilities are measured using enacted or substantively enacted tax rates expected to apply when the asset is realized or the liability settled.  The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the year that substantive enactment or enactment occurs.  To the extent that the Company does not consider it more likely than not that a future tax asset or portion thereof will be recovered, it produces a valuation allowance  j) Stock-based compensation  The fair value of stock options granted is determined using the Black-Scholes option pricing model and recorded as stock-based compensation expense over the vesting period of the stock options.  k) Warrants  Proceeds from issuances by the Company of units consisting of shares and warrants are allocated based on the fair value method, whereby the fair value of warrants is determined using the Black-Scholes option pricing model and recorded as contributed surplus.  The difference between the fair value of the warrants and proceeds received is allocated to share capital.  l) Basis and diluted loss per share  Loss per share is calculated based on the weighted average number of common shares outstanding during the reported period.  Basic loss per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding in the year.  The Company uses the treasury stock method to compute the dilutive effect of options, warrants and similar instruments.  Under this method, the dilutive effect on loss per share is recognized on the use of the proceeds that could be obtained upon exercise of options, warrants and similar instruments.  It assumes that the proceeds would be used to purchase common shares at the average market price during the year.  For the years  m) Measurement Uncertainty  The preparation of these consolidated financial statements in accordance with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and the reported amount of revenues and expenses during the period.  Areas requiring significant management estimates include valuation of intangible assets, estimated useful life of intangible assets, estimate useful life of patent application and development costs, stock based compensation expense, and valuation of share purchase warrants.  Actual results could differ from these estimates.  n) Financial instruments  The Companys financial instruments consist of cash and equivalents, accounts receivable, subscriptions receivable, accounts payable and accrued liabilities.  The fair value of these instruments approximates the carrying amounts due to the immediate or short-term maturity of these financial instruments.  Alda Pharmaceuticals Corp. 2007 20F/A Page 78------------------------------------------------------------------------------------------------------------------------------------------------   ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007AND 2006  It is managements option that the Company is not exposed to significant interest, currency, or credit risk arising from these financial instruments.  4. FURNITURE AND EQUIPMENT  Furniture and equipment at June 30, 2007 and 2006 consist of the following:  Historical CostAccumulated Amortization2007
Net2006
NetFurniture and Fixtures$      7,683$       6,550$   1,133$   2,670Computer Equipment24,11523,7663495,529$    31,798$     30,316$   1,482$   8,199  5. PATENTS APPLICATION AND DEVELOPMENT COSTS  Patent application and development costs at June 30, 2007 and 2006 were determined as follows:  Historical CostAccumulated Amortization2007
Net2006
NetPatents Application and Development Costs$    42,617$       2,131$   40,486$          -  6. INTANGIBLE ASSETS  The intangible assets balance represents the carrying amount of certain intellectual property acquired in its Qualifying Transactions.  The opening balance of Intangibles as at July 1, 2006 was determined as follows:  Original Purchase Cost$  540,000Less:Impairment Loss in 2004$   (179,000)Impairment Loss in 2005(245,000)Impairment Loss in 2006-(424,000)Balance as at June 30, 2006$  116,000  At June 30, 2005, the carrying cost of the intangible assets was written down to the estimated net recoverable amount, and an impairment loss of $245,000 was charged against earnings for the 2005 year.  Effective July 1, 2006, the Company changed its estimate of the useful life of the intangible assets from an infinite life to a finite life of 20 years.  The impact of this change in estimate was to increase amortization by $5,800 for the year ended June 30, 2007.  The carrying amount as at June 30, 2007 and 2006 consist of the following:  Balance as at June 30, 2006Accumulated Amortization2007
Net2006
NetIntangible Assets$    116,000$       5,800$ 110,200$ 116,000   Alda Pharmaceuticals Corp. 2007 20F/A Page 79------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007AND 2006   7. SHAREHOLDERS EQUITY  a) Share Subscriptions Received  At June 30, 2006, the Company had received amounts totaling $25,000 representing subscriptions by purchasers in respect to the private placement described in Note 7(b)(iv) to whom shares and warrants had not yet been issued.  The corresponding shares were issued subsequent to year end.  b) Share Capital  Authorized: Unlimited common shares without par value  Effective August 19, 2005, the authorized share capital of the Company was increased to an unlimited number of common shares without par value.  Issued and outstanding:  20072006Number of SharesAmountNumber
of SharesAmountBeginning Balance20,800,404$1,969,56215,784,404$ 1,796,285Private Placement (i)/(ii)--5,016,000185,592Share Issue Costs--( 12,315)Private Placement (iii)/(iv)9,430,000467,480--Finders Fees-(  6,180)--Warrant Exercised (v)1,062,000120,006--Options Exercised (v)900,000108,000--Ending Balance32,192,404$ 2,658,86820,800,404$ 1,969,562  i) On December 23, 2005, the Company completed a private placement of 3,916,000 units of the Company at a price of $0.05 per unit for gross proceeds of $195,800. Each unit consists of one common share of the company and one share purchase warrant, each warrant entitling the holder to purchase one common share at a price of $0.10 per share for a period of 12 months following the closing date.  Legal fees in the amount of $5,352 were incurred in connection with the private placement.  ii) On June 22, 2006, the Company completed a private placement of 1,100,000 units of the Company at a price of $0.05 per unit for gross proceeds of $55,000.  Each unit consists of one common share of the Company and one share purchase warrant, each warrant entitling the holder to purchase one common share at a price of $0.10 per share for a period of 12 months following the closing date.  Legal fees in the amount of $6,963 were incurred in connection with the private placement.  iii) On September 13, 2006, the Company completed a private placement of 1,430,000 units of the Company at a price of $0.05 per unit for gross proceeds of $71,500.  Each unit consists of one common share of the Company and one share purchase warrant, each warrant entitling the holder to purchase one common share at a price of $0.10 per share for a period of 12 months following the closing date.   Alda Pharmaceuticals Corp. 2007 20F/A Page 80------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  7. SHAREHOLDERS EQUITY (CONTINUED)  b) Share Capital (Continued)  i) On June 7, 2007, the Company completed a private placement of 8,000,000 units of the Company at a price of $0.10 per unit for gross proceeds of $800,000.  Each unit consists of one common share of the Company and one share purchase warrant.  Each warrant entitles the holder to acquire one additional common share at a price of $0.20 per share until June 7, 2008 and, thereafter at a price of $0.30 per share until June 7, 2009.  Finders fees in the amount of $6,180 were charged against the share capital in connection with the private placement.  ii) During the current year, 900,000 options and 1,062,000 warrants were exercised by the holders at a price of $0.10 per unit for gross proceeds of $196,200.  Option values of $18,000 previously recorded in contributed surplus for options were credited to share capital.  c) Escrowed shares:  During the year ended June 30, 2007, 733,163 common shares included in issued share capital were fully released from the escrow (2006: 1,466,324).  Escrow shares were released on a staged basis, with a release occurring every six months.  As at June 30, 2007, no more escrow were shares held in the trust (2006: 733,163).  d) Stock options:  A summary of the Companys stock options and changes during each year is presented below:  Year Ended
June 30, 2007Year Ended
June 30, 2006Number of
SharesWeighted Average Exercise PriceNumber of
SharesWeighted Average Exercise PriceOutstanding, beginning of the year537,647$       0.191,290,000$     0.19Granted during year-consulting/officers (i)/(v)2,130,0000.10---directors (ii) to (v)1,050,0000.11---employees (ii)/(iv)350,0000.10--Expired/exercised/cancelled
during year(1,587,647)0.13(752,353)0.20Outstanding, end of year2,480,000$       0.11537,647$     0.19   Alda Pharmaceuticals Corp. 2007 20F/A Page 81------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  7. SHAREHOLDERS EQUITY (CONTINUED)  d) Stock options (continued):  The following table summarizes information about stock options outstanding at June 30, 2007:  Number of SharesExercise PriceExpiry
DateNumber Exercisable530,000$     0.10August 2, 2008530,000300,000$     0.10August 2, 2011100,000500,000$     0.11August 12, 2009500,0001,150,000$     0.12May 3, 20091,150,0002,480,0002,280,000  (i) During the year ended June 30, 2007, the Company granted options to acquire 730,000 common shares of the Company to certain consultants and scientific advisors for their services provided to the Company.  These options have an exercise price of $0.10 per share.  430,000 of these options have an exercisable period of two years from the date of grant; the remaining 300,000 options have an exercisable period of five years from the date of grant. 530,000 options vested immediately.  The remaining options are subject to other performance criteria. The options to acquire 430,000 common shares of the Company have an estimated fair value of $0.02 per share ($8,600) and the options to acquire 300,000 common shares of the Company have an estimated fair value of $0.04 per share ($12,000).  $12,600 was recognized.  (ii) During the year ended June 30, 2007, the Company granted options to acquire 1,150,000 common shares of the Company to employees, directors and senior officers.  The options have an exercise price of $0.10 with an exercisable term of two years from the date of the grant.  All options vested immediately with an estimated fair value of $0.02 per share resulting in $23,000 in stock based compensation expense being recognized.  (iii) During the year ended June 30, 2007, options granted to an employee to acquire 150,000 common shares of the Company were cancelled due to the employees departure.  The related expense of $3,000 ($0.02 per share), previously booked in wages and benefits in the Statement of Operations, was reversed and charged against the contributed surplus.  (iv) During the year ended June 30, 2007, the Company granted options to acquire 500,000 common shares of the Company to employees and directors.  The options have an exercise price of $0.11 with an exercisable term of two years from the date of the grant.  All options vested immediately with an estimated fair value of $0.07 per share resulting in $35,000 in stock based compensation expense being recognized.  (v) During the year ended June 30, 2007, the Company granted options to acquire 1,150,000 common shares of the Company to directors, consultants and officers.  The options have an exercise price of $0.12 with and exercisable term of two years from the date of grant. All options vested immediately with an estimated fair value of $0.07 per share resulting in $80,500 in stock based compensation expense being recognized.  Alda Pharmaceuticals Corp. 2007 20F/A Page 82------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  7. SHAREHOLDERS EQUITY (CONTINUED)  d) Stock options (continued): Stock-based compensation expense is presented in the Statement of Operations and Deficit as follows:  200720062005Consulting/Officers$         83,600$                  -$           925Investor Relations2,0001,1564,312Wages and Benefits62,500-11,000Total Stock-Based Compensation$       148,100$           1,156$      16,237  The fair value of each option was estimated as at the date of grant using the Black-Scholes   option-pricing model with the following weighted-average assumptions:  20072006Dividend yield0%-Expected volatility128.90%-Risk free interest rate4.19%-Expected average option term2.25 years-  e) Warrants  The Company has issued warrants entitling the holders to acquire common shares of the Company.  A summary of changes in unexercised warrants is presented below. Warrants
@ $0.235
(1)Warrants
@ $0.20
(2)Agent Warrants
@ $0.20
(3)Warrants
@ $0.10
(4)Warrants
@ $0.10
(5)Warrants
@ $0.10
(6)Warrants
@ $0.10
(7)Warrants
@ $0.20
(8)TotalOutstanding ,
June 30, 20056,000,0003,000,000220,500-----9,220,500Granted during year---3,916,0001,100,000---5,016,000Expired during year(6,000,000)-------(6,000,000)Outstanding,
June 30, 2006-3,000,000220,5003,916,0001,100,000---8,236,500Granted during year-----1,430,000-8,000,0009,430,000Warrant extended-----3,916,000-3,916,000Warrant exercised----(   80,000)-( 982,000)-(1,062,000)Expired during year-(3,000,000)( 220,500)(3,916,000)(1,020,000)---(8,516,500)Outstanding, June 30, 2007-----1,430,0002,934,0008,000,00012,364,000  (1) Terms of the warrants were amended to reduce the exercise price to $0.235 per share, exercisable until November 13, 2005. (2) Exercisable until September 15, 2006, granted pursuant to private placement. Warrants expired. (3) Exercisable until September 15, 2006, granted pursuant to private placement. Warrants expired. (4) Warrants granted pursuant to private placement expired on December 22, 2006. (5) Exercisable until June 22, 2007, granted pursuant to private placement. Warrants expired.  Alda Pharmaceuticals Corp. 2007 20F/A Page 83------------------------------------------------------------------------------------------------------------------------------------------------   ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  (6) Exercisable until September 12, 2007, granted pursuant to private placement. (7) Terms of the warrants in (4) were amended to extend the exercisable period of the warrants to December 22, 2007 at the exercise price of $0.10 per share. (8) Exercisable at a price of $0.20 per share until June 7, 2008 and, thereafter at a price of $0.30 per share until June 7, 2009, granted pursuant to private placement.   The fair value of each warrant was estimated as at the date of grant using the Black-Scholes pricing model with the following weighted-average assumptions:  20072006Dividend yield0%0%Expected volatility128.10%114.96%Risk free interest rate4.20%3.47%Expected average option term1.85 years1 year  7. SHAREHOLDERS EQUITY (CONTINUED)  f) Contributed surplus - Warrants:  Contributed surplus attributed to the issuance of warrants at June 30, 2007 and 2006, and activity during the 2007 and 2006 years, are summarized as follows:  20072006Balance, beginning of year$      163,413$       98,205Warrants issued to agent--Private Placement (Note 7(b)(i))--Private Placement (Note 7(b)(ii)&(iii))-65,208Private Placement (Note 7(b)(iv)&(v))404,020-Warrant Exercised (Note 7(b)(vi))(    13,806)-Balance, end of year$     553,627$     163,413  g) Contributed surplus - Options:  Contributed surplus attributed to the granting of stock options at June 30, 2007 and 2006, and activity during the 2007and 2006 years, are summarized as follows:  20072006Balance, beginning of year$         41,094$       39,938Options issued to employees12,000-Options issued to directors53,500-Options issued to consultants85,6001,156Options forfeited / cancelled(    3,000)-Options exercised(  18,000)-Balance, end of year$     171,194$       41,094   Alda Pharmaceuticals Corp. 2007 20F/A Page 84------------------------------------------------------------------------------------------------------------------------------------------------   ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006   8. GAIN ON LEGAL SETTLEMENT  (i) A company opposing a trademark application made in Canada by ALDA commenced legal proceedings during the 2003 year claiming damages in respect to alleged infringement of trademark.  ALDA had filed a Statement of Defence.  The Statement of Claim was subsequently amended to add the Company as a defendant in the action.  On May 23, 2005, the Company entered into a Settlement agreement with that company, whereby the Company agreed to terminate the use, and application for registration of, the trademark Viralex. The Company must discontinue the use of that trademark in advertising and other promotional disclosures, liquidate its inventory of goods bearing the trademark Viralex, and rename the Viralex product within twelve months from the date of the agreement, in consideration for payment of $30,000 (US). These funds were held in escrow by the Companys lawyer until the Company issued a press release regarding the settlement of the trademark dispute, and withdrew its application for the Viralex trademark, which occurred during the period ended September 30, 2005.  (ii) On August 2, 2005, the Company received the proceeds from the Companys lawyer regarding the settlement of the trademark dispute. The proceeds of the settlement for a total amount of $37,383 ($30,000 (US)) have been recorded in the Statement of Operations and Deficit as Gain on legal settlement for the period ended September 30, 2005.  During the 2005 year, the Company commenced legal action against the competitor described above with respect to certain alleged defamatory statements made by the competitor.  This claim was settled effective July 12, 2006, by an agreement under which the Company is to receive an amount of $15,000 from the competitor.  The proceeds of the settlement, net of associated legal costs in the amount of $4,455, have been recognized in the Statement of Operations and Deficit for the period ended June 30, 2007.  9. MAJOR CUSTOMERS  For the year ended June 30, 2007, revenue from each of four customers exceeded 10% of total revenue (2006: four customers; 2005: five customers).  Revenue from these customers totaled $162,837 (2006: $149,544; 2005: $175,958).  10. COMMITMENTS  (i) Effective July 1, 2007, the Company entered into an agreement to lease its office premises with a term of one year.  The Companys minimum lease payment obligations under the agreement as at July 1, 2007, totaled $25,971, payable in the 2008 year.  (ii) During the 2006 year, the Company entered into an agreement with its product supplier.  Under the agreement, the supplier assumes all the costs of manufacturing of the Companys T36® products, and as consideration, receives a percentage, ranging from 40% to 65%, of the Companys selling price.  The supplier also has tight of first refusal to manufacture other products from the Company.  The agreement can be terminated by either party with 90 days written notice.  Alda Pharmaceuticals Corp. 2007 20F/A Page 85------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  11. INCOME TAXES  (i) As at June 30, 2007, the Company had approximately $2,305,000 of unutilized non-capital losses for tax purposes, which expire as follows:  Year2008$      14,051200976,818201060,9152014603,2552015582,7932026463,5282027450,897  The potential future income tax benefit which may arise from claiming these losses has not been reflected in these financial statements, as the Companys ability to realize the benefit is uncertain.  (ii) Following is a reconciliation of the expected income tax benefit from the loss for each year based on applicable statutory income tax rate, to the actual amount:  200720062005Loss at statutory rate$     191,67334.1%$129,00134.1%$  283,48335.6%Net effect of non-deductible
expenses(50,968)2,93597,303Expected increase in tax asset140,705131,936380,786Effect of tax rate reduction-(28,640)( 8,397)Temporary difference due to debit to equity2,106--Increase in allowance for
uncertain realization(142,811)(103,2936)(372,389)Increase in tax asset per financial
statements$                -$          -$           -  The income tax effects of losses carried forward and of cumulative temporary differences that give rise to a future tax asset are summarized as follows:  20072006Tax losses carried forward$     768,019$       614,264Temporary differences  intangible assets81,29979,321Temporary differences  property and equipment9,2375,663Temporary differences  financing costs24,89841,394Net tax asset before allowance for uncertain realization883,453740,642Allowance for uncertain realization(883,453)(740,642)Tax asset per financial statement$                -$                  -   Alda Pharmaceuticals Corp. 2007 20F/A Page 86------------------------------------------------------------------------------------------------------------------------------------------------   ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  12. RELATED PARTY TRANSACTIONS  a) During the year ended June 30, 2007, the Company paid consulting fees of $120,000 (2006: $120,000; 2005: $134,000) to companies controlled by directors of the Company.  b) During the year ended June 30, 2007, the Company paid rent of $28,371 (2006: $30,912; 2005: $25,265) to a company controlled by a director of the Company.  c) During the year ended June 30, 2007, the Company paid consulting fees of $60,000 (2006: $60,000; 2005: $70,000) to a major shareholder of ALDA.  d) Included in $293,600 Subscriptions receivable are $105,000 (2006: $nil) owing by directors of the Company.  These transactions were measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.  13. LICENSE AND OPTION AGREEMENT  Effective January 11, 2006, the Company entered into an agreement with its wholly owned subsidiary, Sirona, whereby it granted to Sirona an exclusive license in respect to therapeutic applications of the Companys T36® technology including an option to develop and commercialize such applications.  The agreement is to expire at the later of 20 years from the date of the agreement and the last expiry of any patent obtained related to the technology.  Management of the Company has indicated that the purpose of the agreement is to allow Sirona to pursue independent financing arrangements.   14. STATEMENTS OF CASH FLOWS  SUPPLEMENTARY INFORMATION  a) Cash paid in respect to interest and income taxes was as follows:  200720062005Cash paid during the year for interest$   1,324$         -$         -Cash paid during the year for income taxes$           -$         -$         -  b) Significant non-cash transactions occurring during the 2007 year were as follows:  (i) The estimated fair value of the options granted to consultants, officers, directors and employees described in Notes 7(d), totaling $148,100, was charged to operations for the 2007 year.  c) Significant non-cash transactions occurring during the 2006 year were as follows:  (i) A portion of the estimated fair value of the options granted to consultants, officers, directors and employees described in Notes 7(d), totaling $1,156, was charged to operations for the 2006 year.  Alda Pharmaceuticals Corp. 2007 20F/A Page 87------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006  15. SUBSEQUENT EVENTS  a) Subsequent to the year ended June 30, 2007, 2,790,000 warrants at an exercise price of $0.10 per warrant and 100,000 options at an exercise price of $0.10 per options were exercised for total gross proceeds of $289,000.  b) Subsequent to the year ended June 30, 2007, the Company arranged a private placement of up to 2,000,000 units at a price of $0.12 per unit for gross proceeds of $240,000.  Each unit consists of one common share of the Company and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of the Company at a price of $0.24 per common share for a period of 12 months from the date of closing and at a price of $0.36 per common share for the subsequent period of 12 months.  The $0.12 private placement was closed on August 13, 2007.  Finders fee in the amount of $6,300 was charged against the share capital in connection with the closing of the private placement.  16. UNITED STATES GENERALLY ACCEPTED ACCOUNTING PRINCIPLES  These financial statements have been prepared in accordance with Canadian generally accepted accounting principles in Canada (Canadian GAAP) which are substantially the same as principles applicable in the United States (US GAAP) and practices prescribed by the United States Securities and Exchange Commission (SEC), except for the following:  a) Comprehensive income:  Statement of Financial Accounting Standards No. 130 requires the reporting of Comprehensive Income.  Comprehensive income includes net income plus other comprehensive income.  Other comprehensive income includes all changes in equity of a company during the period arising from non-owner sources.  The Company did not have any other comprehensive income during the years ended June 30, 2007 and 2006.  b) Product development costs:  Under Canadian GAAP, product development costs are charged as an expense in the period incurred except in circumstances where the market and feasibility of the product have been established, and recovery of development costs can reasonably be regarded as assured, in which case such costs are capitalized.  US GAAP requires that these expenditures be expense in the year incurred.  The Company has not capitalized any product development costs during the years ended June 30, 2007 and 2006.  c) Recent United States Accounting Pronouncements:  Selected recent pronouncements issued by the Financial Accounting Standards Board (FASB) are summarized below.  None of these changes are expected to have a material impact on the financial statements of the Company.  Alda Pharmaceuticals Corp. 2007 20F/A Page 88------------------------------------------------------------------------------------------------------------------------------------------------  ALDAPHARMACEUTICALS CORP. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2007 AND 2006   16. UNITED STATES GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (CONTINUED)  c) Recent United States Accounting Pronouncements  (i) In December of 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 123 (revised 2004) (Share-Based Payments) (SFAS 123R).  SFAS 123R is a revision of SFAS 123, and supersedes APB 25.  SFAS 123R requires that the fair value of employees awards of share-based payments which are issued, modified, repurchased or cancelled after the implementation date, is to be measured as of the date the award is issued, modified, repurchased or cancelled and the resulting cost recognized in the statement of earnings over the service period.  SFAS 123R will be effective for the Companys year ended June 30, 2007.  (ii) The Fair Value Option for Financial Assets and Financial Liabilities  In February 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities  Including an Amendment of FASB Statement No. 115.  This statement permits entities to choose to measure many financial instruments and certain other items at fair value.  Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option.  However, the amendment to SFAS No. 115 Accounting for Certain Investments in Debt and Equity Securities applies to all entities with available-for-sale and trading securities.  SFAS No. 159 is effective as of the beginning of an entitys first fiscal year that begins after November 15, 2007.  Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provision of SFAS No. 157, Fair Value Measurements.  (iii) Fair Value Measurements  In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS No. 157, Fair Value Measurements.  The objective of SFAS No. 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements.  SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements.  SFAS No. 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements.  The provisions of SFAS No. 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007.  (iv) Accounting for Uncertainty in Income taxes  In June 2006, the Financial Accounting Standards Board (FASB) issued Interpretation No. 48 (FIN 48).  FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprises financial statements in accordance with FASB Statement No. 109 Accounting for Income Taxes (SFAS 109).  The interpretation prescribes a recognition threshold and measurement attribute to the financial statement recognition and measurement of tax position taken or expected to be taken in a tax return.  FIN 48 also provides accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.  FIN 48 is effective for fiscal years beginning after December 15, 2006.  We will adopt the provisions of FIN 48 on July 1, 2007.  17. COMPARATIVE FIGURES  Certain comparative figures for the 2005 and 2006 years have been reclassified to conform to the presentation adopted for the 2007 year.  Alda Pharmaceuticals Corp. 2007 20F/A Page 89------------------------------------------------------------------------------------------------------------------------------------------------   [alda200720famend2005.jpg]ALDA Pharmaceuticals Corp.
635 Columbia Street, New Westminster, British Columbia,V3M 1A7
Telephone:604-521-8300; Facsimile:604-521-8322      Form 51-102F1 Managements Discussion & Analysis for the year ended June 30, 2007  October 26, 2007         The statements contained in this report that are not purely historical are forward-looking statements. Forward looking statements  include statements regarding our expectations, hopes, intentions or strategies regarding the future. Forward looking statements include: statements regarding future products or products or product development; statements regarding future selling, general and administrative costs and research and development spending; and our product development strategy; statements regarding future capital expenditures and financing requirements; and similar forward looking statements. It is important to note that our actual results could differ materially from those in such forward-looking statements.    Alda Pharmaceuticals Corp. 2007 20F/A Page 90------------------------------------------------------------------------------------------------------------------------------------------------  ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  1.1 Date  This Management Discussion and Analysis (MD&A) is dated October 26, 2007 and should be read in conjunction with the consolidated financial statements of ALDA Pharmaceuticals Corp. (ALDA or the Company) for the financial year ended June 30, 2007. All financial information is expressed in Canadian dollars and is prepared in accordance with Canadian generally accepted accounting principles (GAAP).  1.2 Overall Performance  On November 13, 2003, ALDA Pharmaceuticals Corp., formerly Duft Biotech Capital Ltd., completed the acquisition of the assets of 513947 BC Ltd. formerly ALDA Pharmaceuticals Inc. (the Qualifying Transaction) and a $1.2 Million financing arranged by Canaccord Capital Corporation (the Financing).ALDA trades on the TSX Venture Exchange in Vancouver, Canada under the symbol APH.  ALDA has developed a patent-pending infection control formulation, referred to as T36®, which is incorporated into therapeutic applications such as treatments for topical and vulvovaginitis infections, hand hygiene products, a skin antiseptic for clinical and consumer use and a first-aid ointment. Studies have been performed on the T36® formulation which demonstrates its ability to kill all types of infectious micro-organisms within 3 minutes and tuberculosis within 5 minutes. Toxicology studies on animals have also demonstrated that the T36® formulation is not toxic.  There is competition in all of the therapeutic markets that the company has targeted. However, the T36® formulation is not expensive to manufacture and can be used in a broad variety of infection-control products. Toxicology and efficacy studies have already demonstrated that the T36® formulation is not toxic and is effective at killing all bacteria, viruses and fungi. The intended applications are topical, except for the vulvovaginitis treatment, so that registration is expected be faster and less expensive than for drugs that are taken internally. Rather than disrupting metabolic pathways, the T36® formulation consists of four anti-microbial ingredients in relatively low concentrations that act synergistically to disrupt the physical structure of the infectious agents. This approach prevents microbial resistance from developing. None of the active ingredients are known to have any significant side effects on humans.  ALDA has started studies that will satisfy the registration requirements of Health Canada, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMeA) for the targeted applications. In other parts of the world, FDA or EMeA testing is generally accepted for registration applications. If the company decides to register the products in China, it is likely that the testing will have to be repeated in China unless there is harmonization of the requirements in the meantime.  The overall strategy for the T36® products is to first secure registration as prescription products so that marketing and sales can be focused on pharmaceutical distributors that serve physicians. As efficacy and safety of the products are established, registration as over-the-counter (OTC) products will be sought. Once OTC status is secured, the sales and marketing focus will shift to distributors that serve pharmacies.  To complete this plan, the company will need to raise money in the public markets. This will increase the number of shares outstanding and will lead to further dilution of existing shareholders.  Market knowledge of the ALDA name is limited.  ALDA will need to devote considerable resources to educate new markets about the products the Company offers.  In establishing new markets, the Company will be competing with companies that are potentially already entrenched in such markets or that may be better funded than the Company.  ALDA also faces significant costs and risks associated with the protection and exploitation of its intellectual property, given that the patents have not yet been granted to the Company.  Competitors with significantly more resources may have an advantage over the Company in terms of the establishment, protection and exploitation of patents and other intellectual property.  All of these factors are material to the Company and its business.  Alda Pharmaceuticals Corp. 2007 20F/A Page 91------------------------------------------------------------------------------------------------------------------------------------------------   ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  1.3 Selected Annual Information Year Ended OnJune 30, 2007June 30, 2006June 30, 2005Revenue$256,243$223,586$240,998Net Loss$562,090$378,301$796,301Basic Loss Per Share$      0.02$      0.02$      0.06Diluted Loss Per Share$      0.02$      0.02$      0.06Patent Application$  40,486$            -$            -Total Assets$854,166$216,872$300,893Long-Term Liabilities$           0$           0$           0  At June 30, 2007, the Company had $356,127 in cash with $293,600 in subscriptions to a private placement to be received.  The improvement of the Companys cash position compared to June 30, 2006 was primarily attributed to funds received from a private placement arranged by the Company prior to June 30, 2007. For the same reasons, current assets increased by $609,325 from $92,673 to $701,998.  Patent application and development costs incurred during the 2007 year were capitalized with a useful life of 20 years.  Accounts payable and accrued liabilities increased by $14,764.  1.4 Results of Operations  Sales For the year ended June 30, 2007, sales increased to $256,243 (2006: $223,586).  Reported sales were primarily due to the sale of the companys surface disinfectant, T36® Disinfectant, through its distributors to the first responders, dental and beauty markets. In 2006, the Company also introduced T36® Hand Sanitizer which was also being sold through the same distributors.  Cost of sales For the year ended June 30, 2007, the cost of sales incurred was $165,920, representing 64% of total sales (2006: $142,379; 64%). Cost of sales includes the direct costs of the inventory sold during the period plus warehousing costs and handling charges.  Gross Profit (Loss) For the year ended June 30, 2007, gross profit of $90,323 was recognized (2006: $81,207). The percentage of gross profit has remained relatively stable over the last three years.  Advertising and promotion Advertising and promotion costs for the year ended June 30, 2007 were $12,766 (2006: $12,169).  The Company has put new efforts into attracting new customers by providing lectures, sending samples of T36® Disinfectant and literature to potential new customers and distributors.  Due to the closing of recent private placements, the Company has more resources to further increase its presence in the market.  Consulting Consulting fees for the year ended June 30, 2007 were $308,600 (2006: $183,218).  Included in $308,600 consulting fees were $180,000 paid to executives of the company as a form of remuneration for their services provided to the Company.  The related party transactions were summarized as follows. · $60,000 to 503213 BC Ltd., a company controlled by Dr. Terrance G. Owen, President & CEO, for services related to directing the technical aspects of research and development, product testing, domestic and international product registrations and intellectual property protection; negotiating and establishing  Alda Pharmaceuticals Corp. 2007 20F/A Page 92------------------------------------------------------------------------------------------------------------------------------------------------  ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  1.4 Results of Operations (continued)  Consulting (continued)  · international marketing agreements; assisting with domestic and international sales and marketing strategies,  · marketing materials, internet marketing and investor relations activities; directing the companys legal and accounting professionals; advising officers and directors of company matters and ensuring that the regulatory requirements of the company are fulfilled.  ● $60,000 to 612480 BC Ltd., a company controlled by Peter Chen CFO, for advising on the financial aspects of research and development, product testing, domestic and international product registrations and intellectual property protection; negotiating and establishing international marketing agreements; assisting with domestic and international sales and marketing strategies, marketing materials, internet marketing and investor relations activities; directing the companys legal and accounting professionals; advising officers and directors of company matters and ensuring that the regulatory requirements of the company are fulfilled.  ● $60,000 to 680806 BC Ltd., a company controlled by Dr. Allan Shapiro for advising on and assisting with research and development, marketing and sales, product testing, domestic and international product registrations and intellectual property protection and attending conferences, conducting seminars and training sessions and providing presentations at conferences.  Of the $308,600 in consulting fees, $82,000 were related to stock options granted to executives, officers and consultants of the Company.  The balance was paid to third party consultants for services provided in marketing and business development.  Investor relations The investor relations activities amounted to $65,039 for the year ended June 30, 2007 (2006:$ 52,808). Freeform Communications Inc. (Freeform) received a total of $38,300 from the Company; $2,000 were related to stock options granted to Freeform over the year. The Company retained Rhone Alternative Marketing Partners (RAMP) to raise funds in Europe to undertake the testing and registration of the topical therapeutic applications of ALDAs T36® technology.  Over the year RAMP received a total of $20,000 from the Company. Other investor relations expenses incurred during the 2007 fiscal year were $6,739 for the dissemination of news releases provided by Canada Newswire and CCN Matthews.  Legal and accounting fees Legal and accounting fees were totaled $53,697 for the year ended June 30, 2007 (2006: $63,179).  Accounting fees primarily consisted of the cost of the year-end audits and for reviewing the quarterly statements. Legal fees in 2007 consisted of closings of private placements, advising the Company on general legal matters, and attending to preparation of required documentation to the TSX Venture Exchange and the securities commissions.  Legal and accounting fees (continued) As announced in a news release issued by the company on September 13, 2007, Berris Mangan resigned as the Companys auditor due to a decision by Berris Mangan to focus its practice on TSX-listed companies with Canadian reporting responsibilities. The Company confirmed that there are no reportable events (as such term is defined in National Instrument 51-102 of the Canadian Securities Administrators) and appointed HLB Cinnamon Jang Willoughby, Chartered Accountants (CJW) as the interim auditor to conduct the year-end audit.  Alda Pharmaceuticals Corp. 2007 20F/A Page 93------------------------------------------------------------------------------------------------------------------------------------------------  ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  Product Registration and Development Costs Total costs incurred in this category for the year ended June 30, 2007 was $42,617 and capitalized under patent  application and development costs. (2006: $ 18,377). Patent costs incurred during the year were capitalized with an amortization period of 20 years rather than expensed.  A new category has been added to the Balance Sheet to reflect this change in accounting practices. Costs in this category include the fees paid to the regulatory consultants in Canada and the US to pursue the registration of the companys products in the United Kingdom and the United States. Costs spent on laboratory testing and intellectual property protection are also included in this category. Other than the patent costs which were capitalized, there were no development expenses for the year ended June 30, 2007  Wages and benefits Wages and benefits were $116,633 for the year ended June 30, 2007 (2006: $75,903). Costs in this category include the wages paid to accounting and administrative assistance and to sales and marketing staff as well as the expenses related to stock options granted to certain directors and employees.  Included in wages were $62,500 related to stock-based compensation.  1.4 Results of Operations (continued)  Loss from operations The loss from operations was $562,090 for the year ended June 30, 2007 (2006: $380,026).  Losses for the year ended June 30, 2007 were greater than for previous years due to non-cash stock options granted to certain officers, consultants, directors and an employee during the year.  The amortization expense increased to $16,281, an increase of 97% compared to previous years.  Such increase was mainly due to the amortization of intangible assets and the capitalized patent application costs.   A number of initiatives were taken during the year to promote further growth of the company, including private placements, expanding the patent portfolio of the company, seeking expert advice on product registrations undertaking laboratory tests of T36® Disinfectant, preparing marketing materials, evaluating new manufacturing facilities, and seeking out new distributors and customers.  Comparing to the 2006 fiscal year, sales of T36® Disinfectant for the 2007 fiscal year increased by 14%, while expenses increased by approximately 33%.  Loss from operations (continued) Management continues to work towards the launch of new products, including T36® Personal Disinfectant, T36® Hand Sanitizer and the therapeutic products. The pursuit of the new therapeutics products requires the Company to invest continuously in product development, clinical trials, product registrations and intellectual property protection.  As a result, further losses will be anticipated in the subsequent periods. Management continues to work towards the launch of new products, including T36® Personal Disinfectant, T36® Hand Sanitizer and the therapeutic products. The pursuit of the new therapeutics products requires the Company to invest continuously in product development, clinical trials, product registrations and intellectual property protection.  As a result, further losses will be anticipated in the subsequent periods.  Other income (Loss) Interest income earned from the deposits for the year ended June 30, 2007 was zero (2006: $1,725).  The intangible asset originally estimated at $540,000 was written down to $116,000 in the 2005 fiscal year due to the devaluation of the assets purchased by the Company for its Qualifying Transaction.  Because the management of the Company anticipated that the net recoverable amount of the intangible asset exceeded the carrying value, no further impairment loss was recognized for the 2006 year.  The anticipated net recoverable amount was calculated based on the undiscounted future cash flows.  During 2007 fiscal year, the carrying value of intangible asset was determined to have an estimated finite life of 20 years.  Alda Pharmaceuticals Corp. 2007 20F/A Page 94------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  During the 2005 fiscal year, the Company entered into a settlement agreement with a claimant, whereby the Company agreed to terminate the use, and application for registration of, the trademark Viralex. The settlement agreement required the Company to liquidate its inventory of goods bearing the trademark within twelve months from the date of the agreement in all advertising and other promotional means. In connection with the settlement of the trademark depute, a gain of $37,383 ($30,000 US), previously held by the Companys lawyer, was recognized the Company and reported in the Statement of Operations and Deficit as a gain on legal settlement for the 2006 year.  During the 2005 year, the Company commenced legal action against the competitor described above with respect to certain alleged defamatory statements made by the competitor.  This claim was settled effective July 12, 2006, by an agreement under which the Company is to receive an amount of $15,000 from the competitor.  The proceeds of the settlement, net of associated legal costs in the amount of $4,455, have been recognized in the Statement of Operations and Deficit for the period ended June 30, 2007.  1.4 Results of Operations (continued)  Loss for the year The loss for the year ended June 30, 2007 was $562,090 (2006: $378,301).  The increases in losses for 2007 were mainly due to higher levels of non-cash stock-based compensation to consultants, directors, officer and an employee while losses for 2006 were offset by a gain of a legal settlement in connection with the settlement of the trademark depute.  Use of proceeds  The net proceeds received from the closing of recent private placements will be used for working capital including such activities as starting initial clinical trails of the T36® formulation in therapeutic products, registering T36® products in major markets, seeking expert advice on product regulatory issues, re-branding and advertising current and new lines of products and seeking possible registration of ALDAs securities in foreign jurisdictions.  1.5 Summary of Quarterly Results. Quarter endedJun/07Mar/06Dec/06Sep/06Jun/06Mar/06Dec/05Sep/05Revenue61,43372,87964,35657,57558,72447,69460,28556,883Net loss302,34584,83178,32496,59167,371118,084137,21355,633Loss/share0.000.000.000.000.000.010.010.00Total assets854,166176,316175,743208,281216,8722207,800319,192237,141  The revenues generated from the sale of T36® Disinfectant have been relatively consistent while a reduction in operating expenses has been realized. Resources spent in patenting, research and development, and product registrations have been capitalized with an amortization period of 20 years. The greater loss recognized in 2007 fiscal year was mainly due the non-cash stock options granted to certain officers, directors, consultants and an employee and increased consulting fees and wages.  No further impairment loss was recognized from the intangible assets as the intangible assets were determined to have a definite life of 20 years commencing July 1, 2006.   Prior to July 1, 2006, the intangible assets deemed to have an indefinite life subject to annual test of impairment.  $245,000 impairment loss on intangible assets was incurred for the fiscal year 2005 which reduced the carrying value of the intangible assets to $116,000. No further impairment loss was recognized for the fiscal year 2006.  In connection with the settlement of legal disputes, the Company recognized a net gain of $10,545 and $37,383 in fiscal years 2007 and 2006, respectively.  Total assets were increased over the quarters as a result of receiving external funding from the private placements. All resources will be used in marketing, product development, intellectual property protection and the other requirements of an operating company that is introducing a new technology and products to the market  Alda Pharmaceuticals Corp. 2007 20F/A Page 95------------------------------------------------------------------------------------------------------------------------------------------------  ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  1.6 Liquidity  Although the company generates revenues from the sale of its lead product, T36®Disinfectant, sales are still occurring only in Canada. Approvals have been obtained for T36®Disinfectant in the European Union and China and the Company will be pursuing opportunities in these markets. The company has also established a plan for the development, testing, registration and marketing of therapeutic applications of the T36® formulation The Company will need to undertake further financings in order pursue these plans and these financings will lead to the dilution of current shareholders of the Company.  1.7 Capital resources  On September 13, 2006, the Company raised net proceeds of $71,500 by selling a total of 1,430,000 Units of the Companys at price of $0.05 per Unit. Each Unit consisted of one common share of the Company and one warrant that entitled the holder to purchase one additional common share at a price of $0.10 per share for a period of 12 months following the closing date.  The estimated fair value of warrants being $20,020 was allocated to contributed surplus for warrants. On June 7, 2007, the Company completed a private placement of 8,000,000 Units at a price of $0.10 per unit for net proceeds of $793,820.  Each Unit consist of one common share and one warrant that entitles the holder to purchase one additional common share at a exercise price of $0.20 per share until June 7, 2008 and, thereafter at a price of $0.30 per share until June 7, 2009.  The estimated fair value of warrants being $384,000 was allocated to contributed surplus for warrants. The net proceeds will be used for general working capital. As of June 30, 2007, the Company received funds of $196,200 from the exercise of 1,062,000 warrants and 900,000 options at an exercise price of $0.10.  Option values of $18,000 previously recorded in contributed surplus for options were credited to share capital.  Warrant values of $13,806 previously recorded in contributed surplus for warrants were credited to share capital. At June 30, 2007, the Company had 32,192,404 outstanding common shares. 4,240,500 warrants expired without being exercised.  Subsequent to the closing of two private placements, the Company has a total of 12,364,000 outstanding warrants exercisable at an exercise price range of $0.10 to $0.20 before the date of expiration. During the period, the Company received an approval from TSX to extend 3,916,000 warrants granted pursuant to private placement by a year to December 21, 2007 at the same exercise price of $0.10 per share.  The outstanding stock options as at June 30, 2007 were 2,480,000 with a weighted average exercise of $0.11 per options. There is no guarantee that the Company will derive any proceeds from the exercise of outstanding warrants and there is no assurance that additional funding will be available to the Company to fulfill its business objectives.  There can be no assurance that the Company will be able to obtain adequate financing in the future or that the terms of such financing will be favourable.  Many of the Company products still require further development and laboratory testing in order to obtain required regulatory approvals.  A lack of funds will impair the ability of the Company to complete such tests.  A lack of funds will also impair the Companys ability to establish marketing and sales plans once the products have been approved for sale.  If adequate financing is not available when required, the Company may be required to delay, scale back or eliminate various activities and may be unable to continue in operation.  ALDA may seek such additional financing through debt or equity offerings, but there can be no assurance that such financing will be available on terms acceptable to the Company or at all.  Any equity offering will result in dilution to the ownership interests of the Companys shareholders and may result in dilution to the value of such interests.  1.8 Off-Balance Sheet Arrangements  The company is not aware of any off-balance sheet transactions requiring disclosure.  Alda Pharmaceuticals Corp. 2007 20F/A Page 96------------------------------------------------------------------------------------------------------------------------------------------------  ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  1.9 Transactions with Related Parties  a) During the 2007 year, the Company incurred consulting fees of $120,000 (2006: $120,000) to companies controlled by directors of the Company.  b) During the 2007 year, the Company incurred premises rent of $28,371 (2006: $30,912) to a company controlled by a director of the Company.  e) During the 2007 year, the Company incurred consulting fees of $60,000 (2006: $60,000) to a major shareholder of ALDA.  f) Included in $293,600 Subscriptions receivable are $105,000 owing by directors of the Company.  These transactions were measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.  1.10 Fourth Quarter, 2007  During the fourth quarter ended June 30, 2007, there were no extraordinary events that affected the Company. Sales for the quarter were close to the average sales recorded per quarter for the last two years. A private placement for $800,000 was completed on June 7, 2007. There were no significant year-end adjustments except that certain comparative figures for the 2006 have been reclassified to conform to the presentation adopted for the 2007 year.  1.11 Proposed transactions  The company is not aware of any proposed transactions requiring disclosure.  1.12 Critical Accounting Estimates  The company is a venture issuer and is not required to provide critical accounting estimates.  1.13 Changes in Accounting Policies Including Initial Adoption  Effective July 1, 2001, the Company adopted the new recommendations of the Canadian Institute of Chartered Accountants Accounting Handbook Section 3870, Stock-based Compensation and Other Stock-based Payments ("CICA 3870"). During the year ended June 30, 2004, CICA 3870 was amended to require the use of the fair value-based method to account for stock options granted to employees. In accordance with the revised recommendations, the Company has prospectively applied the fair value-based method to all stock options granted to employees on or after July 1, 2003, whereby compensation cost is measured at fair value at the date of grant and is expensed over the vesting period.  Effective July 1, 2003, the Company adopted the recommendations of the Canadian Institute of Chartered Accountants Handbook, Section 3063, Impairment of long-lived assets ("CICA 3063"). The new recommendations were applied prospectively to all long-lived assets held for use by the Company after July 1, 2003.  The financial statements include a note providing reconciliation to United States Generally Accepted Accounting Standards (GAAS).  Patent application and development costs include all expenditures attributable to efforts by the Company to develop, and bring to commercial production a new product as well as to acquire legal protections for its proprietary products, such as trademarks and patents.  Such amounts are charged as an expense in the period  Alda Pharmaceuticals Corp. 2007 20F/A Page 97------------------------------------------------------------------------------------------------------------------------------------------------  ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007  incurred except in circumstances where the market and technical feasibility of the product have been established, and recovery of patent application and development costs can reasonably be regarded as assured and future values can be realized, in which case such costs are capitalized.  In the latter case, patent application and development costs are amortized on a systematic basis over the patent life of 20 years.  The carrying amount of intangible assets which are determined to have a finite useful life are amortized on a systematic basis over the useful life of 20 years.  1.14 Financial Instruments  The Company's financial instruments consist of cash and equivalents, accounts receivable, subscriptions receivable, accounts payable and accrued liabilities. The fair value of these instruments approximates their carrying values except where otherwise noted. It is management's opinion that the Company is not exposed to significant interest, currency, or credit risk arising from these financial instruments except where otherwise noted.  1.15 Other MD&A Requirements (a) Additional Information  Additional information relating to the Company can be found on the Canadian Securities Administrators System for Electronic Document Analysis and Retrieval (SEDAR) database at www.sedar.com.  (b) Disclosure of Outstanding Share Data The following table summarizes our outstanding share capital as at June 30, 2007: SecurityNumberEach class and series of voting or equity securities for which
there are securities outstanding:
Common Shares32,192,404Each class and series of securities for which there are
securities outstanding if the securities are convertible into,
or exercisable or exchangeable for, voting or equity
securities
Stock Options
Warrants
Convertible Debentures2,480,000
12,364,000
0Each class and series of voting or equity securities that are
issuable on the conversion, exercise or exchange of
outstanding securities above
Common Shares47,036,404  (c) Disclosure Controls and Procedures  The management of ALDA is responsible for establishing and maintaining disclosure controls and procedures for the Company and has designed such disclosure controls and procedures, or caused them to be designed under ALDA managements supervision, to provide reasonable assurance that material information relating to the Company, including its consolidated subsidiaries, is made known to ALDA management by others within those entities particularly during the period covered by this MD&A.  Alda Pharmaceuticals Corp. 2007 20F/A Page 98------------------------------------------------------------------------------------------------------------------------------------------------   ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2007   ALDA management has evaluted the effectiveness of the Companys disclosure controls and procedures for the period covered by this MD&A and based on that evaluation, management has concluded that the disclosure controls and procedures are effective.  (d) Internal Control Over Financial Reporting  The Companys management is responsible for establishing and maintaining adequate internal control over financial reporting.  Management has considered the effectiveness of design of the Companys internal controls and procedures over financial reporting and has noted several weaknesses in internal controls over financial reporting such as a lack of segregation of duties because of limited staff members. Management intends to initiate steps to remedy the noted shortcomings over the next fiscal year by carrying out a management assessment of the weakness with a view to improving areas where weaknesses exist and implementing procedures aimed at minimizing the risk of material error in its financial reporting.  1.16 Subsequent Events to June 30, 2007  a) Subsequent to the year ended June 30, 2007, 2,790,000 warrants at an exercise price of $0.10 per warrant and 100,000 options at an exercise price of $0.10 per options were exercised for total gross proceeds of $289,000.  b) Subsequent to the year ended June 30, 2007, the Company arranged a private placement of up to two (2) millions Units at a price of 12 cents per unit for gross proceeds of $240,000 as announced in a news release issued by the company on July 10, 2007. Each Unit consists of one common Share of the Company and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of the Company at a price of 24 cents per common share for a period of 12 months from the date of closing and at a price of 36 cents per common share for the subsequent period of 12 months.  The 12 cent private placement was closed on August 13, 2007.  Finders fee in the amount of $6,300 was charged against the share capital in connection with the closing of the private placement.  c) Subsequent to the year ended June 30, 2007 and as announced in a news release issued by the company on September 13, 2007, Berris Mangan resigned as the Companys auditor due to a decision by Berris Mangan to focus its practice on TSX-listed companies with Canadian reporting responsibilities. The Company confirmed that there are no reportable events (as such term is defined in National Instrument 51-102 of the Canadian Securities Administrators) and appointed HLB Cinnamon Jang Willoughby, Chartered Accountants (CJW) as the interim auditor to conduct the year-end audit.  d) Subsequent to the year ended June 30, 2007, the Company arranged a private placement of up to 3,500,000 Units at a price of 15 cents per unit for gross proceeds of $525,000 as announced in a news release issued by the company on October 23, 2007.  Each Unit consists of one common Share of the Company and one non-transferable Share purchase Warrant entitling the holder to acquire one additional common share of the Company at a price of 30 cents per common share for a period of 12 months from the date of closing and at a price of 45 cents per common share for the subsequent period of 12 months.  This arrangement has not yet been approved by TSX Venture Exchange.   Alda Pharmaceuticals Corp. 2007 20F/A Page 99------------------------------------------------------------------------------------------------------------------------------------------------       ALDA PHARMACEUTICALS CORP. CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004       Alda Pharmaceuticals Corp. 2007 20F/A Page 100------------------------------------------------------------------------------------------------------------------------------------------------      Forging strong relationships.  Providing clear business advice[alda200720famend2007.gif]  AUDITORS' REPORT To the Shareholders of ALDA Pharmaceuticals Corp.  We have audited the consolidated balance sheets of ALDA Pharmaceuticals Corp. ("the Company") as at June 30, 2006 and 2005 and the consolidated statements of operations and deficit and cash flows for the years ended June 30, 2006, 2005 and 2004.  These financial statements are the responsibility of the company's management.  Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. In our opinion these consolidated financial statements present fairly, in all material respects, the financial position of the company as at June 30, 2006 and 2005 and the results of its operations and its cash flows for the years ended June 30, 2006, 2005 and 2004 in accordance with Canadian generally accepted accounting principles.  Vancouver, Canada
September 15, 2006[alda200720famend2009.gif]      [alda200720famend2011.gif]BERRIS  MANGAN  ELLIOTT  SHIKAZE  GALBRAITH AXWORTHY INFANTI

A PARTNERSHIP OF INCORPRATED PROFESSIONALS1827 West 5th Avenue
Vancouver, BC  V6J 1P5
604.682.8492  tel
604.683.4782  fax

www.berrismangan.com   Alda Pharmaceuticals Corp. 2007 20F/A 101
------------------------------------------------------------------------------------------------------------------------------------------------------------     Forging strong relationships.  Providing clear business advice[alda200720famend2013.gif]       COMMENTS BY AUDITORS FOR U.S READERS ON CANADA-U.S. REPORTING DIFFERENCE  In the United States, reporting standards for auditors require the addition of an explanatory paragraph (following the opinion paragraph) when the financial statements are affected by conditions and events that cast substantial doubt on the Company's ability to continue as a going concern, such as those described in Note 1 to the financial statements.  Our report to the shareholders dated September 15, 2006 is expressed in accordance with Canadian reporting standards which do not require a reference to such events and conditions in the auditors' report when these are adequately disclosed in the financial statements.   Vancouver, Canada
September 15, 2006[alda200720famend2015.gif]      [alda200720famend2017.gif]BERRIS  MANGAN  ELLIOTT  SHIKAZE  GALBRAITH AXWORTHY INFANTI

A PARTNERSHIP OF INCORPRATED PROFESSIONALS1827 West 5th Avenue
Vancouver, BC  V6J 1P5
604.682.8492  tel
604.683.4782  fax

www.berrismangan.com   Alda Pharmaceuticals Corp. 2007 20F/A 102
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 1. CONSOLIDATED BALANCE SHEETS (EXPRESSED IN CANADIAN DOLLARS) AS AT JUNE 30  20062005ASSETSCurrent AssetsCash and equivalents$
28,480$
71,663Receivables29,05632,105Inventory31,28043,668Prepaids3,85712,989Note receivable (Note 5)-7,98892,673168,413Property and Equipment (Note 6)8,19916,480Intangible Assets (Note 7)116,000116,000$
216,872$
300,893LIABILITIESCurrent LiabilitiesAccounts payable and accrued liabilities$
59,504$
29,865SHAREHOLDERS' EQUITYShare Subscriptions Received (Note 8a)25,000-Share Capital (Note 8b)2,094,7701,856,285Deficit(2,041,701)(1,663,400)157,368271,028$
216,872$
300,893 Commitments(Note 12)  Approved By The Directors "Terrance Owen" Director "Peter Chen" Director   See accompanying notes to the financial statements  Alda Pharmaceuticals Corp. 2007 20F/A 103
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 2. CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30   200620052004Sales$ 223,586$  239,271$  111,363Cost Of Sales142,379150,075Gross Profit (Loss)81,20789,196(11,479)ExpensesAdvertising and promotion12,16927,68526,456Amortization8,2818,2174,382Conferences66612,03511,437Consulting  (Notes 14(a) and (c))183,218210,561224,622Filing fees22,83421,54420,262Interest and bank charges(Note 14(d))1,5681,6852,055Investor relations52,80890,77959,038Legal and accounting63,17857,83345,763Office and miscellaneous25,45030,42628,564Product development--2,100Product registration18,37754,29338,280Rent (Notes 14(b))30,91225,26521,562Travel3,2524,5126,402Wages and benefits75,90397,38945,660498,616642,224536,583Loss before other items(417,409)(553,028)(548,062)Impairment loss on intangible assets (Note 7)-(245,000)(179,000)Gain (loss) on legal settlements (Note 10a)37,383-(10,000)Loss from operations(380,026)(798,028)(737,062)Interest income1,7251,7275,583Loss For The Year(378,301)(796,301)(731,479)Deficit, Beginning of Year(1,663,400)(867,099)(135,620)Deficit, End of Year$ (2,041,701)$ (1,663,400)$ (867,099)Basic and diluted loss per share$  0.02$  0.06$  0.08Weighted average number of shares outstanding17,857,70913,663,8569,027,179    See accompanying notes to the financial statements  Alda Pharmaceuticals Corp. 2007 20F/A 104
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 3  CONSOLIDATED STATEMENTS OF CASH FLOWS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30  200620052004Cash Provided By (Used For)Operating ActivitiesNet loss for the year$
(378,301)$
(796,301)$
(731,479)Items not involving cash:Amortization8,2818,2174,382Stock-based compensation (Note 8(d))1,15616,23723,701Impairment loss on intangible assets-245,000179,000(368,864)(526,847)(524,396)Changes in non-cash working capital items:Decrease (increase) in receivables3,04922,544(39,729)Decrease (increase) in inventory12,388101,248(129,916)Decrease (increase) in prepaids9,132(984)(12,005)Increase (decrease) in accounts
payable and accrued liabilities29,639(677)(49,414)(314,656)(404,716)(755,460)Investing Activities
Deferred acquisition costs--(45,555)Purchase of property and equipment-(642)(26,617)Advances of note receivable--(44,520)Repayments of note receivable7,988-35,0127,988(642)(81,680)Financing Activities
Share subscriptions received (refunded)25,000-(39,295)Loan advances received (repaid)--(23,604)Issuance of share capital (net of issue costs)238,485250,8701,086,854263,485250,8701,023,955Decrease in Cash and Equivalents(43,183)(154,488)186,815Cash and Equivalents, Beginning of Year71,663226,15139,336Cash and Equivalents, End of Year$
28,480$
71,663$
226,151    See accompanying notes to the financial statements  Alda Pharmaceuticals Corp. 2007 20F/A 105
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 4  NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  1. Basis of Presentation  These consolidated financial statements include the accounts of ALDA Pharmaceuticals Corp. ("the Company") and its wholly-owned subsidiary, Sirona Therapeutics Corp. ("Sirona").  The name of the subsidiary was changed on January 10, 2006 from ALDA Institute For Preventative Health Care Inc.  Sirona is an inactive company, the shares of which were acquired pursuant to the asset purchase agreement described in Note 9.  These financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business.  At June 30, 2006, the Company has a history of operating losses, and a cumulative deficit of $2,041,701.  The Company has yet to achieve a level of revenues adequate to achieve profitability.  The Company has also not yet secured patents that it is seeking in respect to its proprietary product.  The application of the going concern assumption is dependent on the ability of the Company to obtain necessary patents, to secure sufficient financing, and to develop profitable operations.  Management of the Company believes that it will succeed in meeting those objectives, allowing the continued operation of the Company.  2. Description of Operations  The Company was incorporated under the Company Act of British Columbia on May 30, 2000 and was classified as a Capital Pool Company as defined by the policies of the TSX Venture Exchange ("the Exchange").  The Company completed its required Qualifying Transaction on November 13, 2003 (see Note 9).  As a result of the Company completing the Qualifying Transaction, it ceased to be a Capital Pool Company, and its shares resumed trading on the Exchange effective November 19, 2003.  The Company's main business activity is the development, production and marketing of infection control agent products, principally a disinfectant product marketed as "T36" (formerly marketed as "Viralex").  Effective November 26, 2003, the name of the Company was changed from Duft Biotech Capital Ltd. to ALDA Pharmaceuticals Corp.  3. Significant Accounting Policies  a) Cash and equivalents  Cash and equivalents include cash and highly liquid market instruments with original terms to maturity of less than ninety days at the time of acquisition.  b) Accounts receivable  Accounts receivable is presented net of an allowance for doubtful accounts.  The allowance for doubtful accounts reflects estimates of probable losses in accounts receivable.  The allowance is determined based on balances outstanding for over 90 days at the period end date, historical experience and other current information.  The Company extends credit to customers and distributors, and requires credit checks of all new distributors.  c) Inventory Inventory of the Company's finished goods and related raw materials is reported at the lesser of cost and estimated net realizable value.  Cost is determined using the first in, first out cost flow assumption.  Alda Pharmaceuticals Corp. 2007 20F/A 106
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 5 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  3. Significant Accounting Policies (continued)  d) Property and equipment  Property and equipment is recorded at cost and amortized using the following annual rates:  Furniture and fixtures 20% Straight line Computer equipment 30% Straight line  In the year of acquisition, amortization is calculated at one-half of the above-noted rates.  e) Impairment of long-lived assets  The Company reviews for the impairment of long-lived assets, including property and equipment, held for use, whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable from expected future cash flows.  The assessment of recoverability is made based on projected undiscounted future net cash flows that are directly associated with the asset's use and eventual disposition.  The amount of the impairment, if any, is measured as the difference between the carrying amount and the fair value of the impaired assets, and is presented as an impairment loss in the current period.  f) Intangible assets  The cost of intangible assets which are determined to have an indefinite life, is not amortized, but is tested for impairment on an annual basis, based on a comparison of the fair value of the intangible asset with its carrying amount.  The carrying amount is adjusted for impairment as necessary and any excess of the carrying amount over the fair value of the intangible asset is charged to earnings in the current period.  Intangible assets which are determined to have a finite useful life are amortized on a systematic basis over the estimated remaining useful life.  g) Revenue recognition  The revenue of the Company is primarily derived from the sale of the Company's T36 products. Revenue is recognized at the time of shipment to the customer, and invoicing, provided that collection of the amount billed to the customer is considered reasonably assured.  Revenue is recognized net of any expected sales returns.  The Company accepts returns of damaged goods and unopened products.  h) Product development and registration costs  Product development costs include all expenditures attributable to efforts by the Company to develop, and bring to commercial production a new product.  Such amounts are charged as an expense in the period incurred except in circumstances where the market and technical feasibility of the product have been established, and recovery of development costs can reasonably be regarded as assured, in which case such costs are capitalized.  Product registration costs related to efforts by the Company to acquire legal protections for its proprietary products, such as trademarks and patents, are expensed when incurred.  Alda Pharmaceuticals Corp. 2007 20F/A 107
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 6. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  3. Significant Accounting Policies (continued)  i) Income taxes  Future tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Future tax assets and liabilities are measured using enacted or substantively enacted tax rates expected to apply when the asset is realized or the liability settled.  To the extent that the Company does not consider it more likely than not that a future tax asset or portion thereof will be recovered, it provides a valuation allowance.  j) Stock-based compensation  The Company accounts for stock options issued to employees and directors before July 1, 2003 by the settlement method, which results in no compensation expense.  Consideration paid by employees and directors on the exercise of stock options is recorded as share capital.  The Company discloses, on a supplemental basis, the pro forma effect of accounting for such stock options as if the fair value based method had been applied, using the Black-Scholes model.  For stock options granted on or after July 1, 2003, the fair value-based method is applied, using the Black-Scholes model.  Compensation cost is measured at fair value at the date of grant and is expensed on a systematic basis over the vesting period, taking into account expected forfeiture rates.  The fair value of the option granted by the Company is initially reported as contributed surplus. If the option is exercised, the amount is transferred to share capital.  The Company accounts for all stock-based payments to non-employees granted on or after July 1, 2001 using the fair value based method.  k) Warrants  Proceeds from issuances by the Company of units consisting of shares and warrants are allocated based on the residual method, whereby the carrying amount of the warrants is determined based on any difference between gross proceeds and the fair market value of the shares.  If the proceeds from the offering are less than or equal to the estimated fair market value of shares issued, a nil carrying amount is assigned to the warrants.  l) Earnings per share  Earnings per share is calculated based on the weighted average number of common shares outstanding during the reporting period.  Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding in the year.  The Company uses the treasury stock method for calculating diluted earnings per share.  Diluted earnings per share is computed similarly to basic earnings per share, except that the weighted average number of common shares outstanding is increased to include additional shares that are potentially issued, if the effect on earnings per share is dilutive.  The number of additional shares potentially issued is calculated by assuming that the proceeds from the shares so issued are used to acquire shares of common stock at the average market price during the reported year.   Alda Pharmaceuticals Corp. 2007 20F/A 108
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 7. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  3. Significant Accounting Policies (continued)  m) Use of estimates  The preparation of financial statements in conformity with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting year.  Actual results could differ from the estimates.  4. Adoption Of  New Accounting Principles  a) Stock-based compensation  During the year ended June 30, 2004, the recommendations of the Canadian Institute of Chartered Accountants Accounting Handbook Section 3870 (Stock-based Compensation and other Stock-Based Payments) was amended to require the use of the fair value-based method to account for stock options granted to employees and directors.  In accordance with the revised recommendations, the Company prospectively applied the fair value-based method to all stock options granted to employees and directors on or after July 1, 2003, whereby compensation cost is measured at fair value at the date of grant and is expensed over the vesting period.  b) Impairment of long-lived assets  Effective July 1, 2003, the Company adopted the recommendations of the Canadian Institute of Chartered Accountants Handbook Section 3063 (Impairment of long-lived assets).  The new recommendations were applied prospectively to all long-lived assets held for use by the Company after July 1, 2003.   5. Note Receivable  The balance at June 30, 2005 represents a loan to ALDA (see Note 9) which was fully repaid in the 2006 year, along with accrued interest in the amount of $1,012.   6. Property and Equipment  a) Property and equipment at June 30, 2006 consisted of the following:  Accumulated Cost Amortization Net Furniture and fixtures $ 7,683 $ 5,013 $ 2,670 Computer equipment 22,482 16,953 5,529 $     30,165 $         21,966 $        8,199   Alda Pharmaceuticals Corp. 2007 20F/A 109
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 8. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  6. Property And Equipment (continued)  b) Property and equipment at June 30, 2005 consisted of the following:  Accumulated Cost Amortization Net Furniture and fixtures $ 7,683 $ 3,476 $ 4,207 Computer equipment 22,482 10,209 12,273 $     30,165 $     13,685 $     16,480  7. Intangible Assets  The intangible assets balance represents the carrying amount of certain intellectual property acquired by the Company as described in Note 9.  These assets were determined to have an indefinite life.  At June 30, 2006, the net recoverable amount estimated by management of the Company exceeds the carrying amount, so no impairment loss has been recognized for the 2006 year.  At June 30, 2005, the carrying cost of the intangible assets was written down to the estimated net recoverable amount, and an impairment loss of $245,000 was charged against earnings for the 2005 year.  An impairment loss of $179,000 was charged against earnings for the 2004 year.  The impairment losses are based on revised cash flow projections prepared by management of the Company and the Company's slower than anticipated progress towards securing of legal protections for its proprietary product and development of a market for its product.  The net recoverable amounts were estimated by management of the Company based on expected future cash flows that could be reasonably predicted.  The carrying amount of Intangible Assets was determined as follows:  Original purchase cost (Note 9) $ 540,000 Impairment loss in 2004 (179,000) Balance at June 30, 2004 $ 361,000 Impairment loss in 2005 (245,000) Balance at June 30, 2005 and 2006 $ 116,000   Alda Pharmaceuticals Corp. 2007 20F/A 110
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 9. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity  (a) Share Subscriptions Received  At June 30, 2006, the Company had received amounts totalling $25,000 representing subscriptions by purchasers in respect to the private placement described in Note 18(a), to whom shares and warrants had not yet been issued.  Activity relating to share subscriptions is summarized as follows:  Balance at June 30, 2004 and 2005 $ - Share subscriptions received during 2006 year 25,000 Balance at June 30, 2006 $     25,000  (b) Share Capital  Authorized:  Unlimited common shares, without par value  Effective August 19, 2005, the authorized share capital of the Company was increased to an unlimited number of common shares without par value.  Issued and outstanding:  200620052004Number
of SharesAmountNumber of SharesAmountNumber of SharesAmountBalance at beginning of year15,784,404$1,856,28512,784,404$1,607,6202,451,475$279,309Private placement (i)----346,66652,000Asset purchase (ii)----3,711,263262,457Shares issued to sponsor (ii----75,00015,000Public offering (iii)----6,000,0001,200,000Shares issued to agent (iii)----200,00040,000Private placement (iv)--3,000,000300,000--Private placements (v)5,016,000250,800----Share issue costs---(51,335)-(241,146)Balance at end of year20,800,404$2,094,77015,784,404$1,856,28512,784,404$1,607,620  i) During the 2004 year, the Company completed a private placement of 346,666 common shares of the Company at a price of $0.15 per share.  ii) Effective November 13, 2003, the Company completed a Qualifying Transaction as described in  Note 9.  As part of the consideration paid, the Company issued 3,711,263 common shares.  The Company also issued 75,000 common shares at a deemed price of $0.20 per share in payment of fees to a sponsoring broker in connection with the Qualifying Transaction.  Alda Pharmaceuticals Corp. 2007 20F/A 111
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 10. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity (continued)  Issued and outstanding (continued):  iii) Effective November 13, 2003, the Company completed a brokered public offering of 6,000,000 units at a price of $0.20 per unit for gross proceeds of $1,200,000.  Each unit consisted of one common share of the Company and one non-transferable share purchase warrant.  Each share purchase warrant entitled the holder to acquire one common share of the Company at a price of $0.30 per share, for a period of 18 months following the closing date.  Under an agency agreement in respect to the offering, the Company paid to the agent a cash commission of $120,000 and an administration fee of $7,500, and granted agent warrants to purchase up to 900,000 common shares of the Company at an exercise price of $0.20 per share, for a period of 18 months following the closing date, which vested immediately.  The agent was also issued 200,000 units consisting of one common share at a deemed price of $0.20 per share and one share purchase warrant.  Each share purchase warrant entitled the agent to purchase one common share of the Company at a price of $0.30 per share for a period of 18 months following the closing date.  iv) On March 15, 2005, the Company completed a private placement of 3,000,000 units of the Company at a price of $0.10 per unit for gross proceeds of $300,000.  Of the units issued, 795,000 units were placed on a non-brokered basis, and 2,205,000 units were placed on a brokered basis.  Each unit consisted of one common share of the Company and one share purchase warrant, each warrant entitling the holder to purchase one common share at a price of $0.20 per share for a period of 18 months following the closing date.  In connection with the brokered private placement, the Company paid a cash commission of 10% of the gross proceeds, a corporate finance fee of $10,000 and legal and other costs totaling $17,080.  The Company also issued 220,500 agent warrants, each warrant entitling the agents to purchase one common share of the Company, at a price of $0.20 per share for a period of 18 months following the closing date.  v) On December 23, 2005, the Company completed a private placement of 3,916,000 units of the Company at a price of $0.05 per unit for gross proceeds of $195,800.  Each unit consists of one common share of the Company and one share purchase warrant, each warrant entitling the holder to purchase one common share at a price of $0.10 per share for a period of 12 months following the closing date.  Legal fees in the amount of $5,352 were incurred in connection with the private placement.  On June 22, 2006, the Company completed a private placement of 1,100,000 units of the Company at a price of $0.05 per unit for gross proceeds of $55,000.  Each unit consists of one common share of the Company and one share purchase warrant, each warrant entitling the holder to purchase one common share at a price of $0.10 per share for a period of 12 months following the closing date.  Legal fees in the amount of $6,963 were incurred in connection with the private placement.  c) Escrowed shares  Included in issued share capital at June 30, 2006 are 733,163 common shares held in escrow, which are released on a staged basis, with a release occuring every six months.  During the 2006 year, 1,466,324 common shares were released from escrow (2005: 1,466,318).  Alda Pharmaceuticals Corp. 2007 20F/A 112
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 11. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity (continued)  d) Stock options  A summary of the Company's stock options, and changes during each year is presented below:  Year Ended
June 30, 2006Year Ended
June 30, 2005Year Ended
June 30, 2004Number
of
SharesWeighted
Average
Exercise
PriceNumber
of
SharesWeighted
Average
Exercise
PriceNumber
of
SharesWeighted
Average
Exercise
PriceOutstanding, beginning of year1,290,000$0.19990,000$0.19237,647$0.17Granted during year-consultants ((ii) / (iii))----390,0000.20-directors ((i) / (iv))--200,0000.20362,3530.20-employees (v)--100,0000.20--Expired during the year(752,353)0.20----Outstanding, end of year537,647$0.191,290,000$0.19990,000$0.19   The following table summarizes information about stock options outstanding at June 30, 2006:  Number
of SharesExercise
PriceExpiry
DateNumber
Exercisable237,647$0.17July 31, 2006237,647100,000$0.20August 1, 2006100,000100,000$0.20December 22, 2006100,00020,000$0.20February 28, 200720,00080,000$0.20April 4, 200780,000537,647537,647  (i) During the 2004 year, the Company granted options to acquire 362,353 common shares to directors of the Company.  The options have an exercise price of $0.20 per share, and are exercisable for a period of two years from the date of grant.  The options vested immediately.  The estimated fair value of the options of $14,494 ($ 0.04 per share) was recognized for the 2004 year.  (ii) During the 2004 year, the Company granted options to acquire 190,000 common shares to consultants of the Company.  The options have an exercise price of $0.20 per share and are exercisable for a period of two years from the date of grant.  Options to acquire 150,000 shares vested immediately, and options to acquire 40,000 shares vested over a one year period.  Of the total expense related to the estimated fair value of the options ($0.04 per share), $925 was recognized for the 2005 year and $6,675 for the 2004 year.   Alda Pharmaceuticals Corp. 2007 20F/A 113
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 12. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity (continued)  d) Stock options (continued)  (iii) During the 2004 year, the Company granted options to acquire 200,000 common shares of the Company to consultants providing investor relations services to the Company.  The options have an exercise price of $0.20 per share, and are exercisable for a period of two years from the date of grant.  Options to acquire 100,000 shares vest over a two year period, and options to acquire another 100,000 shares vested over a one year period.  The options have an estimated fair value of $8,000 ($0.04 per share).  The related expense was charged to operations over the vesting periods ($1,156 for the 2006 year; $4,312 for the 2005 year; and $2,532 for the 2004 year).  (iv) During the 2005 year, the Company granted options to acquire 200,000 common shares of the Company to two directors.  The options have an exercise price of $0.20 per share and are exercisable for a period of two years from the date of grant.  The options vested immediately.  The estimated fair value of the options of $6,000 ($0.03 per share) was recognized for the 2005 year.  (v) During the 2005 year, the Company granted options to acquire 100,000 common shares of the Company to an employee.  The options have an exercise price of $0.20 per share and are exercisable for a period of two years from the date of grant.  The options vested immediately.  The estimated fair value of the options of $5,000 ($0.05 per share) was recognized for the 2005 year.  Stock-based compensation expense is presented in the Statement of Operations and Deficit as follows:  200620052004Consulting
Investor relations
Wages and benefits$             -
1,156
-$     925
4,312
11,000$ 6,675
2,532
14,494Total stock-based compensation$    1,156$  16,237$ 23,701  The fair value-based accounting method was applied to all stock options granted during the 2005 and 2004 years.  No options were granted during the 2006 year.  The fair value of each option was estimated as at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:  2005 2004 Dividend yield 0% 0% Expected volatility 81% 42% Risk free interest rate 3.12% 2.25% Expected average option term 2 years 2 years  Had compensation expense for the Company's stock-based employee compensation plan been determined for each year based on the fair value at the grant date for options granted before July 1, 2003, the Company's net loss and loss per share would have been as follows:   Alda Pharmaceuticals Corp. 2007 20F/A 114
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 13. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity (continued)  d) Stock options (continued)  2006 2005 2004 Loss for the year - as reported $ 378,301 $ 796,301 $ 731,479 Loss for the year - pro forma 378,301 796,301 731,479 Loss per share - as reported 0.02 0.06 0.08 Loss per share - pro forma 0.02 0.06 0.08  The Black-Scholes model, used by the Company to calculate option values was developed to estimate fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differs from the Company's stock option awards.  This model also requires highly subjective assumptions, including future stock price, volatility, and expected time until exercise, which greatly affect the calculated values.  Alda Pharmaceuticals Corp. 2007 20F/A 115
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 13. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity (continued)  e) Warrants  The Company has issued warrants entitling the holders to acquire common shares of the Company.  A summary of changes in unexercised warrants is presented below.  Warrants
@ $0.30
(1)Warrants
@ $0.235
(2)Agent Warrants
@ $0.20
(3)Warrants
@ $0.30
(4)Warrants
@ $0.20
(5)Agent Warrants
@ $0.20
(6)Warrants
@ $0.10
(7)Warrants
@ $0.10
(8)TotalOutstanding,
June 30, 2003---------Granted during year6,000,000-900,000200,000-----Outstanding,
June 30, 20046,000,000-900,000200,000----7,100,000Granted during year----3,000,000220,500--3,220,500Cancelled on repricing(6,000,000)-------(6,000,000)Granted on repricing-6,000,000------6,000,000Expired during year--(900,000)(200,000)----(1,100,000)Outstanding,
June 30, 2005-6,000,000--3,000,000220,500--9,220,500Granted during year------3,916,0001,100,0005,016,000Expired during year-(6,000,000)------(6,000,000)Outstanding,
June 30, 2006----3,000,000220,5003,916,0001,100,0008,236,500  (1) Exercisable until May 14, 2005, granted pursuant to public offering (Note (b)(iii)) (2) The terms of the warrants in (1) were amended during the 2005 year to reduce the exercise price to $0.235 per share, exercisable until November 13, 2005. (3) Exercisable until May 14, 2005, granted pursuant to public offering (Note (b)(iii)) (4) Exercisable until May 14, 2005, granted pursuant to public offering (Note (b)(iii)) (5) Exercisable until September 15, 2006, granted pursuant to private placement (Notes (b)(iv)) (6) Exercisable until September 15, 2006, granted pursuant to private placement (Note (b)(iv)) (7) Exercisable until December 22, 2006, granted pursuant to private placement (Note (b)(v)) (8) Exercisable until June 22, 2007, granted pursuant to private placement (Note (b)(v))   Alda Pharmaceuticals Corp. 2007 20F/A 116
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  8. Shareholders' Equity (continued)  e) Warrants (continued)  The fair value of agent warrants to acquire 220,500 common shares of the Company at a price of $0.20 per share, as described in Note 8(b)(iv), was estimated to be approximately $0.01 per warrant (totaling $2,205), using the Black-Scholes option pricing model.  The fair value of agent warrants to acquire 900,000 common shares of the Company at a price of $0.20 per share, as described in Note 8(b)(iii), was estimated to be approximately $0.04 per warrant (totaling $36,000), using the Black-Scholes option pricing model.  f) Contributed surplus  Contributed surplus at June 30, 2006, 2005 and 2004, and activity during the 2006, 2005 and 2004 years, are summarized as follows: 200620052004Balance, beginning of year$ 78,143$ 59,701$              -Warrants issued to agent (Note 8(e))-2,20536,000Options issued to employees (Note 8(d)(v))-5,000-Options issued to consultants (Note 8(d)(ii) and (iii))-6,00014,494Balance, end of year1,1565,2379,207$ 79,299$ 78,143$ 59,701  9. Asset Purchase Agreement  Effective November 13, 2003 the Company completed a purchase of assets of ALDA Pharmaceutical Inc. (subsequently 513947 B.C. Ltd.) ("ALDA").  This acquisition represented the Company's "Qualifying Transaction" pursuant to the policies of the TSX Venture Exchange (the "Exchange") as they relate to Capital Pool Companies.  The Asset Purchase Agreement provided for the Company to purchase substantially all of the assets and undertaking of ALDA, principally comprised of certain intellectual property rights of ALDA related to an infection control agent product developed by it (including certain drug identification numbers, and trademark and patent applications), as well as inventory, capital assets, the shares of ALDA Institute For Preventative Health Care Inc., a non-competition agreement, and certain contracts, for a deemed purchase price of $800,000.  The deemed purchase price was paid by the Company by the issuance of 3,711,263 common shares (the "Payment Shares") to ALDA at a deemed price of $0.20 per share, and the set off of a loan and accrued interest totaling $57,747 owing by ALDA to the Company.  The Payment Shares are subject to an escrow agreement under  which ten percent of the shares subject to escrow were released on November 14, 2003.  An additional fifteen percent of the shares are to be released after every six month period commencing November 14, 2003, the first release occurring May 14, 2004.  Under the Asset Purchase Agreement, the Company assumed responsibility for all obligations arising subsequent to November 13, 2003 pursuant to any leases, contracts and licenses of ALDA, which relate to the former business of ALDA.  Cash expenditures were incurred by the Company in respect to the asset purchase transaction totaling $219,796.  Alda Pharmaceuticals Corp. 2007 20F/A 117
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 15. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  9. Asset Purchase Agreement (continued)  The purchase cost was determined based on estimated fair value of assets acquired, allocated as follows:  Intangible assets (intellectual property) $   540,000 Inventory 15,000 Total $   555,000  The corresponding amounts assigned to consideration given by the Company for the assets purchased were as follows:  Cash (transaction costs) $ 219,796 Loan due from ALDA 57,747 Share capital - sponsor 15,000 Share capital - vendor 262,457 $ 555,000  10. Legal Settlements  a) A company opposing a trademark application made in Canada by ALDA (see Note 9) commenced legal proceedings during the 2003 year claiming damages in respect to alleged infringement of trademark.  ALDA had filed a Statement of Defence.  The Statement of Claim was subsequently amended to add the Company as a defendant in the action.  Effective May 23, 2005, the Company entered into a settlement agreement with the claimant, whereby the Company agreed to terminate the use, and application for registration of, the trademark "Viralex". The Company was required to discontinue the use of the trademark in advertising and other promotional disclosures, liquidate its inventory of goods bearing the trademark "Viralex", and rename the Viralex product within twelve months from the date of the agreement, in consideration for payment of $30,000 (US).  These funds were held in escrow by the Company's lawyer until the Company issued a press release regarding the settlement of the trademark dispute, and withdrew its application for the "Viralex" trademark, which occurred during the 2006 year.  On August 2, 2005, the Company received the proceeds from the settlement totalling $37,383 ($30,000 (US)).  The proceeds are reported in the Statement of Operations and Deficit as a gain on legal settlement for the 2006 year.  b) During the 2004 year, the Company paid an amount of $10,000 in settlement of a legal claim made by a competitor relating to certain promotional disclosures made by the Company.   11. Major Customers  The revenue of the Company for the 2006 year from each of four customers exceeded 10% of total revenue (2005: five customers; 2004: three customers).  Revenue from these customers totaled $149,544 (2005: $175,958; 2004: $47,007).  Alda Pharmaceuticals Corp. 2007 20F/A 118
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 16. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  12. Commitments  a) Effective January 1, 2006, the Company entered into an agreement to lease its office premises with a term of one year.  The Company's remaining minimum lease payment obligations under the agreement as at June 30, 2006 totalled $17,070, payable in the 2007 year.  b) During the 2006 year, the Company entered into an agreement with its product supplier.  Under the agreement, the supplier assumes all the costs of manufacturing the Company's T36 products, and as consideration, receives a percentage, ranging from 40% to 65%, of the Company's selling price.  The supplier also has a right of first refusal to manufacture other products for the Company.  The agreement may be terminated by either party with 90 days written notice.  c) The Company has entered into agreements with third parties in other countries in respect to the manufacturing and distribution of the Company's products in those countries.  Obligations of the Company in respect to these agreements will arise when necessary government approvals in those countries are obtained and sales commence.  d) The Company entered into an agreement effective July 21, 2005 with a third party which is to assist the the Company with registration of its T36 product with the United States Environmental Protection Agency.  As consideration, the third party is to receive a declining percentage of net sales of the T36 products in the United States ranging from 1 to 7%, commencing 90 days after registration, for a period of seven years.  13. Income Taxes  a) As at June 30, 2006, the Company had approximately $1,800,000 of unutilised non-capital losses for tax purposes, which expire commencing in the 2008 year. The potential future income tax benefit which may arise from claiming these losses has not been reflected in these financial statements, as the Company's ability to realize the benefit is uncertain.  b) Following is a reconciliation of the expected income tax benefit from the loss for each year based on the applicable statutory income tax rate, to the actual amount:  200620052004Tax asset at statutory rate$129,00134.1%$283,48335.6%$267,72136.6%Net effect of non-deductible expenses2,93597,303(9,904)Expected increase in tax asset131,936380,786257,817Effect of tax rate reduction(28,640)(8,397)(2,706)Increase in allowance for uncertain realization(103,296)(372,389)(255,111)Increase in tax asset per financial statements$-$-$-   Alda Pharmaceuticals Corp. 2007 20F/A 119
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 17. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  13.  Income Taxes (continued)  The income tax effects of losses carried forward and of cumulative temporary differences that give rise to a future tax asset are summarized as follows:  200620052004Tax losses carried forward
Temporary differences - intangible assets
Temporary differences - property and equipment
Temporary differences - financing costs$ 613,800
122,169
5,663
41,394$ 475,972
140,851
2,964
59,943$ 267,180
55,138
40
(15,017)Tax asset before allowance for uncertain realization
Allowance for uncertain realization783,026
(783,026)679,730
(679,730)307,341
(307,341)Tax asset per financial statements$            -$            -$            -  14. Related Party Transactions  a) During the 2006 year, the Company incurred consulting fees of $120,000 (2005: $134,000; 2004: $133,001) to companies controlled by directors of the Company.  b) During the 2006 year, the Company incurred premises rent of $30,912  (2005: $25,265; 2004: $21,562) to a company controlled by a director of the Company.  c) During the 2006 year, the Company incurred consulting fees of $60,000 (2005: $70,000; 2004: $75,000) to a major shareholder of ALDA, the vendor in the asset purchase agreement described in Note 9.  d) During the 2004 year, the Company incurred interest expense of $836 to a company controlled by a director in respect to a loan advanced by that company.  These transactions were measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.   15. Statements of Cash Flows - Supplementary Information  a) Cash paid in respect to interest and income taxes was as follows: 200520042004Income taxes paid$
-$
-$
-Interest paid$
-$
-$
836  b) Significant non-cash transactions occurring during the 2006 year were as follows:  (i) A portion of the estimated fair value of the options granted to consultants described in Note 8(d)(iii), totaling $1,156, was charged to operations for the 2006 year.   Alda Pharmaceuticals Corp. 2007 20F/A 120
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. 18. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  15. Statements of Cash Flows - Supplementary Information  (continued)  c) Significant non-cash transactions occurring during the 2005 year were as follows:  (i) The Company issued warrants with an estimated fair value of $2,205, as described in Note 8(e).  (ii) The Company issued options to directors and employees to acquire 300,000 common shares of the Company, as described in Notes 8(d)(iv) and (v).  The estimated fair value of the options, totaling $11,000, was charged to operations for the 2005 year.  (iii) A portion of the estimated fair value of the options granted to consultants as described in Notes 8(d)(ii) and (iii), totaling $5,237, was charged to operations for the 2005 year.  d) Significant non-cash transactions occurring during the 2004 year were as follows:  (i) The Company issued 3,711,263 common shares at an assigned amount of $262,457, and set off a loan receivable from ALDA in the amount of $57,747, in exchange for certain inventory and intangible assets, pursuant to the Asset Purchase Agreement described in Note 9.  The Company also issued 75,000 common shares to the sponsor at a deemed value of $15,000.  (ii) The Company issued 200,000 units at a deemed value of $40,000 to the agent in connection with the public offering described in Note 8(b)(iii).  (iii) The Company issued warrants with an estimated fair value of $36,000, as described in Note 8(e).  (iv) The Company issued options to directors and consultants to acquire 752,353 common shares of the Company, as described in Notes 8(d)(i), (ii), and (iii).  A portion of the estimated fair value of the options, totaling $23,701, was charged to operations for the 2004 year.  16. Financial Instruments  The Company's financial instruments consist of cash and equivalents, receivables, accounts payable and accrued liabilities, and share subscriptions received.  The fair value of these instruments approximates carrying amounts except where otherwise noted.  It is management's opinion that the Company is not exposed to significant interest, currency, or credit risk  arising from these financial instruments except where otherwise noted.  17. License and Option Agreement  Effective January 11, 2006, the Company entered into an agreement with its wholly owned subsidiary, Sirona, whereby it granted to Sirona an exclusive license in respect to therapeutic applications of the Company's T36 technology including an option to develop and commercialize such applications.  The agreement is to expire at the later of 20 years from the date of the agreement and the last expiry of any patent obtained related to the technology.  Management of the Company has indicated that the purpose of the agreement is to allow Sirona to pursue independent financing arrangements.  Alda Pharmaceuticals Corp. 2007 20F/A 121
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 19. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  18. Subsequent Events  a) On September 13, 2006, the Company completed a non-brokered private placement of 1,430,000 units of the Company at a price of $0.05 per unit, for gross proceeds of $71,500.  Each unit consists of one common share of the Company and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of the Company at a price of $0.10 per share for a period of 12 months from the date of issuance of the warrants.  b) Subsequent to June 30, 2006, options to acquire 237,647 common shares of the Company at a price of $0.17 per share and options to acquire 100,000 common shares of the Company at a price of $0.20 per share expired unexercised.  c) Subsequent to June 30, 2006, options to acquire 1,580,000 common shares of the Company at a price of $0.10 per share, exercisable for a period of two years, were granted to certain directors, employees and consultants of the Company, subject to regulatory approval.  Options to acquire 300,000 common shares of the Company at a price of $0.10 per share, exercisable for a period of five years subject to certain vesting provisions, were granted to a consultant of the Company, subject to regulatory approval.  d) During the 2005 year, the Company commenced legal action against the competitor described in Note 10(a), unrelated to the settlement, with respect to certain alleged defamatory statements made by the competitor after the settlement was completed.  The claim was settled effective July 12, 2006, by an agreement under which the Company is to receive an amount of $15,000 from the competitor.  The proceeds of the settlement, net of associated costs, will be recognized in the Statement of Operations for the 2007 year.  19. Comparative Figures  Certain of the comparative figures for the 2005 and 2004 years have been reclassified to conform to the presentation adopted for the 2006 year.  20. United States Generally Accepted Accounting Principles  These financial statements have been prepared in accordance with generally accepted accounting principles in Canada ("Canadian GAAP") which are substantially the same as principles applicable in the United States ("US GAAP") and practices prescribed by the United States Securities and Exchange Commission ("SEC"), except for the following:  a) Stock-based compensation:  Under Canadian GAAP, the Company accounts for stock options issued to employees and directors by the settlement method and discloses, on a supplemental basis, the pro forma effect of accounting for stock options awarded to employees as if the fair value based method had been applied, using the Black-Scholes model, for stock options granted before July 1, 2003.  For stock options granted on or after July 1, 2003, the fair value-based method is applied, using the Black-Scholes model.  The Company accounts for all stock-based payments to non-employees granted on or after July 1, 2001 using the fair value method.  Alda Pharmaceuticals Corp. 2007 20F/A 122
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 20. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  20. United States Generally Accepted Accounting Principles (continued)  a) Stock-based compensation (continued):  Under US GAAP, Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," ("SFAS 123") encourages, but does not require, companies to record compensation cost for stock-based employee compensation plans at fair value for options granted prior to December 15, 2005.  The Company has chosen the permissable alternative method under SFAS 123 to account for stock-based payments to employees before July 1, 2003 using Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees." ("APB 25").  Under APB 25,  compensation cost for stock options is measured as the excess, if any, of the quoted market price of the Company's stock at the date of the grant over the amount an employee is required to pay for the stock.  There was no such excess amount for stock options granted to employees of the Company prior to July 1, 2003.  SFAS 123 requires pro forma disclosure of the fair value of stock-based employee compensation in the financial statements where fair value is not recorded.  Management of the Company has adopted the fair value expense method alternative under SFAS 123 for options granted to employees on or after July 1, 2003, resulting in no difference in the accounting for such options between Canadian and US GAAP.  b) Comprehensive income:  Statement of Financial Accounting Standards No. 130 requires the reporting of Comprehensive Income.  Comprehensive income includes net income plus other comprehensive income. Other comprehensive income includes all changes in equity of a company during the period arising from non-owner sources.  The Company did not have any other comprehensive income during the 2006, 2005 and 2004 years.  c) Product development costs:  Under Canadian GAAP, product development costs are charged as an expense in the period incurred except in circumstances where the market and technical feasibility of the product have been established, and recovery of development costs can reasonably be regarded as assured, in which case such costs are capitalized.  US GAAP requires that these expenditures be expensed in the year incurred.  The Company has not capitalized any product development costs during the 2006, 2005 and 2004 years.  d) Reconciliation of Canadian GAAP and US GAAP:  For the years ended June 30, 2006, 2005, and 2004 there were no differences in assets, liabilities and shareholders' equity, loss for the period or cash provided by (used in) operating, investing and financing activities under US GAAP, with the amounts reported in these financial statements.   Alda Pharmaceuticals Corp. 2007 20F/A 123
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. 21. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (EXPRESSED IN CANADIAN DOLLARS) FOR THE YEARS ENDED JUNE 30, 2006, 2005 AND 2004  20. United States Generally Accepted Accounting Principles (continued)  e) Recent United States Accounting Pronouncements:  Selected recent pronouncements issued by the Financial Accounting Standards Board ("FASB") are summarized below.  None of these changes are expected to have a material impact on the financial statements of the Company.  (i) In December of 2004, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards No. 123 (revised 2004) (Share-Based Payments) ("SFAS 123R").  SFAS 123R is a revision of SFAS 123, and supersedes APB 25.  SFAS 123R requires that the fair value of employees awards of share-based payments which are issued, modified, repurchased or cancelled after the implementation date, is to be measured as of the date the award is issued, modified, repurchased or cancelled and the resulting cost recognized in the statement of earnings over the service period.  SFAS 123R will be effective for fiscal periods of the Company commencing after June 30, 2006.  (ii) In December of 2004, the FASB issued Statement of Financial Accounting Standards No. 153 (Exchanges of Nonmonetary Assets - An Amendment of APB Opinion No. 29, Accounting for Nonmonetary Transactions) ("SFAS 153").  SFAS 153 eliminates the exception from fair value measurement for nonmonetary exchange of similar productive assets in paragraph 21(b) of Accounting Principles Board ("APB") Opinion No. 29 and replaces it with an exception for exchanges that do not have commercial substance.  SFAS 153 specifies that a nonmonetary exchange has commercial substance if the future cash flows of the entity are expected to change significantly as a result of the exchange.  SFAS 153 is effective for fiscal periods beginning after June 15, 2005, and must be applied prospectively.  (iii) In May of 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, which replaced APB Opinion No. 20, Accounting Changes, and superseded FASB Statement No. 3,  Reporting Accounting Changes in Interim Financial Statements  an amendment of APB Opinion No. 28.  SFAS 154 requires retrospective application of changes in accounting principle to prior period financial statements, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change.  SFAS 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005.  Alda Pharmaceuticals Corp. 2007 20F/A 124
------------------------------------------------------------------------------------------------------------------------------------------------------------     [alda200720famend2019.gif]ALDA Pharmaceuticals Corp.
635 Columbia Street, New Westminster, British Columbia,V3M 1A7
Telephone:604-521-8300; Facsimile:604-521-8322   Form 51-102F1 Managements Discussion & Analysis for the year ended June 30, 2006  October 27, 2006             The statements contained in this report that are not purely historical are forward-looking statements. Forward looking statements  include statements regarding our expectations, hopes, intentions or strategies regarding the future. Forward looking statements include: statements regarding future products or products or product development; statements regarding future selling, general and administrative costs and research and development spending; and our product development strategy; statements regarding future capital expenditures and financing requirements; and similar forward looking statements. It is important to note that our actual results could differ materially from those in such forward-looking statements.  Alda Pharmaceuticals Corp. 2007 20F/A 125
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006  1.1 Date  This Management Discussion and Analysis (MD&A) is dated October 27, 2006 and should be read in conjunction with the consolidated financial statements of ALDA Pharmaceuticals Corp. (ALDA or the Company) for the financial year ended June 30, 2006. All financial information is expressed in Canadian dollars and is prepared in accordance with Canadian generally accepted accounting principles (GAAP).  1.2 Overall Performance  On November 13, 2003, ALDA Pharmaceuticals Corp., formerly Duft Biotech Capital Ltd., completed the acquisition of the assets of 513947 BC Ltd. formerly ALDA Pharmaceuticals Inc. (the Qualifying Transaction) and a $1.2 Million financing arranged by Canaccord Capital Corporation (the Financing).  ALDA has developed a family of wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent pending T36® technology. The emergence of SARS, Norwalk Virus and new strains of influenza have created a market demand for a highly effective, non-toxic and environmentally friendly disinfectant. ALDAs first product, T36® Disinfectant has been tested on over 50 infectious bacteria, viruses and fungi. T 36®Disinfectant kills on contact and is virtually 100% effective in destroying all of them, including HIV, Polio, Legionella and the Norwalk-like virus, within a 3-minute period and Tuberculosis within 5 minutes. T36® Disinfectant has been approved by Health Canada for use as a hospital grade, surface disinfectant and by the Canadian Food Inspection Agency (CFIA). T36® Disinfectant is available through distributors in Canada, the EU and the worldwide web to consumers internationally. The ability to kill Polio and TB means that T36®Disinfectant is also acknowledged to be effective against all bacteria and virus including Avian Flu, SARS, Norwalk Virus, HIV, Legionellaand Hepatitis.  The market for disinfectant products is competitive.  Competitors are already well established in the market for disinfectant products.  The introduction of a new product into an existing market can be met with aggressive marketing, price cutting and distribution impediments by competitors.  To obtain market share, the Company must penetrate a market with established competitors and to obtain sufficient recognition to be able to displace existing disinfectant products.  Substantial funds will have to be spent on marketing and education.  Competitors may be developing new technologies and new products that will offer significant improvements over existing products, including those offered by the Company.  Market knowledge of the ALDA name is limited.  ALDA will need to devote considerable resources to educate new markets about the Company products it offers.  In establishing new markets, the Company will be competing with companies that are potentially already entrenched in such markets or that may be better funded than the Company.  ALDA also faces significant costs and risks associated with the protection and exploitation of its intellectual property.  Competitors with significantly more resources may have an advantage over the Company in terms of the establishment, protection and exploitation of patents and other intellectual property.  All of these factors are material to the Company and its business.   Alda Pharmaceuticals Corp. 2007 20F/A 126
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006   1.3 Selected Annual Information Year Ended OnJune 30, 2006June 30, 2005June 30, 2004Revenue(1)$225,311$240,998$116,946Net Loss$378,301$796,301$731,479Loss Per Share$      0.02$      0.06$      0.08Diluted Loss Per Share$      0.02$      0.06$      0.08Total Assets$216,872$300,893$830,764Long-Term Liabilities$           0$           0$           0 (1)Sales plus Interest Income During the year ended June 30, 2006, cash decreased by $43,183 to $28,480 compared to $71,633 at the year ended June 30, 2005. The operating losses of $380,026 were offset by two completed rounds of financing. Current assets declined by $75,740 from $168,413 on June 30, 2005 to $92,673 on June 30, 2006. This 45% reduction in current assets was due to a $43,183 decrease in cash, a $3,049 decrease in receivables, a $9,132 decrease in prepaid expenses and a $12,388 decrease in inventory as a result of sales.  Current liabilities, consisting of accounts payable and accruals, were increased by $29,639 from $29,865 to $59,504 on June 30, 2006.  1.4 Results of Operations  Sales For the year ended June 30, 2006 sales were $223,586 compared to $239,271 for the year ended on June 30, 2005 and $111,363 for the seven and one-half month period from November 14, 2003, after completion of the Qualifying Transaction, to June 30, 2004. Sales were generated in 2005 and 2006 were from the sale of the companys surface disinfectant, T36® Disinfectant, through its distributors to the first responders, dental and beauty markets. In 2006, the Company also introduced T36® Hand Sanitizer which is also being sold through the same distributors.  Cost of sales The cost of sales for the year ended June 30, 2006 was $142,379 compared to $150,075 for the year ended on June 30, 2005 and $122,842 for the seven and one-half month period from November 14, 2003, after completion of the Qualifying Transaction, to June 30, 2004. Cost of sales includes the direct costs of the inventory sold during the period plus warehousing costs and handling charges. The higher relative cost of sales observed in the 2004 fiscal year was due to the extra costs associated with starting up the operations of the company.  Gross Profit (Loss) In 2006, a gross profit of $81,207 was attained, which was in line with the gross profit of $89,196 or 37% in 2005. A loss of $11,479 was encountered for the seven and one-half month period from November 14, 2003, after completion of the Qualifying Transaction, to June 30, 2004.  Advertising and promotion Advertising and promotion costs for the year ended June 30, 2006 were $12,169 compared to $27,685  for the year ended June 30, 2005 and $26,456 in 2004. Costs in this category were reduced significantly as the Company did not allocate as much advertising as in the 2005 and 2004 fiscal years.  Instead of promoting the name of T36®Disinfectant in selected trade journals, the Company chose to offer and send samples to selected distributors and customers.  Consulting Consulting fees for the year ended June 30, 2006 were $183,218 compared to of $210,561 and $224,622, respectively for the years ended June 30, 2005 and 2004. The remuneration of the executives of the company for services provided through their consulting companies was as follows. · $60,000 to 503213 BC Ltd., a company controlled by Dr. Terrance G. Owen, President & CEO, for services related to directing the technical aspects of research and development, product testing, domestic and international product registrations and intellectual property protection; negotiating and establishing international marketing agreements; assisting with domestic and international sales and marketing strategies, marketing materials, internet marketing and investor relations activities; directing the companys legal and accounting professionals; advising officers and directors of company matters and ensuring that the regulatory requirements of the company are fulfilled.  Alda Pharmaceuticals Corp. 2007 20F/A 127
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006   1.4 Results of Operations (continued)  Consulting (continued)  · $60,000 to 612480 BC Ltd., a company controlled by Peter Chen CFO, for advising on the financial aspects of research and development, product testing, domestic and international product registrations and intellectual property protection; negotiating and establishing international marketing agreements; assisting with domestic and international sales and marketing strategies, marketing materials, internet marketing and investor relations activities; directing the companys legal and accounting professionals; advising officers and directors of company matters and ensuring that the regulatory requirements of the company are fulfilled.  · $60,000 to 680806 BC Ltd., a company controlled by Dr. Allan Shapiro for advising on and assisting with research and development, marketing and sales, product testing, domestic and international product registrations and intellectual property protection and attending conferences, conducting seminars and training sessions and providing presentations at conferences.  Investor relations The investor relations activities amounted to $52,808 for the year ended June 30, 2006 of which $20,300 went to Freeform Communications Inc.  Since January 7, 2004, the date the first investor relations contracts were established, Freeform Communications Inc., received $41,000 for the full 12 months of the 2005 fiscal year and $25,688 for the 6 months of the 2004 fiscal year. E-Vestor Relations received $14,906 for the services provided from June 30, 2005 to December 16, 2005.  During 2005 fiscal year and 2004 fiscal year, E-Vestor received $29,419 and $40,000 respectively. $1,156 was booked as a non-cash expense for stock options granted toE-Vestor. On November 17, 2005, the company engaged the services of Insight Financial Marketing Network Inc. to provide investor relations services.$15,000 was paid to Insight Financial Marketing Network Inc. during the 2006 year. Other investor relations expenses incurred during the 2006 fiscal year were $2,190.24 and $412.00 for the dissemination of news releases provided by Canada Newswire and CCN Matthews respectively.  Legal and accounting fees Legal and accounting fees were $63,178 for the year ended June 30, 2006 compared to $57,833 and $45,763 for the year ended June 30, 2005 and 2004 respectively.  Accounting fees primarily consisted of the cost of the year-end audits and for reviewing the quarterly statements. Legal fees in 2006 included costs for closing of private placements, the completion of legal action against a competitor as announced by the company in a news release dated September 5, 2006, preparing a 20F filing and preparing legal documents for the technology licensing agreement between ALDA and Sirona Therapeutics Corp, the subsidiary of ALDA.  The major legal expense incurred in 2005 fiscal year was the settlement of the trademark dispute in between ALDA as announced in a press release dated May 30, 2005. In the 2004 fiscal year, legal costs were incurred for closing the Qualifying Transaction, the Financing associated with the Qualifying Transaction, required regulatory filings and litigation involving a competitor as announced in new releases issued by the company on May 14, 2004 and June 30, 2005.  Product registration Total costs incurred in this category for the year ended June 30, 2006 was $18,377, compared to $54,293 and $38,280 in the fiscal year ended June 30, 2005 and 2004 respectively. Costs in this category include the fees paid to the regulatory consultants in Canada and the US to pursue the registration of the companys products in the United Kingdom and the United States. Costs spent on laboratory testing and intellectual property protection are also included in this category.  Wages and benefits Wages and benefits were $75,903 for the year ended June 30, 2006 compared to $97,389 for the year ended June 30, 2005 and $45,660 for the year ended June 30, 2004. The wages were paid for accounting and administrative assistance and to sales and marketing staff. The wages for 2004 represent roughly half of that since no employees were hired until half way through the 2004 fiscal year.  Alda Pharmaceuticals Corp. 2007 20F/A 128
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006  Loss from operations The loss from operations was $417,409 for the year ended June 30, 2006 compared to $553,028 for the year ended June 30, 2005 and $548,062 for the year ended June 30, 2004. Having tighter cost control systems in place in the 2006 fiscal year, ALDA successfully reduced the loss by 24% compared to 2005 fiscal year. The greater losses for the years ended June 30, 2004 and 2005 were mainly due to the costs associated with taking over the business acquired through the Qualifying Transaction. Many initiatives were taken to establish a basis for further growth of the company, including expanding the patent portfolio of the company, protecting the trademarks, seeking expert advice on product regulatory issues, undertaking laboratory tests of T36® Disinfectant against new micro-organisms, preparing marketing materials, evaluating manufacturing requirements, undertaking inventory production, seeking out new distributors and customers and other actions expressly intended to increase sales of the company. The losses are also associated with significant one-time costs associated with completion of the Qualifying Transaction the Financing. Comparing to the 2005 fiscal year, 2006 fiscal year sales of T36® Disinfectant decreased somewhat due to less marketing and promotion while expenses decreased by approximately 22%. Management remains committed to launch new products, such as the T36® Disinfectant Cleaner CONCENTRATE, in the foreseeable future as announced in a news release on May 17, 2005. The pursuit of the new products requires the Company to invest continuously in product development, foreign registrations and intellectual property protection.  Other income (Loss) Interest income earned from the deposits for the year ended June 30, 2006 was $1,725 compared to $1,727 and $5,583 in the same periods in 2005 and 2004, respectively.  As of June 30, 2006, the intangible asset of the Company was $116,000.  No impairment loss has been recognized for the 2006 year as the management of the Company anticipated that the net recoverable amount of the intangible asset exceeds the carrying value; the anticipation was based on the revised calculation of the future cash flows. Originally estimated at $540,000, the intangible asset was written down to $361,000 in 2004 and to $116,000 in 2005 due to the devaluation of the assets purchased by the company for its Qualifying Transaction. The devaluation reduces only the intangible assets of the company and sets up a future tax asset that can be carried forward.  During the 2005 fiscal year, the Company entered into a settlement agreement with the claimant, whereby the Company agreed to terminate the use, and application for registration of, the trademark Viralex. The settlement agreement required the Company to liquidate its inventory of goods bearing the trademark within twelve months from the date of the agreement in all advertising and other promotional means. In connection with the settlement of the trademark depute, a gain of $37,383 ($30,000 US), previously held by the Companys lawyer, was recognized the Company and reported in the Statement of Operations and Deficit as a gain on legal settlement for the 2006 year. The Loss on legal settlement in 2004 was for $10,000 paid to a competitor for damaging statements published on the web site of a manufacturers representative engaged by ALDA to work with the companys distributors. As a result, the relationship with the manufacturers representative was terminated. The information was previously disclosed in a news release published by the company on May 14, 2004.  Loss for the year The loss for the year ended June 30, 2006 was reduced by 52% to $378,301; a loss of 2 cents basic and diluted per share comparing to the loss of $796,301, a loss of 6 cents per basic and diluted share for the year ended June 30, 2005 and a loss of $731,479 for the year ended June 30, 2004, a loss of 8 cents per basic and diluted share. The substantial losses in 2005 and 2004 included write-down of the intangible assets acquired through the Qualifying Transaction of $179,000 for 2004 and $245,000 for 2005. Losses for 2004 also included a payment of a $10,000 legal settlement with a competitor.  Use of proceeds The estimated use of proceeds from the private placement as described in a news release issued on November 17, 2005 is provided below. The financing was closed on December 22, 2005.  PurposeProposed use
of fundsEstimated use
of funds to dateVariance
to dateNet proceeds of the Financing$195,800$50,405$145,395New Product Introductions$155,800$ 39,405$116,395U.S. securities fees and expenses$40,000$11,000$29,000   Alda Pharmaceuticals Corp. 2007 20F/A 129
------------------------------------------------------------------------------------------------------------------------------------------------------------    ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006  1.5 Summary of Quarterly Results. Quarter endedJun/06Mar/06Dec/05Sep/05Jun/05Mar/05Dec/04Sep/04Revenue58,73648,03561,44657,09475,21046,64554,74864,395Net loss67,371118,084137,21355,633370,908134,638150,040140,715Loss/share0.000.010.010.000.030.010.010.01Diluted
Loss/share0.000.010.010.000.030.010.010.01Total assets216,872207,800312,192237,141300,893678,887565,527687,826 The revenues generated from the sale of T36® Disinfectant have been relatively consistent while a reduction in operating expenses has been realized. Resources spent in patenting, research and development, and product registrations have declined as these tasks have been largely completed or are in the registration or review process. The greater loss recognized in 2005 fiscal year was mainly due to an impairment loss of $245,000 on intangible assets. Since the arrangement of the Qualifying Transaction, the intangible assets were written down to $116,000 from the initial value of $540,000. With the revised cash flow projection provided by the management of the Company, the estimated net recoverable value of the intangible asset exceeded its carrying value; therefore, no further impairment loss was recognized for the fiscal year 2006. Due to the one time impairment loss of $245,000 in June 30, 2005, total assets of the Company were reduced.  Total assets were increased over the quarters as the Company received external funding from the private placements. All resources were invested in marketing, product development, intellectual property protection and the other requirements of an operating company that is introducing a new technology and products to the market. 1.6 Liquidity  Although the company generates revenues from the sale of its lead product, T36®Disinfectant, sales are still occurring only in Canada. Approvals have been obtained for T36®Disinfectant in the European Union and Malaysia, other approvals are pending in Asia and a distributor in China is seeking approval there. The company now has trained staff in place to undertake sales and marketing initiatives in Canada and internationally as opportunities arise. The company is also focused on developing, testing, patenting, and introducing new products to the market and seeking licenses or partners for certain applications of the T36® technology. The first new product to be introduced is T36® Disinfectant Cleaner CONCENTRATE as announced by the company in a news release dated May 17, 2005. Management is also evaluating the possibility of acquiring technologies that are complementary to T36®and launching similar type of products lines in the subsequent future. It is expected that the company will need to undertake further financings.  1.7 Capital resources  Over the year, the Company raised a total of $250,800 by selling a total of 5,016,000 Units of the Companys at a price of $0.05 per Unit. Each Unit consisted of one Common Share of the Company and one Warrant that entitles the holder to purchase one common share at a price of $0.10 per share for a period of 12 months following the closing date. Financing costs of $12,315 were incurred in the connection of the private placements. The net gross proceeds of $238,485 were to be used for working capital, a 20F filing in the US and new product introductions. As of June 30, 2006, the Company had 20,800,404 outstanding common shares of the Company. Six million warrants priced at $0.235 expired during the 2006 fiscal year, leaving a total of 8,236,500 outstanding warrants exercisable at an exercise price range of $0.10 to $0.20 before the date of expiration. On April 14, 2005, the company proposed to revise the price of the $0.30 Warrants to $0.20 and extend the expiry date to November 13, 2005. On May 4, 2005, the company announced that the TSX Venture Exchange had permitted the extension of 6,000,000 of the Warrants and would allow these Warrants to be re-priced to $0.235. The TSX Venture Exchange did not allow 200,000 Warrants priced at $0.30 or 900,000 Warrants priced at $0.20, held by Canaccord Capital Corporation as compensation for the Financing, to be extended and these Warrants expired on May 14, 2005. All amended warrants relating to the reduction in exercise price expired unexercised. There are 237,647 Options priced at $0.17 that expire on July 31, 2006, 100,000 Options priced at $0.20 that expire on August 1, 2006, 100,000 Options priced at $0.20 that expire on December 22, 2006, 20,000 options priced at $0.20 that expire on February 28, 2007 and 80,000 priced at $0.20 that expire on April 4, 2007.  Alda Pharmaceuticals Corp. 2007 20F/A 130
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006  There is no guarantee that the Company will derive any proceeds from the exercise of outstanding warrants and there is no assurance that additional funding will be available to the Company to fulfill its business objectives.  There can be no assurance that the Company will be able to obtain adequate financing in the future or that the terms of such financing will be favourable.  Many of the Company products still require further development and laboratory testing in order to obtain required regulatory approvals.  A lack of funds will impair the ability of the Company to complete such tests.  A lack of funds will also impair the Companys ability to establish marketing and sales plans once the products have been approved for sale.  If adequate financing is not available when required, the Company may be required to delay, scale back or eliminate various activities and may be unable to continue in operation.  ALDA may seek such additional financing through debt or equity offerings, but there can be no assurance that such financing will be available on terms acceptable to the Company or at all.  Any equity offering will result in dilution to the ownership interests of the Companys shareholders and may result in dilution to the value of such interests.  1.8 Off-Balance Sheet Arrangements  The company is not aware of any off-balance sheet transactions requiring disclosure. 1.9 Transactions with Related Parties  For the year ended June 30, 2006, certain transactions with related parties are detailed in Section 1.4, Results of Operations under the paragraph entitled Consulting.  Rent of $30,912 was paid to Duft Enterprises Corp., a company controlled by Terrance G. Owen, President  & CEO.  1.10 Fourth Quarter, 2006  For the quarter ended June 30, 2006, revenues were $58,736 compared to $75,210 for the same quarter in the previous year during which sales were higher than average.  After completing the startup phase of operations and establishing appropriate cost control measures, the operating expenses incurred by the Company over the fourth quarter ended June 30, 2006 were reduced to $89,572 compared to $159,293 for the same quarter in the previous year. No further impairment loss on intangible assets was recognized in the fourth quarter of 2006.  During the fourth quarter ended June 30, 2006, there were no extraordinary events that affected the company. Sales for the quarter were close to the average sales recorded per quarter for the last two years. A private placement for $55,000 was completed on June 27, 2006. There were no significant year-end adjustments except that approximately $12,000 was reallocated from accrued liabilities and legal expenses to share issuance costs.  1.11 Proposed transactions  The company is not aware of any proposed transactions requiring disclosure.  1.12 Critical Accounting Estimates  The company is a venture issuer and is not required to provide critical accounting estimates.    Alda Pharmaceuticals Corp. 2007 20F/A 131
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006   1.13 Changes in Accounting Policies Including Initial Adoption  Effective July 1, 2001, the Company adopted the new recommendations of the Canadian Institute of Chartered Accountants Accounting Handbook Section 3870, Stock-based Compensation and Other Stock-based Payments ("CICA 3870"). The new recommendations were applied prospectively to all stock-based payments to employees and non-employees granted on or after July 1, 2001. Under CICA 3870, prior to July 1, 2003, the Company was not required to record compensation expense for stock-based compensation awards granted to employees, except for employee awards that were direct awards of stock, called for settlement in cash or other assets, or were stock appreciation rights that called for settlement by the issuance of equity instruments. Consequently the adoption of the standard had no impact on the figures presented other than the pro forma disclosure contained in Note 8(d). During the year ended June 30, 2004, CICA 3870 was amended to require the use of the fair value-based method to account for stock options granted to employees. In accordance with the revised recommendations, the Company has prospectively applied the fair value-based method to all stock options granted to employees on or after July 1, 2003, whereby compensation cost is measured at fair value at the date of grant and is expensed over the vesting period.  Effective July 1, 2003, the Company adopted the recommendations of the Canadian Institute of Chartered Accountants Handbook, Section 3063, Impairment of long-lived assets ("CICA 3063"). The new recommendations were applied prospectively to all long-lived assets held for use by the Company after July 1, 2003.  The financial statements include a note providing reconciliation to United States Generally Accepted Accounting Standards (GAAS).  1.14 Financial Instruments  The Company's financial instruments consist of cash and equivalents, receivables, note receivable, accounts payable and accrued liabilities, and loan payable. The fair value of these instruments approximates their carrying values except where otherwise noted. It is management's opinion that the Company is not exposed to significant interest, currency, or credit risk arising from these financial instruments except where otherwise noted.   Alda Pharmaceuticals Corp. 2007 20F/A 132
------------------------------------------------------------------------------------------------------------------------------------------------------------     ALDA PHARMACEUTICALS CORP. MANAGEMENT DISCUSSION AND ANALYSIS (MD&A) FOR THE YEAR ENDED JUNE 30, 2006  1.15 Other MD&A Requirements (a) Additional Information  Additional information relating to the Company can be found on the Canadian Securities Administrators System for Electronic Document Analysis and Retrieval (SEDAR) database at www.sedar.com.  (b) Disclosure of Outstanding Share Data The following table summarizes our outstanding share capital as at June 30, 2006: SecurityNumberEach class and series of voting or equity securities for which
there are securities outstanding:
Common Shares20,800,404Each class and series of securities for which there are
securities outstanding if the securities are convertible into,
or exercisable or exchangeable for, voting or equity
securities
Stock Options
Warrants
Convertible Debentures537,647
8,236,500
0Each class and series of voting or equity securities that are
issuable on the conversion, exercise or exchange of
outstanding securities above
Common Shares8,774,147  1.16 Subsequent Events to June 30, 2006  (a) The Company announced in a news release dated September 13, 2006 that a non-brokered private placement of 1,430,000 units of the Company had been completed at a price of $0.05 per unit, for gross proceeds of $71,500.  Each unit consists of one common share of the Company and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of the Company at a price of $0.10 per share for a period of 12 months from the date of issuance of the warrants.  (b) Subsequent to June 30, 2006, options to acquire 237,647 common shares of the Company at a price of $0.17 per share and options to acquire 100,000 common shares of the Company at a price of $0.20 per share expired unexercised.  (c) The Company announced in a news release dated August 4, 2006 that options to acquire 1,580,000 common shares of the Company at a price of $0.10 per share, exercisable for a period of two years, were granted to certain directors, employees and consultants of the Company, subject to regulatory approval.  Options to acquire 300,000 common shares of the Company at a price of $0.10 per share, exercisable for a period of five years subject to certain vesting provisions, were granted to a consultant of the Company, subject to regulatory approval.  (d) During the 2005 year, the Company commenced legal action against the competitor described in Note 10(a), unrelated to the settlement, with respect to certain alleged defamatory statements made by the competitor after the settlement was completed.  The claim was settled effective July 12, 2006, by an agreement under which the Company was to receive an amount of $15,000 from the competitor. The Company announced in a news release dated September 5, 2006 that the settlement amount had been paid. The proceeds of the settlement, net of associated costs, will be recognized in the Statement of Operations for the 2007 year.  Alda Pharmaceuticals Corp. 2007 20F/A 133
------------------------------------------------------------------------------------------------------------------------------------------------------------    SIGNATURES The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F A and that it has duly caused and authorized the undersigned to sign this registration report on its behalf. Dated: February 17, 2009ALDA PHARMACEUTICALS CORP.By: /s/Terrance OwenTerrance Owen,President and CEO          Alda Pharmaceuticals Corp. 2007 20F/A 134
------------------------------------------------------------------------------------------------------------------------------------------------------------    Exhibit 99.1    CERTIFICATION PURSUANT TO 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  I, Terrance Owen, certify that:  1.I have reviewed this annual report on Form 20-F/A of ALDA PHARMACEUTICALS CORP.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;4.The companys other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Evaluated the effectiveness of the companys disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andc)Disclosed in this report any change in the companys internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the companys internal control over financial reporting;5.The companys other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the companys auditors and the audit committee of the companys board of directors (or persons performing the equivalent function):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the companys ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the companys internal control over financial reporting.  Date:  February 17, 2009  /s/   Terrance Owen  Terrance Owen, Chief Executive Officer         Alda Pharmaceuticals Corp. 2007 20F/A 135
------------------------------------------------------------------------------------------------------------------------------------------------------------    Exhibit 99.2   CERTIFICATION PURSUANT TO 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  I, Peter Chen, certify that:  1.I have reviewed this annual report on Form 20-F /Aof ALDA PHARMACEUTICALS CORP.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;4.The companys other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Evaluated the effectiveness of the companys disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andc)Disclosed in this report any change in the companys internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the companys internal control over financial reporting;5.The companys other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the companys auditors and the audit committee of the companys board of directors (or persons performing the equivalent function):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the companys ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the companys internal control over financial reporting.  Date:  February 17, 2009  /s/   Peter Chen  Peter Chen, Chief Financial Officer    Alda Pharmaceuticals Corp. 2007 20F/A 136
------------------------------------------------------------------------------------------------------------------------------------------------------------     Exhibit 99.3  Certification Pursuant to 18 U.S.C. Section 1650, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   I, Terrance Owen, President and Chief Executive Officer of ALDA PHARMACEUTICALS CORP. (the Company), certify that to the best of my knowledge:  1. the Annual Report on Form 20-F/A of the Company for the year ended June 30, 2007 as filed with the Securities and Exchange Commission (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and  2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  /s/ Terrance Owen  Terrance Owen Chief Executive Officer February 17, 2009                     Alda Pharmaceuticals Corp. 2007 20F/A 137
------------------------------------------------------------------------------------------------------------------------------------------------------------    Exhibit 99.4   Certification Pursuant to 18 U.S.C. Section 1650, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   I, Peter Chen, Chief Financial Officer of ALDA PHARMACEUTICALS CORP. (the Company), certify that to the best of my knowledge:  1. the Annual Report on Form 20-F/A of the Company for the year ended June 30, 2007 as filed with the Securities and Exchange Commission (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and  2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  /s/ Peter Chen  Peter Chen Chief Financial Officer February 17, 2009    Alda Pharmaceuticals Corp. 2007 20F/A 138
------------------------------------------------------------------------------------------------------------------------------------------------------------